<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topical tacrolimus for atopic dermatitis - Cury Martins, J - 2015 | Cochrane Library</title> <meta content="Topical tacrolimus for atopic dermatitis - Cury Martins, J - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009864.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topical tacrolimus for atopic dermatitis - Cury Martins, J - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009864.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009864.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Topical tacrolimus for atopic dermatitis" name="citation_title"/> <meta content="Jade Cury Martins" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="jadecury@yahoo.com.br" name="citation_author_email"/> <meta content="Ciro Martins" name="citation_author"/> <meta content="Belecara Premium Multispecialty Center" name="citation_author_institution"/> <meta content="Valeria Aoki" name="citation_author"/> <meta content="University of Sao Paulo Medical School Hospital das Clinicas" name="citation_author_institution"/> <meta content="Aecio FT Gois" name="citation_author"/> <meta content="Escola Paulista de Medicina, Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Henrique A Ishii" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Edina MK da Silva" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD009864.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/07/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009864.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009864.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009864.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Topical; Calcineurin Inhibitors [administration &amp; dosage, adverse effects]; Dermatitis, Atopic [*drug therapy, pathology]; Dermatologic Agents [*administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic; Tacrolimus [*administration &amp; dosage, adverse effects, analogs &amp; derivatives]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009864.pub2&amp;doi=10.1002/14651858.CD009864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="PrHmaMrX";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009864\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009864\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","hr","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009864.pub2",title:"Topical tacrolimus for atopic dermatitis",firstPublishedDate:"Jul 1, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009864.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009864.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009864.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009864.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009864.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009864.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009864.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009864.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009864.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009864.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10560 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009864.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-sec-0136"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-sec-0023"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-sec-0024"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-sec-0128"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/appendices#CD009864-sec-0141"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/table_n/CD009864StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/table_n/CD009864StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topical tacrolimus for atopic dermatitis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/information#CD009864-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Jade Cury Martins</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/information#CD009864-cr-0003">Ciro Martins</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/information#CD009864-cr-0004">Valeria Aoki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/information#CD009864-cr-0005">Aecio FT Gois</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/information#CD009864-cr-0006">Henrique A Ishii</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009864.pub2/information#CD009864-cr-0007">Edina MK da Silva</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/information/en#CD009864-sec-0155">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 July 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009864.pub2">https://doi.org/10.1002/14651858.CD009864.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009864-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009864-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009864-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009864-abs-0009">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009864-abs-0001" lang="en"> <section id="CD009864-sec-0001"> <h3 class="title" id="CD009864-sec-0001">Background</h3> <p>Atopic dermatitis (AD) (or atopic eczema) is a chronic inflammatory skin condition that affects children and adults and has an important impact on quality of life. Topical corticosteroids (TCS) are the first‐line therapy for this condition; however, they can be associated with significant adverse effects when used chronically. Tacrolimus ointment (in its 2 manufactured strengths of 0.1% and 0.03%) might be an alternative treatment. Tacrolimus, together with pimecrolimus, are drugs called topical calcineurin inhibitors (TCIs). </p> </section> <section id="CD009864-sec-0002"> <h3 class="title" id="CD009864-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of topical tacrolimus for moderate and severe atopic dermatitis compared with other active treatments. </p> </section> <section id="CD009864-sec-0003"> <h3 class="title" id="CD009864-sec-0003">Search methods</h3> <p>We searched the following databases up to 3 June 2015: the Cochrane Skin Group Specialised Register, CENTRAL in the Cochrane Library (Issue 5, 2015), MEDLINE (from 1946), EMBASE (from 1974), LILACS (from 1982), and the Global Resource of Eczema Trials (GREAT database). We searched six trials registers and checked the bibliographies of included studies for further references to relevant trials. We contacted specialists in the field for unpublished data. </p> <p>A separate search for adverse effects of topical tacrolimus was undertaken in MEDLINE and EMBASE on 30 July 2013. We also scrutinised the U.S. Food and Drug Administration (FDA) websites for adverse effects information. </p> </section> <section id="CD009864-sec-0004"> <h3 class="title" id="CD009864-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) of participants with moderate to severe atopic dermatitis (both children and adults) using topical tacrolimus at any dose, course duration, and follow‐up time compared with other active treatments. </p> </section> <section id="CD009864-sec-0005"> <h3 class="title" id="CD009864-sec-0005">Data collection and analysis</h3> <p>Two authors independently screened and examined the full text of selected studies for compliance with eligibility criteria, risk of bias, and data extraction. Our three prespecified primary outcomes were physician's assessment, participant's self‐assessment of improvement, and adverse effects. Our secondary outcomes included assessment of improvement of the disease by validated or objective measures, such as SCORAD (SCORing Atopic Dermatitis), the EASI (Eczema Area and Severity Index), and BSA (Body Surface Area) scores. </p> </section> <section id="CD009864-sec-0006"> <h3 class="title" id="CD009864-sec-0006">Main results</h3> <p>We included 20 studies, with 5885 participants. The variability of drug doses, outcomes, and follow‐up periods made it difficult to carry out meta‐analyses. </p> <p>A single trial showed that tacrolimus 0.1% was better than low‐potency TCS by the physician's assessment (risk ratio (RR) 3.09, 95% confidence interval (CI) 2.14 to 4.45, 1 study, n = 371, moderate‐quality evidence). It was also marginally better than low‐potency TCS on face and neck areas and moderate‐potency TCS on the trunk and extremities by the physician's assessment (RR 1.32, 95% CI 1.17 to 1.49, 1 study, n = 972, moderate level of evidence) and for some of the secondary outcomes. Compared with pimecrolimus 1%, people treated with tacrolimus were almost twice as likely to improve by the physician's assessment (RR 1.80, 95% CI 1.34 to 2.42, 2 studies, n = 506, moderate quality of evidence). Compared with the lower concentration of 0.03%, the tacrolimus 0.1% formulation reduced the risk of not having an improvement by 18% as evaluated by the physician's assessment (RR 0.82, 95% CI 0.72 to 0.92, 6 studies, n = 1640, high‐quality evidence). Tacrolimus 0.1% compared with moderate‐to‐potent TCS showed no difference by the physician's assessment, and 2 secondary outcomes (1 study, 377 participants) and a marginal benefit favouring tacrolimus 0.1% was found by the participant's assessment (RR 1.21, 95% CI 1.13 to 1.29, 1 study, n = 974, low quality of evidence) and SCORAD. </p> <p>Based on data from 2 trials, tacrolimus 0.03% was superior to mild TCS for the physician's assessment (RR 2.58, 95% CI 1.96 to 3.38, 2 studies, n = 790, moderate‐quality evidence) and the participant's self‐assessment (RR 1.64, 95% CI 1.41 to 1.90, 1 study, n = 416, moderate quality of evidence). One trial showed moderate benefit of tacrolimus 0.03% compared with pimecrolimus 1% on the physician's assessment (RR 1.42, 95% CI 1.02 to 1.98, 1 study, n = 139, low‐quality evidence), but the effects were equivocal when evaluating BSA. In the comparison of tacrolimus 0.03% with moderate‐to‐potent corticosteroids, no difference was found in most of the outcomes measured (including physician's and participant's assessment and also for the secondary outcomes), but in two studies, a marginal benefit favouring the corticosteroid group was found for the EASI and BSA scores. </p> <p>Burning was more frequent in those using calcineurin inhibitors than those using corticosteroid tacrolimus 0.03% (RR 2.48, 95% CI 1.96 to 3.14, 5 studies, 1883 participants, high‐quality evidence), but no difference was found for skin infections. Symptoms observed were mild and transient. The comparison between the two calcineurin inhibitors (pimecrolimus and tacrolimus) showed the same overall incidence of adverse events, but with a small difference in the frequency of local effects. </p> <p>Serious adverse events were rare; occurred in both the tacrolimus and corticosteroid groups; and in most cases, were considered to be unrelated to the treatment. No cases of lymphoma were noted in the included studies nor in the non‐comparative studies. Cases were only noted in spontaneous reports, cohorts, and case‐control studies. Systemic absorption was rarely detectable, only in low levels, and this decreased with time. Exception is made for diseases with severe barrier defects, such as Netherton's syndrome, lamellar ichthyosis, and a few others, with case reports of a higher absorption. We evaluated clinical trials; case reports; and in vivo, in vitro, and animal studies; and didn't find any evidence that topical tacrolimus could cause skin atrophy. </p> </section> <section id="CD009864-sec-0007"> <h3 class="title" id="CD009864-sec-0007">Authors' conclusions</h3> <p>Tacrolimus 0.1% was better than low‐potency corticosteroids, pimecrolimus 1%, and tacrolimus 0.03%. Results were equivocal when comparing both dose formulations to moderate‐to‐potent corticosteroids. Tacrolimus 0.03% was superior to mild corticosteroids and pimecrolimus. Both tacrolimus formulations seemed to be safe, and no evidence was found to support the possible increased risk of malignancies or skin atrophy with their use. The reliability and strength of the evidence was limited by the lack of data; thus, findings of this review should be interpreted with caution. We did not evaluate costs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009864-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009864-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009864-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009864-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009864-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009864-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009864-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD009864-abs-0006">Polski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009864-abs-0002" lang="en"> <h3>Topical tacrolimus for atopic dermatitis</h3> <p><b>Background</b> </p> <p>Atopic dermatitis (AD) (or atopic eczema) is a chronic skin condition that affects the quality of life of both adults and children. Topical corticosteroids (TCS) are the main ointments used for treatment, but there is a risk of side‐effects with their use, such as skin thinning. A class of drugs called topical calcineurin inhibitors, which include topical tacrolimus (and pimecrolimus), might provide an alternative to this problem, but since tacrolimus is a newer ointment compared with corticosteroids, there are still some questions about its effectiveness and safety. </p> <p><b>Review question</b> </p> <p>Is tacrolimus ointment an effective and safe alternative to other treatments for moderate to severe atopic dermatitis (in children and adults)? </p> <p><b>Study characteristics</b> </p> <p>We included 20 studies, with 5885 participants, in this review. We searched for studies until June 2015. We were interested in the physicians' assessment of improvement, the participants' self‐assessment, and any adverse effects. Other outcomes were by objective measures of improvement, such as SCORAD (SCORing Atopic Dermatitis, a tool for measuring atopic dermatitis severity) and the affected body surface area. </p> <p><b>Key results</b> </p> <p>We found tacrolimus 0.1% to be better than low‐potency TCS on the face and neck areas and moderate‐potency TCS on the trunk and extremities. We evaluated the physician's assessment of pimecrolimus 1% and tacrolimus 0.03% in most of the studies. When compared with moderate‐to‐potent corticosteroids, there was a marginal benefit favouring tacrolimus 0.1% by the participant's self‐assessment and SCORAD. </p> <p>Combined results of 2 studies indicated that tacrolimus 0.03% more than doubled the chance of achieving improvement by the physician's assessment compared with mild TCS. Another study found tacrolimus 0.03% to be better than pimecrolimus 1% for the same outcome, while no difference was found on the body surface area of skin affected with disease. For the comparison with moderate‐to‐potent corticosteroids, we found no significant difference in most of the results, but in two studies, we found a slight difference favouring the corticosteroids group. </p> <p>Burning and itching were more frequent in those using tacrolimus than TCS, but we found no difference in skin infection. Symptoms were mild and temporary. The comparison between pimecrolimus and tacrolimus showed the same overall frequency of side‐effects, with local side‐effects being more frequent in the tacrolimus groups. Tacrolimus also showed a longer duration of the local symptoms, between 30 minutes and 12 hours, while pimecrolimus users experienced symptoms for less than 30 minutes. </p> <p>Serious adverse events were rare, occurred both in tacrolimus and TCS groups, and were considered to be unrelated to treatment in most instances. No cases of lymphoma (a type of cancer of the lymph nodes) were noted in the included studies nor in the non‐comparative studies. Cases were only noted retrospectively in studies and reports, with no confirmed relation to the drug. </p> <p>Systemic absorption (substance entering the bloodstream) was rarely detectable, only in low levels and decreased with time. Only in diseases with severe skin barrier problems, such as Netherton's syndrome, lamellar ichthyosis (rare genetic disorders), and a few others, were there case reports of systemic absorption. </p> <p>After evaluating clinical trials, case reports, human and animal studies, we found a lack of evidence associating the use of topical tacrolimus with skin thinning. </p> <p>In summary, tacrolimus ointment seems to be safe and effective for moderate to severe atopic dermatitis in children and adults. It should be used with caution, though, in those having diseases with a severely damaged skin barrier. We found no risk of skin thinning with its use, even for longer periods. We did not find any evidence associating a risk of malignancies with the use of topical tacrolimus. We did not evaluate costs in this review. </p> <p><b>Quality of the evidence</b> </p> <p>The variability of drug doses, results, and follow‐up periods made it difficult to combine the results. The lack of data limited the reliability and strength of the evidence; thus, findings of this review should be interpreted with caution. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009864-sec-0136" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009864-sec-0136"></div> <h3 class="title" id="CD009864-sec-0137">Implications for practice</h3> <section id="CD009864-sec-0137"> <p>Tacrolimus ointment seems to be safe and effective for the treatment of moderate to severe atopic dermatitis in both children and adults. Systemic absorption of tacrolimus may be high in those who have skin diseases that present with permanent severe impairment in the integrity of the skin barrier. Within the context of this review, there is a lack of evidence to support the U.S. Food and Drug Administration's warning of increased risk of malignancies associated with the use of topical tacrolimus. </p> </section> <h3 class="title" id="CD009864-sec-0138">Implications for research</h3> <section id="CD009864-sec-0138"> <p>It was not the objective of this review to evaluate only specific areas of treatment, such as the face and neck region, but this might be an important subject for a future review, since these sensitive areas might be more prone to adverse events of local treatments. </p> <p>Standardisation of outcomes and interventions in trials analysing the same topic should be developed, so that a comparison and combination of results can be better achieved. This review found a good number of well‐designed studies, but as stated earlier, the variability of drug doses, outcomes, and follow‐up periods made ​​it difficult to carry out an adequate meta‐analysis. More studies looking at the population of infants with atopic dermatitis are needed. </p> <p>In terms of safety, in spite of the fact that longer duration trials are lacking, the data available from observational and cohort studies, despite the lower methodological quality, should also be taken into account, since other study designs hardly demonstrate rare events, such as lymphomas. A promising 10‐year prospective registry (planned N = 8000) was created to assess the risk of malignancies in children associated with topical tacrolimus ointment use ('A Prospective Pediatric Longitudinal Evaluation to Assess the Long‐Term Safety (APPLES) of tacrolimus ointment for the treatment of atopic dermatitis' (<a href="./references#CD009864-bbs2-0045" title="NCT00475605 . APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long‐Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT00475605 (accessed 8 October 2014). ">NCT00475605</a>)). APPLES includes participants no older than 16 years of age and was initiated in 2005. The results of this promising study will most definitely contribute to significant and valuable data on this subject. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009864-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009864-sec-0015"></div> <div class="table" id="CD009864-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tacrolimus 0.1% compared with corticosteroids for atopic dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus 0.1% compared with corticosteroids for atopic dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atopic dermatitis<br/> <b>Settings:</b> outpatients, Europe and Canada </p> <p><b>Intervention:</b> tacrolimus 0.1%<br/> <b>Comparison:</b> corticosteroids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.1%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.1% versus hydrocortisone acetate 0.1%: 3 weeks</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.09</b> <br/> (2.14 to 4.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>371<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>157 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>484 per 1000</b> <br/> (335 to 698) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>157 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>485 per 1000</b> <br/> (336 to 699) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.1% versus hydrocortisone butyrate: 3 weeks</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> <br/> (0.78 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>377<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹<sup>,</sup> ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>490 per 1000</b> <br/> (403 to 599) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>490 per 1000</b> <br/> (402 to 599) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: short term (6 months)</b> <br/> Follow‐up: 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.32</b> <br/> (1.17 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>972<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>464 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>612 per 1000</b> <br/> (543 to 691) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>464 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>612 per 1000</b> <br/> (543 to 691) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone acetate 0.1%: 3 weeks</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.91</b> <br/> (1.6 to 5.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>371<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> <br/> (112 to 371) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> <br/> (112 to 370) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone butyrate: 3 weeks</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.59</b> <br/> (3.1 to 6.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>377<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>592 per 1000</b> <br/> (400 to 875) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>592 per 1000</b> <br/> (400 to 875) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: 6 months</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.79</b> </p> <p>(2.99 to 4.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>972</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>524 per 1000</b> </p> <p>(413 to 664)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>524 per 1000</b> </p> <p>(413 to 664)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Participant's self‐assessment of global response of improvement</b> </p> <p>Follow‐up: mean 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>RR 1.21</b> </p> <p>(1.13 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>974</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b>¹<sup>,</sup> ³ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>718 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>868 per 1000</b> </p> <p>(811 to 926)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>718 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>869 per 1000</b> </p> <p>(811 to 926)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to publication bias because only one study was identified and publication bias was strongly suspected.<br/> ²Downgraded one level due to Imprecision: sample size falls below the optimal information size; 95% CI of the estimated effect includes both no effect and appreciable benefit.<br/> ³Downgraded one level due to Imprecision: sample size falls below the optimal information size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009864-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tacrolimus 0.1% compared with pimecrolimus 1% for atopic dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus 0.1% compared with pimecrolimus 1% for atopic dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atopic dermatitis<br/> <b>Settings:</b> outpatients, USA<br/> <b>Intervention:</b> tacrolimus 0.1%<br/> <b>Comparison:</b> pimecrolimus 1% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Pimecrolimus 1%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.1%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.8</b> <br/> (1.34 to 2.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>506<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b> <br/> (270 to 488) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>199 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>358 per 1000</b> <br/> (267 to 482) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ 6 weeks</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.89</b> <br/> (0.47 to 1.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>506<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> <br/> (108 to 392) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b> <br/> (107 to 388) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to publication bias because only one study was identified and publication bias was strongly suspected.<br/> ²Downgraded one level due to inconsistency: there is moderate level of heterogeneity between studies: I² value of 69%.<br/> ³Downgraded one level due to imprecision: 95% CI of the estimate of summary effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009864-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Tacrolimus 0.03% compared with corticosteroids for atopic dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus 0.03% compared with corticosteroids for atopic dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atopic dermatitis<br/> <b>Settings:</b> outpatients, Europe, Tunisia, Pakistan, Morocco, Taiwan<br/> <b>Intervention:</b> tacrolimus 0.03%<br/> <b>Comparison:</b> corticosteroids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Ilustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.03%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.03% 1x/day versus hydrocortisone acetate 1% 2x/day</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.05</b> <br/> (1.36 to 3.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>411<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>136 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>279 per 1000</b> <br/> (185 to 419) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>136 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>279 per 1000</b> <br/> (185 to 419) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.58</b> <br/> (1.96 to 3.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>790<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>376 per 1000</b> <br/> (286 to 493) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>377 per 1000</b> <br/> (286 to 493) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.03% 2x/day versus corticosteroids moderate‐potency 2x/day</b> <br/> Follow‐up: 3 to 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.45</b> <br/> (0.13 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>409<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>527 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> <br/> (69 to 828) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>591 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>266 per 1000</b> <br/> (77 to 928) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.03% 2x/day versus methylprednisolone 0.03% 1x/day</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1</b> <br/> (0.85 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>265<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> <br/> (567 to 793) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> <br/> (567 to 794) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: burning ‐ tacrolimus 0.03% versus steroids</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR2.48</b> <br/> (1.96 to 3.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1883<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>221 per 1000</b> <br/> (174 to 279) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>174 per 1000</b> <br/> (137 to 220) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Participant's self‐assessment of global response of improvement: tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day</b> </p> <p>Follow‐up: 3 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>RR 1.64</b> </p> <p>(1.41 to 1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>416</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>505 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>828 per 1000</b> </p> <p>(712 to 959)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>505 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>828 per 1000</b> </p> <p>(712 to 959)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to publication bias because only very small number of studies were identified and publication bias was strongly suspected.<br/> ²Downgraded one level due to inconsistency: there is moderate level of heterogeneity between studies: I² value of 79%.<br/> ³Downgraded one level due to imprecision: 95% CI of estimated summary effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009864-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Tacrolimus 0.03% compared with tacrolimus 0.1% for atopic dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus 0.03% compared with tacrolimus 0.1% for atopic dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atopic dermatitis<br/> <b>Settings:</b> outpatients, USA, Japan, China<br/> <b>Intervention:</b> tacrolimus 0.03%<br/> <b>Comparison:</b> tacrolimus 0.1% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.1%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.03%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent</b> <br/> Follow‐up: 3 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.82</b> <br/> (0.72 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1640<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>430 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>353 per 1000</b> <br/> (310 to 396) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>445 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b> <br/> (320 to 409) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> <br/> (0.86 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>986<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>573 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>544 per 1000</b> <br/> (492 to 607) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>426 per 1000</b> <br/> (385 to 475) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to imprecision: sample size is below the optimal information size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009864-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Tacrolimus 0.03% versus pimecrolimus 1% for atopic dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus 0.03% versus pimecrolimus 1% for atopic dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atopic dermatitis<br/> <b>Settings:</b> outpatients, USA<br/> <b>Intervention:</b> tacrolimus 0.03% versus pimecrolimus 1% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.03% versus pimecrolimus 1%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.42</b> <br/> (1.02 to 1.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>139<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹<sup>,</sup> ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>609 per 1000</b> <br/> (437 to 849) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>609 per 1000</b> <br/> (438 to 849) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ application site reaction</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.07</b> <br/> (0.6 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>141<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b> <br/> (144 to 457) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b> <br/> (143 to 456) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ burning</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.87</b> <br/> (0.43 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>141<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>197 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>172 per 1000</b> <br/> (85 to 345) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>197 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> <br/> (85 to 345) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ itching</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.37</b> <br/> (0.96 to 5.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>141<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> (81 to 491) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b> <br/> (82 to 494) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ erythema</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.2</b> <br/> (0.89 to 5.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>141<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>186 per 1000</b> <br/> (75 to 461) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>187 per 1000</b> <br/> (76 to 464) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to imprecision: sample size is smaller than the optimal information size.<br/> ²Downgraded one level due to publication bias because only one study was identified and publication bias was strongly suspected.<br/> ³Downgraded one level due to imprecision: 95% CI of the estimate of summary effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009864-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Tacrolimus 0.1% versus ciclosporin for atopic dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus 0.1% versus ciclosporin for atopic dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atopic dermatitis<br/> <b>Settings:</b> outpatients, Italy<br/> <b>Intervention:</b> tacrolimus 0.1% versus ciclosporin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.1% versus ciclosporin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1</b> <br/> (0.31 to 3.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> <br/> (83 to 875) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> <br/> (83 to 876) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to risk of bias: randomisation and allocation concealment procedures were unclear.<br/> ²Downgraded one level due to imprecision: sample size is smaller than optimal information size; 95% CI of the estimate of summary effect includes both no effect and appreciable benefit and harm.<br/> ³Downgraded one level due to publication bias because only one study was identified and publication bias was strongly suspected. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009864-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009864-sec-0016"></div> <section id="CD009864-sec-0017"> <h3 class="title" id="CD009864-sec-0017">Description of the condition</h3> <p>Atopic dermatitis (AD) is a chronic inflammatory skin condition, with periods of inflammation and periods of relapse (<a href="./references#CD009864-bbs2-0114" title="McCollumAD , PaikA , EichenfieldLF . The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatric Dermatology2010;27(5):425‐36. [MEDLINE: 20678096] ">McCollum 2010</a>). It mainly affects infants and young children, but it can persist or relapse in adulthood. Symptoms can also start in adulthood (<a href="./references#CD009864-bbs2-0079" title="EllisCN , ManciniAJ , PallerAS , SimpsonEL , EichenfieldLF . Understanding and managing atopic dermatitis in adult patients. Seminars in Cutaneous Medicine &amp; Surgery2012;31(3 Suppl):S18‐22. [MEDLINE: 23021781] ">Ellis 2012</a>). Clinically, this condition has an acute phase with red scaly patches and a chronic phase with lichenification (skin thickening). In children under two years of age, atopic dermatitis typically occurs on the face as well as the trunk and limbs. In older children and adults, it is found more often on the neck and flexor surfaces (on the inside of the joints, such as the knees and elbows). This is the typical distribution, although any part of the body can be affected (<a href="./references#CD009864-bbs2-0046" title="AkdisCA , AkdisM , BieberT , Bindslev‐JensenC , BoguniewiczM , EigenmannP , et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy2006;61(8):969‐987. [MEDLINE: 16867052] ">Akdis 2006</a>; <a href="./references#CD009864-bbs2-0063" title="BosJD , BrenninkmeijerEE , SchramME , Middelkamp‐HupMA , SpulsPI , SmittJH . Atopic eczema or atopiform dermatitis. Experimental Dermatology2010;19(4):325‐31. [MEDLINE: 20100192] ">Bos 2010</a>). Hand eczema is also a possible manifestation of atopic dermatitis, but it can have other causes, including contact dermatitis (with or without atopy, see below) or idiopathic hand eczema (where the cause is unknown) (<a href="./references#CD009864-bbs2-0082" title="WolffK , GoldsmithLA , KatzSI , GilchrestBA , PallerAS , LeffellDJ . Fitzpatrick's Dermatology in General Medicine. 7th Edition. Vol. 1, United States: The McGraw‐Hill Companies, 2008. ">Fitzpatrick 2008</a>). Itch is a hallmark of the disease, and those affected also tend to have dry skin (<a href="./references#CD009864-bbs2-0062" title="BoguniewiczM , LeungDY . Atopic Dermatitis. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl Mini‐Primer):S475‐S480. [MEDLINE: 16455350] ">Boguniewicz 2006</a>). </p> <p>The term 'atopy' should only refer to those with confirmed immunoglobulin E (IgE) hypersensitivity reactions, where either the finding of specific IgE antibodies in the blood or a skin prick test positive to common allergens has been made (<a href="./references#CD009864-bbs2-0057" title="Bath‐HextallFJ , DelamereFM , WilliamsHC . Dietary exclusions for established atopic eczema. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD005203.pub2] ">Bath‐Hextall 2008</a>). An immunoglobulin is an antibody used by the immune system to identify and neutralise other proteins foreign to the individual (<a href="./references#CD009864-bbs2-0115" title="MedlinePlus® . Medical Dictionary. http://www.merriam‐webster.com/medlineplus/antibody (accessed 30 July 2013). ">Medline Plus® a</a>). The skin prick test to identify common allergens is a method used for the diagnosis of allergies, which tries to provoke small, controlled allergic reactions (<a href="./references#CD009864-bbs2-0116" title="MedlinePlus® . Medical Dictionary. http://www.merriam‐webster.com/medlineplus/prick%20test (accessed 30 July 2013). ">Medline Plus® b</a>). However, 40% of children with atopic dermatitis do not have atopy (<a href="./references#CD009864-bbs2-0066" title="BöhmeM , SvenssonA , KullI , NordvallSL , WahlgrenCF . Clinical features of atopic dermatitis at two years of age: a prospective, population‐based case‐control study. Acta Dermato‐Venereologica2001;81(3):193‐7. [MEDLINE: 11558876] ">Böhme 2001</a>). In a recent review of allergy nomenclature, a proposal was made to replace the previously used terms 'atopic dermatitis' or 'atopic eczema' with the term 'eczema', including in this term both those with and without atopy (<a href="./references#CD009864-bbs2-0063" title="BosJD , BrenninkmeijerEE , SchramME , Middelkamp‐HupMA , SpulsPI , SmittJH . Atopic eczema or atopiform dermatitis. Experimental Dermatology2010;19(4):325‐31. [MEDLINE: 20100192] ">Bos 2010</a>; <a href="./references#CD009864-bbs2-0098" title="JohanssonSG , BieberT , DahlR , FriedmannPS , LanierBQ , LockeyRF , et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy &amp; Clinical Immunology2004;113(5):832‐6. [MEDLINE: 15131563] ">Johansson 2004</a>). Since this is a recently defined term and still not used by all authors, we used the term 'atopic dermatitis' in this review, even in those people without IgE hypersensitivity. </p> <p>There has been an increase in the prevalence of atopic dermatitis in recent decades, and it has become a public health issue in industrialised countries, where the prevalence stays at around 10% to 20% in children and 1% to 3% in adults (<a href="./references#CD009864-bbs2-0053" title="AshcroftDM , DimmockP , GarsideR , SteinK , WilliamsHC . Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta‐analysis of randomised controlled trials. BMJ2005;330(7490):516. [MEDLINE: 15731121] ">Ashcroft 2005</a>; <a href="./references#CD009864-bbs2-0081" title="FinchJ , MunhutuMN , Whitaker‐WorthDL . Atopic dermatitis and nutrition. Clinics in Dermatology2010;28(6):605‐14. [MEDLINE: 21034985] ">Finch 2010</a>; <a href="./references#CD009864-bbs2-0082" title="WolffK , GoldsmithLA , KatzSI , GilchrestBA , PallerAS , LeffellDJ . Fitzpatrick's Dermatology in General Medicine. 7th Edition. Vol. 1, United States: The McGraw‐Hill Companies, 2008. ">Fitzpatrick 2008</a>). Multicentre ecological studies in many countries around the world also confirmed this high prevalence, with differences encountered between and within countries (<a href="./references#CD009864-bbs2-0056" title="AsherMI , StewartAW , MallolJ , MontefortS , LaiCK , Aït‐KhaledN , et al. Which population level environmental factors are associated with asthma, rhinoconjunctivitis and eczema? Review of the ecological analyses of ISAAC Phase One. Respiratory Research2010;11:8. [MEDLINE: 20092649] ">Asher 2010</a>; <a href="./references#CD009864-bbs2-0092" title="HarropJ , ChinnS , VerlatoG , OlivieriM , NorbäckD , WjstM , et al. Eczema, atopy and allergen exposure in adults: a population‐based study. Clinical &amp; Experimental Allergy2007;37(4):526‐35. [MEDLINE: 17430349] ">Harrop 2007</a>; <a href="./references#CD009864-bbs2-0121" title="OdhiamboJA , WilliamsHC , ClaytonTO , RobertsonCF , AsherMI , ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. Journal of Allergy &amp; Clinical Immunology2009;124(6):1251‐8. [MEDLINE: 20004783] ">Odhiambo 2009</a>; <a href="./references#CD009864-bbs2-0159" title="WilliamsH , RobertsonC , StewartA , Aït‐KhaledN , AnabwaniG , AndersonR , et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. Journal of Allergy &amp; Clinical Immunology1999;103(1 Pt 1):125‐38. [MEDLINE: 9893196] ">Williams 1999</a>). In agricultural countries, this rate is lower, which may be due to children having more intense contact with mites and infections in early childhood, providing a protective effect against allergy development. This is an explanation put forward by the hygiene hypothesis (<a href="./references#CD009864-bbs2-0082" title="WolffK , GoldsmithLA , KatzSI , GilchrestBA , PallerAS , LeffellDJ . Fitzpatrick's Dermatology in General Medicine. 7th Edition. Vol. 1, United States: The McGraw‐Hill Companies, 2008. ">Fitzpatrick 2008</a>; <a href="./references#CD009864-bbs2-0152" title="StrachanDP . Hay fever, hygiene, and household size. BMJ1989;299(6710):1259‐60. [MEDLINE: 2513902] ">Strachan 1989</a>). </p> <p>The exact cause of atopic dermatitis is not entirely clear, but it is probably due to the interaction between environmental and genetic factors (<a href="./references#CD009864-bbs2-0057" title="Bath‐HextallFJ , DelamereFM , WilliamsHC . Dietary exclusions for established atopic eczema. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD005203.pub2] ">Bath‐Hextall 2008</a>). What is already known is that affected individuals frequently have a damaged or defective skin barrier as well as alterations in the response of their immune system to immunological triggers (<a href="./references#CD009864-bbs2-0108" title="LugerTA . Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. Journal of the European Academy of Dermatology &amp; Venereology2011;25(3):251‐8. [MEDLINE: 21294777] ">Luger 2011</a>). The genes affecting the formation of epidermal barrier proteins, such as filaggrin, and other genes regulating the production of cytokines (inflammatory substances) that are involved in the immune response are likely to be involved (<a href="./references#CD009864-bbs2-0081" title="FinchJ , MunhutuMN , Whitaker‐WorthDL . Atopic dermatitis and nutrition. Clinics in Dermatology2010;28(6):605‐14. [MEDLINE: 21034985] ">Finch 2010</a>). </p> <p>The rate of staphylococcal colonisation (bacterial growth) on the skin is around 90% compared with only 5% in people with healthy skin. So, those with atopic dermatitis are more likely to develop infections (<a href="./references#CD009864-bbs2-0074" title="Czarnecka‐OperaczM , JenerowiczD . Topical calcineurin inhibitors in the treatment of atopic dermatitis ‐ an update on safety issues. Journal Der Deutschen Dermatologischen Gesellschaft2012;10(3):167‐72. [MEDLINE: 21974750] ">Czarnecka‐Operacz 2012</a>; <a href="./references#CD009864-bbs2-0109" title="MaciasES , PereiraFA , RietkerkW , SafaiB . Superantigens in dermatology. Journal of the American Academy of Dermatology2011;64(3):455‐72. [MEDLINE: 21315950] ">Macias 2011</a>). </p> <p>The role of diet, nutrition, and food allergy in the development, prevention, and treatment of atopic dermatitis is still controversial. In a Cochrane review on exclusion diets, with the exception "of an egg‐free diet in infants with a positive specific IgE to eggs", no evidence of benefit of dietary exclusions was found (<a href="./references#CD009864-bbs2-0057" title="Bath‐HextallFJ , DelamereFM , WilliamsHC . Dietary exclusions for established atopic eczema. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD005203.pub2] ">Bath‐Hextall 2008</a>). Phase one of the International Study of Asthma and Allergies in Childhood (ISAAC) (<a href="./references#CD009864-bbs2-0080" title="EllwoodP , AsherMI , BjörksténB , BurrM , PearceN , RobertsonCF . Diet and asthma, allergic rhinoconjunctivitis and atopic eczema symptom prevalence: an ecological analysis of the International Study of Asthma and Allergies in Childhood (ISAAC) data. ISAAC Phase One Study Group. European Respiratory Journal2001 Mar;17(3):436‐43. [MEDLINE: 11405522] ">Ellwood 2001</a>) tried to correlate the differences found in atopic dermatitis prevalence with the food intake characteristics of the participating countries. They found some negative associations, but with all the limitations of an ecological analysis. Because of all the controversial data and the methodological difficulties, caution should be taken in interpreting results and recommending dietary restrictions for children with atopic dermatitis (<a href="./references#CD009864-bbs2-0081" title="FinchJ , MunhutuMN , Whitaker‐WorthDL . Atopic dermatitis and nutrition. Clinics in Dermatology2010;28(6):605‐14. [MEDLINE: 21034985] ">Finch 2010</a>). </p> <p>The mechanism that generates pruritus (itch) in atopic dermatitis is still not completely understood, as antihistamines (a class of drugs that act against many types of pruritus) are not as effective in controlling itch in this condition as they are in other pruritic dermatoses (<a href="./references#CD009864-bbs2-0082" title="WolffK , GoldsmithLA , KatzSI , GilchrestBA , PallerAS , LeffellDJ . Fitzpatrick's Dermatology in General Medicine. 7th Edition. Vol. 1, United States: The McGraw‐Hill Companies, 2008. ">Fitzpatrick 2008</a>). An important part of any management of chronic atopic dermatitis is the avoidance or disruption of the scratch‐itch cycle, as anything that perpetuates these symptoms inevitably worsens the damage to the skin (<a href="./references#CD009864-bbs2-0063" title="BosJD , BrenninkmeijerEE , SchramME , Middelkamp‐HupMA , SpulsPI , SmittJH . Atopic eczema or atopiform dermatitis. Experimental Dermatology2010;19(4):325‐31. [MEDLINE: 20100192] ">Bos 2010</a>). </p> <section id="CD009864-sec-0018"> <h4 class="title">Impact of the disease</h4> <p>Atopic dermatitis has an important impact on an individual and their family. Many studies have assessed the ways in which it can affect quality of life. This disease can affect the social, emotional, and physical health of a person. Symptoms and visible lesions can cause behavioural problems, dependency, irritability, sleep loss, pain, itch, physical fatigue, shame, low self‐esteem, anxiety, problems with relationships, and emotional distress (<a href="./references#CD009864-bbs2-0111" title="MaksimovićN , JankovićS , MarinkovićJ , SekulovićLK , ZivkovićZ , SpirićVT . Health‐related quality of life in patients with atopic dermatitis. Journal of Dermatology2012;39(1):42‐7. [MEDLINE: 22044078] ">Maksimovic 2012</a>). There is also an important economic impact due to frequent visits to physicians, frequent treatments, and days lost at work, which may lead to less opportunities (<a href="./references#CD009864-bbs2-0064" title="BrenninkmeijerEE , LegierseCM , Sillevis SmittJH , LastBF , GrootenhuisMA , BosJD . The course of life of patients with childhood atopic dermatitis. Pediatric Dermatology2009 Jan‐Feb;26(1):14‐22. [MEDLINE: 19250399] ">Brenninkmeijer 2009</a>; <a href="./references#CD009864-bbs2-0070" title="ChamlinSL , FriedenIJ , WilliamsML , ChrenMM . Effects of atopic dermatitis on young American children and their families. Pediatrics2004;114(3):607‐11. [MEDLINE: 15342828] ">Chamlin 2004</a>). The severity of the disease bears a close relation to the degree of impact on a person's quality of life. The estimated annual costs of illness are high: billions of dollars in some high‐income countries, such as the UK, the US, and Germany (<a href="./references#CD009864-bbs2-0053" title="AshcroftDM , DimmockP , GarsideR , SteinK , WilliamsHC . Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta‐analysis of randomised controlled trials. BMJ2005;330(7490):516. [MEDLINE: 15731121] ">Ashcroft 2005</a>). </p> </section> <section id="CD009864-sec-0019"> <h4 class="title">Treatment options</h4> <p>Emollients are the basic treatment for atopic dermatitis, and they are used in both acute and chronic phases; they do not reduce inflammation of acute lesions, but in all phases of treatment, they act by helping to hydrate the skin and restore or keep the integrity of the epidermal barrier (<a href="./references#CD009864-bbs2-0076" title="EichenfieldLF , TomWL , ChamlinSL , FeldmanSR , HanifinJM , SimpsonEL , et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology2014;70(2):338‐51. [MEDLINE: 24290431] ">Eichenfield 2014</a>). Acute flares, though, must be taken care of with additional therapeutic options (<a href="./references#CD009864-bbs2-0108" title="LugerTA . Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. Journal of the European Academy of Dermatology &amp; Venereology2011;25(3):251‐8. [MEDLINE: 21294777] ">Luger 2011</a>). </p> <p>Traditionally, topical corticosteroids (TCS) are the most commonly used topical agents (<a href="./references#CD009864-bbs2-0096" title="HultschT , KappA , SpergelJ . Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology2005;211(2):174‐87. [MEDLINE: 16088174] ">Hultsch 2005</a>). They act via a number of pathways to reduce inflammation (<a href="./references#CD009864-bbs2-0108" title="LugerTA . Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. Journal of the European Academy of Dermatology &amp; Venereology2011;25(3):251‐8. [MEDLINE: 21294777] ">Luger 2011</a>). They are an effective treatment though with potential adverse effects, most of which are local to the site of application; however, they can occasionally cause adverse effects systemically (<a href="./references#CD009864-bbs2-0053" title="AshcroftDM , DimmockP , GarsideR , SteinK , WilliamsHC . Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta‐analysis of randomised controlled trials. BMJ2005;330(7490):516. [MEDLINE: 15731121] ">Ashcroft 2005</a>; <a href="./references#CD009864-bbs2-0034" title="NeumannE , AmtageD , Bruckner‐TudermanL , MockenhauptM . A single‐center open‐label long‐term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis. Journal Der Deutschen Dermatologischen Gesellschaft2008;6(7):548‐53. [MEDLINE: 18248495] ">Neumann 2008</a>). </p> <p>Topical corticosteroids can cause skin thinning, telangiectasias (visible enlarged blood vessels on the skin), and striae (linear depressions of the skin with skin thinning) (<a href="./references#CD009864-bbs2-0082" title="WolffK , GoldsmithLA , KatzSI , GilchrestBA , PallerAS , LeffellDJ . Fitzpatrick's Dermatology in General Medicine. 7th Edition. Vol. 1, United States: The McGraw‐Hill Companies, 2008. ">Fitzpatrick 2008</a>). Other effects include perioral dermatitis, tinea incognito, corticosteroid‐induced acne, rosacea (chronic inflammation of the skin on the face), and hypertrichosis (excessive hair growth) (<a href="./references#CD009864-bbs2-0050" title="AntilleC , SauratJH , LubbeJ . Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Archives of Dermatology2004;140(4):457‐60. [MEDLINE: 15096374] ">Antille 2004</a>; <a href="./references#CD009864-bbs2-0085" title="FujiwaraS , OkuboY , IrisawaR , TsuboiR . Rosaceiform dermatitis associated with topical tacrolimus treatment. Journal of the American Academy of Dermatology2010;62(6):1050‐2. [MEDLINE: 20466178] ">Fujiwara 2010</a>; <a href="./references#CD009864-bbs2-0155" title="TerakiY , HitomiK , SatoY , IzakiS . Tacrolimus‐induced rosacea‐like dermatitis: a clinical analysis of 16 cases associated with tacrolimus ointment application. Dermatology2012;224(4):309‐14. [MEDLINE: 22626964] ">Teraki 2012</a>). Systemic absorption can cause hormonal changes, with adrenal gland suppression, higher blood glucose and blood pressure levels, and an alteration in bone density (<a href="./references#CD009864-bbs2-0042" title="WonCH , SeoPG , ParkYM , YangJM , LeeKH , SungKJ , et al. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. Journal of Dermatological Treatment2004;15(1):30‐4. [MEDLINE: 14754647] ">Won 2004</a>). People with atopic dermatitis and parents of children being treated with corticosteroids are usually worried about all of the possible adverse effects, causing a "corticosteroid phobia"; this can lead to incorrect use of the medication, with less frequent applications and shorter periods of treatment (<a href="./references#CD009864-bbs2-0114" title="McCollumAD , PaikA , EichenfieldLF . The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatric Dermatology2010;27(5):425‐36. [MEDLINE: 20678096] ">McCollum 2010</a>). As these side‐effects are greater with prolonged use and because of corticosteroid phobia, seeking other treatment options is important, especially for those with moderate to severe atopic dermatitis (<a href="./references#CD009864-bbs2-0055" title="AshcroftDM , ChenL , GarsideR , SteinK , WilliamsHC . Topical pimecrolimus for eczema. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005500.pub2] ">Ashcroft 2007</a>; <a href="./references#CD009864-bbs2-0108" title="LugerTA . Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. Journal of the European Academy of Dermatology &amp; Venereology2011;25(3):251‐8. [MEDLINE: 21294777] ">Luger 2011</a>). </p> <p>A corticosteroid‐sparing therapy has emerged for the treatment of moderate to severe atopic dermatitis; this therapy belongs to a class of agents called the topical calcineurin inhibitors (TCI): pimecrolimus and tacrolimus (<a href="./references#CD009864-bbs2-0136" title="RustinMH . The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. British Journal of Dermatology2007;157(5):861‐73. [MEDLINE: 17854353] ">Rustin 2007</a>). Calcineurin is a protein that can activate the immune system and the production of inflammatory substances (<a href="./references#CD009864-bbs2-0124" title="PatelTS , GreerSC , SkinnerRBJr . Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. American Journal of Clinical Dermatology2007;8(4):189‐94. [MEDLINE: 17645374] ">Patel 2007</a>). Tacrolimus and pimecrolimus are topical immunosuppressive agents. Systemic immunosuppressive therapies are reserved only for severe recalcitrant cases, because of their potentially serious adverse effects (<a href="./references#CD009864-bbs2-0055" title="AshcroftDM , ChenL , GarsideR , SteinK , WilliamsHC . Topical pimecrolimus for eczema. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005500.pub2] ">Ashcroft 2007</a>; <a href="./references#CD009864-bbs2-0135" title="RoekevischE , SpulsPI , KuesterD , LimpensJ , SchmittJ . Efficacy and safety of systemic treatments for moderate‐to‐severe atopic dermatitis: A systematic review. Journal of Allergy &amp; Clinical Immunology2014;133(2):429‐438. [MEDLINE: 24269258] ">Roekevisch 2014</a>; <a href="./references#CD009864-bbs2-0146" title="SimonD , BieberT . Systemic therapy for atopic dermatitis. Allergy2014;69(1):46‐55. [MEDLINE: 24354911] ">Simon 2014</a>). </p> </section> </section> <section id="CD009864-sec-0020"> <h3 class="title" id="CD009864-sec-0020">Description of the intervention</h3> <p>Topical tacrolimus is an immunomodulator; it might improve the control of acute flares and the prevention of new flares due to its immunomodulating mechanism of action (<a href="./references#CD009864-bbs2-0082" title="WolffK , GoldsmithLA , KatzSI , GilchrestBA , PallerAS , LeffellDJ . Fitzpatrick's Dermatology in General Medicine. 7th Edition. Vol. 1, United States: The McGraw‐Hill Companies, 2008. ">Fitzpatrick 2008</a>). It has a more selective action when compared with corticosteroids, with possible similar efficacy but less adverse events, making it more acceptable for long‐term use for this chronic condition (<a href="./references#CD009864-bbs2-0053" title="AshcroftDM , DimmockP , GarsideR , SteinK , WilliamsHC . Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta‐analysis of randomised controlled trials. BMJ2005;330(7490):516. [MEDLINE: 15731121] ">Ashcroft 2005</a>; <a href="./references#CD009864-bbs2-0055" title="AshcroftDM , ChenL , GarsideR , SteinK , WilliamsHC . Topical pimecrolimus for eczema. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005500.pub2] ">Ashcroft 2007</a>). It is generally well tolerated, but the most common adverse effect is skin burning at the site of application; however, irritation tends to decrease or stop within a week (<a href="./references#CD009864-bbs2-0065" title="BreuerK , WerfelT , KappA . Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. American Journal of Clinical Dermatology2005;6(2):65‐77. [MEDLINE: 15799678] ">Breuer 2005</a>). Topical tacrolimus is not associated with tachyphylaxis (a decrease in response to a drug after its administration); growth retardation; rebound effect (the tendency of some medications to cause a return of symptoms after sudden discontinuation) (<a href="./references#CD009864-bbs2-0065" title="BreuerK , WerfelT , KappA . Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. American Journal of Clinical Dermatology2005;6(2):65‐77. [MEDLINE: 15799678] ">Breuer 2005</a>; <a href="./references#CD009864-bbs2-0031" title="KangS , PallerA , SoterN , SatoiY , RicoMJ , HanifinJM . Safe treatment of head/neck AD with tacrolimus ointment. Journal of Dermatological Treatment2003;14(2):86‐94. [MEDLINE: 12775315] ">Kang 2003</a>); or irreversible local adverse effects, such as those that occur with TCS, making it a good corticosteroid‐sparing therapy for atopic dermatitis (<a href="./references#CD009864-bbs2-0058" title="BekerskyI , FitzsimmonsW , TanaseA , MaherRM , HodoshE , LawrenceI . Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. Journal of the American Academy of Dermatology2001;44(1 Suppl):S17‐27. [MEDLINE: 11145792] ">Bekersky 2001</a>; <a href="./references#CD009864-bbs2-0083" title="FK506 Ointment Study Group. Long‐term study of FK506 (tacrolimus) ointment in patients with atopic dermatitis ‐ analysis at time of completion of 2‐year observation. Journal of Clinical Therapeutics and Medicines2001;17(5):705‐726. ">FK506 Ointment Study Group 2001</a>; <a href="./references#CD009864-bbs2-0106" title="LottiT , BuggianiG , TroianoM , AssadGB , DelescluseJ , DeGiorgiV , et al. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatologic Therapy2008;21(Suppl 1):S20‐6. [MEDLINE: 18727812] ">Lotti 2008</a>). It is also of great importance for the treatment of the face, eyelids, and intertriginous areas, which may be more sensitive to the adverse effects of corticosteroids (<a href="./references#CD009864-bbs2-0025" title="DossN , ReitamoS , DubertretL , FeketeGL , KamounMR , LahfaM , et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double‐blind trial. British Journal of Dermatology2009;161(2):427‐34. [MEDLINE: 19416227] ">Doss 2009</a>; <a href="./references#CD009864-bbs2-0031" title="KangS , PallerA , SoterN , SatoiY , RicoMJ , HanifinJM . Safe treatment of head/neck AD with tacrolimus ointment. Journal of Dermatological Treatment2003;14(2):86‐94. [MEDLINE: 12775315] ">Kang 2003</a>). </p> <p>The U.S. Food and Drug Administration (FDA) first approved tacrolimus in 2000 for short‐term and non‐continuous treatment of moderate to severe atopic dermatitis, but it has also been used for many other diseases for which it is not licensed (<a href="./references#CD009864-bbs2-0024" title="DelRossoJQ , ConteET . An Investigator‐Blinded Evaluation of Fluocinonide 0.1% Cream in the Treatment of Atopic Dermatitis and Psoriasis Vulgaris. Cosmetic Dermatology2007;20(9):545‐52. [EMBASE: 2007500429] ">del Rosso 2007</a>; <a href="./references#CD009864-bbs2-0106" title="LottiT , BuggianiG , TroianoM , AssadGB , DelescluseJ , DeGiorgiV , et al. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatologic Therapy2008;21(Suppl 1):S20‐6. [MEDLINE: 18727812] ">Lotti 2008</a>; <a href="./references#CD009864-bbs2-0125" title="PitarchG , TorrijosA , MahiquesL , Sánchez‐CarazoJL , ForteaJM . Systemic absorption of topical tacrolimus in Pyoderma gangrenosum. Acta Dermato‐Venereologica2006;86(1):64‐65. [MEDLINE: 16585995] ">Pitarch 2006</a>; <a href="./references#CD009864-bbs2-0147" title="SkowronF , DalleS , MarcillyMC , BalmeB , ThomasL . Important systemic absorption of topical tacrolimus during treatment of severe pemphigus vulgaris. Annales de Dermatologie et de Venereologie2005;132(3):263‐5. [MEDLINE: 15924053] ">Skowron 2005</a>). Concern has been raised about the increased risk of malignancies with tacrolimus, such as skin cancer and lymphomas. The FDA announced in 2006 that the long‐term safety of tacrolimus had not been established. Since then, it has had a 'black box' warning (<a href="./references#CD009864-bbs2-0060" title="BergerTG , DuvicM , VanVoorheesAS , VanBeekMJ , FriedenIJ , American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. Journal of the American Academy of Dermatology2006;54(5):818‐23. [MEDLINE: 16635663] ">Berger 2006</a>). This warning was based on the possible risks of systemic absorption (already proved to be minimal) (<a href="./references#CD009864-bbs2-0091" title="HarperJ , SmithC , RubinsA , GreenA , JacksonK , ZigureS , et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. Journal of Investigative Dermatology2005;124(4):695‐9. [MEDLINE: 15816825] ">Harper 2005</a>), data from solid organ transplantation using the same drug (blood concentrations were much higher than with the topical use) (<a href="./references#CD009864-bbs2-0118" title="MitamuraT , DoiY , KawabeM , LiljaH , MotomuraM , OishiY , et al. Inhibitory potency of tacrolimus ointment on skin tumor induction in a mouse model of an initiation‐promotion skin tumor. Journal of Dermatology2011;38(6):562‐70. [MEDLINE: 21352294] ">Mitamura 2011</a>), animal studies (results not directly transferable to people) (<a href="./references#CD009864-bbs2-0124" title="PatelTS , GreerSC , SkinnerRBJr . Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. American Journal of Clinical Dermatology2007;8(4):189‐94. [MEDLINE: 17645374] ">Patel 2007</a>), and a few case reports (with no proven causative relation) (<a href="./references#CD009864-bbs2-0122" title="OrmerodAD . Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?. British Journal of Dermatology2005;153(4):701‐5. [MEDLINE: 16181449] ">Ormerod 2005</a>). This topic is still controversial, with no strong supporting evidence in the literature, leading to a large number of comments from different organisations against this 'black box' warning (<a href="./references#CD009864-bbs2-0060" title="BergerTG , DuvicM , VanVoorheesAS , VanBeekMJ , FriedenIJ , American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. Journal of the American Academy of Dermatology2006;54(5):818‐23. [MEDLINE: 16635663] ">Berger 2006</a>; <a href="./references#CD009864-bbs2-0107" title="LugerTA , GollnickH . Viewpoint of the German Dermatologic Society (DDG) concerning the decision of the American Food and Drug Administration (FDA) on the use of pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis (neurodermatitis) [Stellungnahme Der Deutschen Dermatologischen Gesellschaft (DDG) Zur Entscheidung Der Amerikanischen Arzneimittelbehorde (FDA) Uber Die Verwendung Von Pimecrolimus‐Creme Und Tacrolimus‐Salbe Zur Behandlung Der Atopischen Dermatitis (Neurodermitis)]. Journal Der Deutschen Dermatologischen Gesellschaft2005;3(6):415‐6. [MEDLINE: 15892843] ">Luger 2005</a>; <a href="./references#CD009864-bbs2-0134" title="RingJ , BarkerJ , BehrendtH , BraathenL , DarsowU , DubertretL , et al. Review of the potential photo‐cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. Journal of the European Academy of Dermatology &amp; Venereology2005;19(6):663‐71. [MEDLINE: 16268869] ">Ring 2005</a>; <a href="./references#CD009864-bbs2-0143" title="SegalAO , EllisAK , KimHL . CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy, Asthma, &amp; Clinical Immunology : Official Journal of the Canadian Society of Allergy &amp; Clinical Immunology2013;9(1):24. [MEDLINE: 23837743] ">Segal 2013</a>). </p> </section> <section id="CD009864-sec-0021"> <h3 class="title" id="CD009864-sec-0021">How the intervention might work</h3> <p>Topical tacrolimus acts by inhibiting calcineurin, thus, inhibiting T‐cell proliferation and the production of many inflammatory cytokines, such as interleukin (IL)‐2, IL‐3, IL‐4, IL‐12, tumour necrosis factor (TNF), and interferon (IFN)‐γ. Therefore, it may be effective in treating eczema, which is an immune‐mediated skin disorder (<a href="./references#CD009864-bbs2-0065" title="BreuerK , WerfelT , KappA . Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. American Journal of Clinical Dermatology2005;6(2):65‐77. [MEDLINE: 15799678] ">Breuer 2005</a>; <a href="./references#CD009864-bbs2-0136" title="RustinMH . The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. British Journal of Dermatology2007;157(5):861‐73. [MEDLINE: 17854353] ">Rustin 2007</a>). </p> </section> <section id="CD009864-sec-0022"> <h3 class="title" id="CD009864-sec-0022">Why it is important to do this review</h3> <p>Nowadays, topical corticosteroids are the first‐line therapy for atopic dermatitis. They have proven efficacy; however, they also have a confirmed risk of the associated development of adverse effects with chronic use. Since atopic dermatitis is a chronic disease and prolonged treatment is often necessary, the search for new treatments with less side‐effects is an important issue. </p> <p>Topical tacrolimus might be an excellent alternative to this problem, but since it is a newer agent compared with topical corticosteroids, there are still some questions about its efficacy and safety. Therefore, it is still a second‐line therapy. </p> <p>This review is of great importance in order to help establish more accurate guidance for the use of topical tacrolimus in this very prevalent skin disease, as well as assessing the risks associated with its use. </p> <p>The plans for this review were published as a protocol '<i>Topical tacrolimus for atopic dermatitis</i>' <a href="./references#CD009864-bbs2-0165" title="Cury MartinsJ , MartinsC , AokiV , Leonardi‐BeeJ , GoisAFT , IshiiHA , et al. Topical tacrolimus for atopic dermatitis. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD009864] ">Cury Martins 2012</a>. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009864-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009864-sec-0023"></div> <p>To assess the efficacy and safety of topical tacrolimus for moderate and severe atopic dermatitis compared with other active treatments. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009864-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009864-sec-0024"></div> <section id="CD009864-sec-0025"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009864-sec-0026"> <h4 class="title">Types of studies</h4> <p>We included all randomised controlled clinical studies, both published and unpublished.</p> </section> <section id="CD009864-sec-0027"> <h4 class="title">Types of participants</h4> <p>People with moderate to severe atopic dermatitis who a physician had diagnosed, with no restrictions on age, sex, or ethnicity. </p> </section> <section id="CD009864-sec-0028"> <h4 class="title">Types of interventions</h4> <p>Topical tacrolimus at any dose, course duration, and follow‐up time compared with other active treatments. </p> <p>We only considered including a placebo (vehicle) group in more complex comparisons of combined treatment approaches, e.g., topical corticosteroids alongside tacrolimus versus either tacrolimus plus placebo or topical corticosteroids plus placebo. </p> </section> <section id="CD009864-sec-0029"> <h4 class="title">Types of outcome measures</h4> <section id="CD009864-sec-0030"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009864-list-0001"> <li> <p>Physician's assessment of global response of improvement.</p> </li> <li> <p>Participant's self‐assessment of global response of improvement.</p> </li> <li> <p>Occurence and severity of adverse effects.</p> </li> </ol> </p> </section> <section id="CD009864-sec-0031"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009864-list-0002"> <li> <p>Improvement of disease assessed by a validated or objective measure, such as the following:</p> </li> </ol> <ul class="plain" id="CD009864-list-0003"> <li> <ul id="CD009864-list-0004"> <li> <p>affected Body Surface Area (BSA);</p> </li> <li> <p>Eczema Area and Severity Index (EASI);</p> </li> <li> <p>relapse (over a period of up to one year); or</p> </li> <li> <p>quality of life.</p> </li> </ul> </li> </ul> </p> <p>For validated scores and classification criteria, please see <a href="./appendices#CD009864-sec-0142">Appendix 1</a>. </p> <section id="CD009864-sec-0032"> <h6 class="title">Timing of outcome assessment</h6> <p>We used the end point closest to three months (one to six months) for short‐term benefit and the end point closest to three years (one year or longer) for longer‐term benefit. We considered the longer‐term data as the primary end point, since this was clinically more important for atopic dermatitis as it is a chronic inflammatory skin condition with a relapsing course. As most of the included studies reported short‐term data, we analysed only the rapid onset of improvement. </p> </section> <section id="CD009864-sec-0033"> <h6 class="title">Reactive treatment</h6> <p>This review focused on the reactive treatment of active eczema, leaving the preventive treatment aside, which is a separate topic that was recently reviewed by Schmitt et al (<a href="./references#CD009864-bbs2-0139" title="SchmittJ , vonKobyletzkiL , SvenssonA , ApfelbacherC . Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta‐analysis of randomized controlled trials. British Journal of Dermatology2011;164(2):415‐28. [MEDLINE: 20819086] ">Schmitt 2011</a>). </p> </section> </section> </section> </section> <section id="CD009864-sec-0034"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant randomised controlled clinical trials (RCTs) regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD009864-sec-0035"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases up to 3 June 2015:</p> <p> <ul id="CD009864-list-0005"> <li> <p>the Cochrane Skin Group Specialised Register using the following terms: (dermatitis or eczema or neurodermatitis) AND (tacrolimus or protopic or "fk 506" or fk506); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2014, Issue 9) using the search strategy in <a href="./appendices#CD009864-sec-0143">Appendix 2</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD009864-sec-0144">Appendix 3</a>; </p> </li> <li> <p>EMBASE via Ovid (from 1974) using the strategy in <a href="./appendices#CD009864-sec-0145">Appendix 4</a>; and </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <a href="./appendices#CD009864-sec-0146">Appendix 5</a>. </p> </li> </ul> </p> <p>We searched the following database using the on‐screen menus to navigate to the topic "topical immunomodulatory agents", up to 8 October 2014: </p> <p> <ul id="CD009864-list-0006"> <li> <p>the Global Resource of Eczema Trials. Centre of Evidenced Based Dermatology. Accessed at <a href="http://www.greatdatabase.org.uk" target="_blank">www.greatdatabase.org.uk</a>. </p> </li> </ul> </p> <section id="CD009864-sec-0036"> <h5 class="title">Trials registers</h5> <p>We searched the following trials registers up to 14 June 2015 using the following search terms: eczema, dermatitis, atopic dermatitis, topical calcineurin inhibitors, tacrolimus, FK506 and FK 506. </p> <p> <ul id="CD009864-list-0007"> <li> <p>The metaRegister of Controlled Trials (<a href="http://www.controlled-trials.com/" target="_blank">www.controlled‐trials.com</a>). </p> </li> <li> <p>The US National Institutes of Health Ongoing Trials Register (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>The Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au/" target="_blank">www.anzctr.org.au</a>). </p> </li> <li> <p>The World Health Organization International Clinical Trials Registry platform (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/trialsearch</a>). </p> </li> <li> <p>The EU Clinical Trials Register (<a href="http://www.clinicaltrialsregister.eu" target="_blank">www.clinicaltrialsregister.eu</a>). </p> </li> <li> <p>The Ongoing Skin Trials Register (<a href="http://www.nottingham.ac.uk/ongoingskintrials" target="_blank">www.nottingham.ac.uk/ongoingskintrials</a>). </p> </li> </ul> </p> </section> </section> <section id="CD009864-sec-0037"> <h4 class="title">Searching other resources</h4> <section id="CD009864-sec-0038"> <h5 class="title">References from included studies</h5> <p>We checked the bibliographies of included studies for further references to relevant trials. </p> </section> <section id="CD009864-sec-0039"> <h5 class="title">Unpublished literature</h5> <p>We contacted specialists in the field for any possibly relevant unpublished data.</p> </section> <section id="CD009864-sec-0040"> <h5 class="title">Adverse effects</h5> <p>We searched the following databases for reports of adverse effects in non‐randomised studies on 30 July 2013: </p> <p> <ul id="CD009864-list-0008"> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD009864-sec-0147">Appendix 6</a>; and </p> </li> <li> <p>EMBASE via Ovid (from 1974) using the strategy in <a href="./appendices#CD009864-sec-0148">Appendix 7</a>. </p> </li> </ul> </p> <p>We also scrutinised the U.S. Food and Drug Administration (FDA) websites with periodic reports of manufacturer and surveillance databases for both topical corticosteroids (TCS) and tacrolimus, with the purpose of identifying possible rare side‐effects, such as skin cancer and lymphomas (a cancer of the lymphocytes) that might not have been published. We did not include data from trials under scrutiny until a consensus was reached (see the Study Selection Form in <a href="./appendices#CD009864-sec-0149">Appendix 8</a>). </p> </section> </section> </section> <section id="CD009864-sec-0041"> <h3 class="title" id="CD009864-sec-0041">Data collection and analysis</h3> <section id="CD009864-sec-0042"> <h4 class="title">Selection of studies</h4> <p>After merging the search results and removing duplicate records, we examined titles and abstracts to select the relevant reports. Two authors (JCM and EMKS) independently screened the trials identified by the literature search. We retrieved and examined the full text of selected studies for compliance with eligibility criteria. We documented the reasons for exclusion of individual trials. We consulted a third author (CRM) for any disagreements in any stage of the analysis. </p> </section> <section id="CD009864-sec-0043"> <h4 class="title">Data extraction and management</h4> <p>Two authors (JCM and EMKS) extracted data independently and collected data on a paper data extraction form. We resolved discrepancies in the results by discussion. We collected the following information: study features (design, participants, interventions) and outcomes (types of outcome measures, timing of outcomes, adverse events). </p> </section> <section id="CD009864-sec-0044"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>In order to assess the risk of bias, we independently assessed the quality of the studies included in the review according to the criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009864-bbs2-0094" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We assessed the following domains, rating them as at low, unclear, or high risk of bias. </p> <p>(a) Was the sequence generation adequate?<br/> (b) Was allocation adequately concealed?<br/> (c) Was knowledge by participants, personnel, and outcome assessors of the allocated interventions adequately prevented during the study?<br/> (d) Were incomplete outcome data adequately addressed?<br/> (e) Are reports of the study free of selective outcome reporting?<br/> (f) Was the study apparently free of other problems that could put it at a high risk of bias, like baseline imbalance, deviation from the study protocol, early termination, and insensitive instruments used to measure outcomes? </p> <p>We reported these assessments for each individual study in the 'Risk of bias' table located in the '<a href="./references#CD009864-sec-0162" title="">Characteristics of included studies</a>' tables. We tried to contact the study author(s) to seek clarification in cases of uncertainty over data. </p> </section> <section id="CD009864-sec-0045"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous variables, we calculated risk ratios (RR) and 95% confidence intervals (CIs). For continuous outcomes that used similar scales, we calculated mean differences (MD) and 95% CIs. For continuous outcomes that used different scales, we calculated standardised mean differences (SMD) and 95% CIs. When study authors had not provided the necessary information, we inserted narratively any data from primary studies that were not parametric (e.g., effects reported as medians, quartiles, etc.) or without sufficient statistical information (e.g., standard deviations, number of participants, etc.). </p> </section> <section id="CD009864-sec-0046"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was based on the individual participant (unit to be randomised for interventions to be compared), i.e., the number of observations in the analysis should match the number of individuals randomised. </p> <p>We did not find any cross‐over studies that we considered adequate for inclusion in the meta‐analysis. If we had included them, we would have included the data using the results of paired analyses (<a href="./references#CD009864-bbs2-0078" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. [MEDLINE: 11914310] ">Elbourne 2002</a>). </p> </section> <section id="CD009864-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>For missing or unavailable data, we contacted the study authors for additional information. In case of non‐response, irrespective of the type of data, we reported dropout rates in the '<a href="./references#CD009864-sec-0162" title="">Characteristics of included studies</a>' tables of the review and, where possible, used intention‐to‐treat analysis (<a href="./references#CD009864-bbs2-0094" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>If appropriate, we would have imputed the missing data with replacement values. For dichotomous outcomes, we would have assumed the missing data were treatment failures, and for continuous outcomes, we would have imputed the mean observed. We would have performed sensitivity analyses excluding the participants with missing data to assess the strength of the results. </p> </section> <section id="CD009864-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>We qualified inconsistency among the pooled estimates using the I² statistic: ((Q ‐ df)/Q) x 100% test, where Q is the Chi² statistic and df represents the degree of freedom. This illustrates the percentage of the variability in effect estimates resulting from heterogeneity, rather than sampling error (<a href="./references#CD009864-bbs2-0094" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>The following represented the thresholds for the interpretation of the I² statistic:</p> <p> <ul id="CD009864-list-0009"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity; and</p> </li> <li> <p>75% to 100%: considerable heterogeneity (<a href="./references#CD009864-bbs2-0094" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </li> </ul> </p> </section> <section id="CD009864-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>In future updates of this review, if we include a sufficient number of studies assessing the same comparators and outcomes (at least 10), we will assess publication bias by drawing a funnel plot (trial effect versus trial size). </p> </section> <section id="CD009864-sec-0050"> <h4 class="title">Data synthesis</h4> <p>If we identified no substantial heterogeneity, we computed pooled estimates of the treatment effect for each outcome under a fixed‐effect model. Otherwise, if we identified substantial heterogeneity, we performed a random‐effects analysis. </p> </section> <section id="CD009864-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis included types of intervention and duration of follow up. We analysed combined data from both adults and children. If we found substantial heterogeneity and there were sufficient data, we investigated the possible causes by further exploring the impact of the condition on the individuals (i.e., participant characteristics, degree and duration of the intervention, adjuvant drugs) using subgroup analyses. </p> </section> <section id="CD009864-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>If there were an adequate number of studies, we would have performed sensitivity analyses based on separation of studies according to our assessment of the risk of bias of allocation concealment (high, low, or unclear) and blinding of outcome assessment (high, low, or unclear). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009864-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009864-sec-0053"></div> <section id="CD009864-sec-0054"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD009864-sec-0162" title="">Characteristics of included studies</a>; <a href="./references#CD009864-sec-0163" title="">Characteristics of excluded studies</a>. </p> <section id="CD009864-sec-0055"> <h4 class="title">Results of the search</h4> <p><a href="#CD009864-fig-0001">Figure 1</a> displays the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) study flow diagram. Seven hundred and seventy‐five records were identified through searching the Skin Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and LILACS (the Latin American and Caribbean Health Science Information database). One additional record was found in the trials registers and other sources. Of these 776 records, 7 were duplicates. We assessed a total of 769 records for eligibility. Of these, we excluded 720 after assessing the titles and abstracts. We identified one study as ongoing (<a href="./references#CD009864-bbs2-0045" title="NCT00475605 . APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long‐Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT00475605 (accessed 8 October 2014). ">NCT00475605</a>). We obtained the remaining 48 records and read them as full text articles. We further excluded 23 records and added 1 to studies awaiting classification (<a href="./references#CD009864-bbs2-0044" title="DrakeL , PrendergastM , MaherR , BrenemanD , KormanN , SatoiY , et al. The impact of tacrolimus ointment on health‐related quality of life of adult and pediatric patients with atopic dermatitis. Journal of the American Academy of Dermatology2001;44(1 Suppl):S65‐72. [MEDLINE: 11145797] ">Drake 2001</a>). We included the remaining 20 studies reported in 24 papers. </p> <div class="figure" id="CD009864-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD009864-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD009864-sec-0056"> <h4 class="title">Included studies</h4> <p>This review included 20 studies, with a total of 5885 participants. <a href="#CD009864-tbl-0007">Table 1</a> summarises the overall features of the different treatments and participants in the included studies. </p> <div class="table" id="CD009864-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of treatment and participants in included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number of participants </b> </p> <p><b> (n = 5885)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Age</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Follow up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Classification of AD</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0001" title="AntigaE , VolpiW , TorchiaD , FabbriP , CaproniM . Effects of tacrolimus ointment on Toll‐like receptors in atopic dermatitis. Clinical &amp; Experimental Dermatology2011;36(3):235‐41. [MEDLINE: 21070333] ">Antiga 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (21 to 65 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs hydrocortisone butyrate 0.1% ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (SCORAD)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0002" title="BieberT , VickK , Folster‐HolstR , Belloni‐FortinaA , StadtlerG , WormM , et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy2007;62(2):184‐9. [MEDLINE: 17298428] ">Bieber 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> <p>(2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment (BID) vs methylprednisolone aceponate 0.1% ointment (evening) and vehicle ointment (morning) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe flare (IGA &gt; 4) history of moderate to severe AD</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0003" title="BoguniewiczM , FiedlerVC , RaimerS , LawrenceID , LeungDY , HanifinJM . A randomized, vehicle‐controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy &amp; Clinical Immunology1998;102(4 Pt 1):637‐44. [MEDLINE: 9802373] ">Boguniewicz 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Older children</p> <p>(7 to 16 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment vs tacrolimus 0.1% ointment vs tacrolimus 0.3% ointment vs vehicle ointment (BID) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0004" title="CaproniM , TorchiaD , AntigaE , TerranovaM , VolpiW , delBiancoE , et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. British Journal of Dermatology2007;156(2):312‐9. [MEDLINE: 17223872] ">Caproni 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs hydrocortisone butyrate 0.1% ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (SCORAD)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0005" title="DossN , KamounMR , DubertretL , CambazardF , RemitzA , LahfaM , et al. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with moderate‐to‐severe atopic dermatitis: evidence from a randomized, double‐blind non‐inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy &amp; Immunology2010;21(2 Pt 1):321‐9. [MEDLINE: 19563466] ">Doss 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> <p>(2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment vs fluticasone 0.005% ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) and with prior inadequate response to topical corticosteroids </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0006" title="DouX , LiuL‐L , XieZ‐Q , ChenL‐J , LiL , FengS‐Y , et al. The impact of tacrolimus ointment on health‐related quality of life of Chinese adult and pediatric patients with atopic dermatitis (Chinese). Journal of Clinical Dermatology2006;35(1):50‐2. ">Dou 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment vs tacrolimus 0.1% ointment vs vehicle ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0007" title="DraelosZ , NayakA , PariserD , ShupackJL , ChonK , AbramsB , et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‐blind comparison. Journal of the American Academy of Dermatology2005;53(4):602‐9. [MEDLINE: 16198779] ">Draelos 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs pimecrolimus 1% cream (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (IGA)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0008" title="FleischerABJr , AbramovitsW , BrenemanD , JaraczE , US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment2007;18(3):151‐7. [MEDLINE: 17538803] ">Fleischer 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; = 16 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs pimecrolimus 1% cream (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (IGA)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0009" title="HanifinJM , LingMR , LangleyR , BrenemanD , RafalE . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. Journal of the American Academy of Dermatology2001;44(Suppl 1):S28‐38. [EMBASE: 2001020450] SoterNA , Fleischer JrAB , WebsterGF , MonroeE , LawrenceI . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. Journal of the American Academy of Dermatology2001;44(1 Suppl):S39‐46. [DOI: 10.1067/mjd.2001.109817; EMBASE: 2001020451] ">Hanifin 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>632</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; = 16 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs tacrolimus 0.03% ointment vs vehicle ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0010" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma, &amp; Immunology 007;98(1):51‐6. [MEDLINE: 17225720] ">Hung 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults and</p> <p>children</p> <p>(9 months to 33 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment (BID) alone or with fusidic acid 2% cream vs fluticasone propionate 0.05% cream (BID) alone or with fusidic acid 2% cream </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 (for safety)</p> <p>139 (for efficacy)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (2 to 17 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment vs pimecrolimus 1% cream (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate (IGA)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0012" title="Otsuki , M , Kawashima , M , Shibata , Y , Nakagawa , H , Harada , S . Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis‐Phase III Double‐blinded Comparison with Vehicle Ointment. Journal of Clinical Therapeutics &amp; Medicines (Rinsho Iyaku)2003;19:569‐95. ">Otsuki 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment vs tacrolimus 0.1% ointment vs vehicle ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0013" title="PacorML , DiLorenzoG , MartinelliN , MansuetoP , RiniGB , CorrocherR . Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clinical &amp; Experimental Allergy2004;34(4):639‐45. [MEDLINE: 15080819] ">Pacor 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults and</p> <p>children (13 to 45 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment (BID) vs ciclosporin 3 mg/kg orally</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0014" title="PallerA , EichenfieldLF , LeungDY , StewartD , AppellM . A 12‐week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology2001;44(1 Suppl):S47‐57. [MEDLINE: 11145795] ">Paller 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment vs tacrolimus 0.1% ointment vs vehicle ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0015" title="AbramovitsW , FleischerABJr , JaraczE , BrenemanD . Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology2008;7(12):1153‐8. [MEDLINE: 19137769] PallerAS , LebwohlM , FleischerABJr , AntayaR , LangleyRG , KirsnerRS , et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology2005;52(5):810‐22. [MEDLINE: 15858471] ">Paller 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs pimecrolimus 1% cream (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (IGA)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>570</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (16 to 70 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs tacrolimus 0.03% ointment vs hydrocortisone butyrate 0.1% ointment (BID) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>560</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs tacrolimus 0.03% ointment vs hydrocortisone acetate 1% ointment (BID) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment (OD) vs tacrolimus 0.03% ointment (BID) vs hydrocortisone acetate 1% ointment (BID) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>972</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; = 18 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs hydrocortisone butyrate 0.1% ointment (on trunk and extremities) and hydrocortisone acetate 1% ointment (on face and neck) (BID) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0020" title="Sikder MdAU , Al MamunS , KhanRM , ChowdhuryAH , KhanHM , HoqueMM . Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis ‐ An open randomized comparative study. Journal of Pakistan Association of Dermatologists2005;15(4):304‐12. [EMBASE: 2006159825] ">Sikder 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Older children (7 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment (BID) vs clobetasone butyrate 0.05% cream (BID) vs clobetasone butyrate 0.05% cream (morning) and tacrolimus 0.03% ointment (evening) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AD: atopic dermatitis.<br/> BID: twice a day.<br/> IGA: Investigators' Global Assessment.<br/> OD: once daily.<br/> SCORAD: SCORing Atopic Dermatitis.<br/> vs: versus. </p> </div> </div> <section id="CD009864-sec-0057"> <h5 class="title">Design</h5> <p>All included studies were randomised, comparative, parallel group studies.</p> <p>Three of the studies were single centre (<a href="./references#CD009864-bbs2-0001" title="AntigaE , VolpiW , TorchiaD , FabbriP , CaproniM . Effects of tacrolimus ointment on Toll‐like receptors in atopic dermatitis. Clinical &amp; Experimental Dermatology2011;36(3):235‐41. [MEDLINE: 21070333] ">Antiga 2010</a>; <a href="./references#CD009864-bbs2-0004" title="CaproniM , TorchiaD , AntigaE , TerranovaM , VolpiW , delBiancoE , et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. British Journal of Dermatology2007;156(2):312‐9. [MEDLINE: 17223872] ">Caproni 2007</a>; <a href="./references#CD009864-bbs2-0010" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma, &amp; Immunology 007;98(1):51‐6. [MEDLINE: 17225720] ">Hung 2007</a>); the remaining represented multicentre trials. </p> </section> <section id="CD009864-sec-0058"> <h5 class="title">Participants</h5> <p>Thirteen studies defined atopic dermatitis according to the Hanifin and Rajka criteria (<a href="./appendices#CD009864-sec-0142">Appendix 1</a>), while in the other studies, a physician clinically diagnosed atopic dermatitis. </p> <p>Seventeen of the studies included participants with moderate or severe atopic dermatitis (using the Rajka and Langeland criteria (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>), the SCORing Atopic Dermatitis (SCORAD) classification, or the Investigators' Global Assessment (IGA) classification ‐ view <a href="./appendices#CD009864-sec-0142">Appendix 1</a>); one study included participants with moderate or severe atopic dermatitis (Rajka and Langeland criteria (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>) or IGA) who showed inadequate response to topical corticosteroids (<a href="./references#CD009864-bbs2-0005" title="DossN , KamounMR , DubertretL , CambazardF , RemitzA , LahfaM , et al. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with moderate‐to‐severe atopic dermatitis: evidence from a randomized, double‐blind non‐inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy &amp; Immunology2010;21(2 Pt 1):321‐9. [MEDLINE: 19563466] ">Doss 2010</a>). One study included only participants with moderate atopic dermatitis (IGA criteria) (<a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a>), and another study included participants with a severe flare (IGA &gt; 4) and prior history of moderate to severe atopic dermatitis (<a href="./references#CD009864-bbs2-0002" title="BieberT , VickK , Folster‐HolstR , Belloni‐FortinaA , StadtlerG , WormM , et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy2007;62(2):184‐9. [MEDLINE: 17298428] ">Bieber 2007</a>). </p> <p>We classified participants as adults or paediatric age groups according to the study authors' definitions: participants considered as adults were older than age 16 or 18 years, depending on the study; participants considered in the 'paediatric' age group were between 6 months or 2 years and 16 or 18 years old, depending on the study. Eight studies included only adult participants (&gt; = 16 or 18 years) (<a href="./references#CD009864-bbs2-0001" title="AntigaE , VolpiW , TorchiaD , FabbriP , CaproniM . Effects of tacrolimus ointment on Toll‐like receptors in atopic dermatitis. Clinical &amp; Experimental Dermatology2011;36(3):235‐41. [MEDLINE: 21070333] ">Antiga 2010</a>; <a href="./references#CD009864-bbs2-0004" title="CaproniM , TorchiaD , AntigaE , TerranovaM , VolpiW , delBiancoE , et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. British Journal of Dermatology2007;156(2):312‐9. [MEDLINE: 17223872] ">Caproni 2007</a>; <a href="./references#CD009864-bbs2-0006" title="DouX , LiuL‐L , XieZ‐Q , ChenL‐J , LiL , FengS‐Y , et al. The impact of tacrolimus ointment on health‐related quality of life of Chinese adult and pediatric patients with atopic dermatitis (Chinese). Journal of Clinical Dermatology2006;35(1):50‐2. ">Dou 2006</a>; <a href="./references#CD009864-bbs2-0007" title="DraelosZ , NayakA , PariserD , ShupackJL , ChonK , AbramsB , et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‐blind comparison. Journal of the American Academy of Dermatology2005;53(4):602‐9. [MEDLINE: 16198779] ">Draelos 2005</a>; <a href="./references#CD009864-bbs2-0008" title="FleischerABJr , AbramovitsW , BrenemanD , JaraczE , US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment2007;18(3):151‐7. [MEDLINE: 17538803] ">Fleischer 2007</a>; <a href="./references#CD009864-bbs2-0009" title="HanifinJM , LingMR , LangleyR , BrenemanD , RafalE . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. Journal of the American Academy of Dermatology2001;44(Suppl 1):S28‐38. [EMBASE: 2001020450] SoterNA , Fleischer JrAB , WebsterGF , MonroeE , LawrenceI . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. Journal of the American Academy of Dermatology2001;44(1 Suppl):S39‐46. [DOI: 10.1067/mjd.2001.109817; EMBASE: 2001020451] ">Hanifin 2001</a>; <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a>; <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a>). Another 10 studies included only paediatric participants (6 months to 18 years) (<a href="./references#CD009864-bbs2-0002" title="BieberT , VickK , Folster‐HolstR , Belloni‐FortinaA , StadtlerG , WormM , et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy2007;62(2):184‐9. [MEDLINE: 17298428] ">Bieber 2007</a>; <a href="./references#CD009864-bbs2-0005" title="DossN , KamounMR , DubertretL , CambazardF , RemitzA , LahfaM , et al. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with moderate‐to‐severe atopic dermatitis: evidence from a randomized, double‐blind non‐inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy &amp; Immunology2010;21(2 Pt 1):321‐9. [MEDLINE: 19563466] ">Doss 2010</a>; <a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a>; <a href="./references#CD009864-bbs2-0012" title="Otsuki , M , Kawashima , M , Shibata , Y , Nakagawa , H , Harada , S . Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis‐Phase III Double‐blinded Comparison with Vehicle Ointment. Journal of Clinical Therapeutics &amp; Medicines (Rinsho Iyaku)2003;19:569‐95. ">Otsuki 2003</a>; <a href="./references#CD009864-bbs2-0014" title="PallerA , EichenfieldLF , LeungDY , StewartD , AppellM . A 12‐week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology2001;44(1 Suppl):S47‐57. [MEDLINE: 11145795] ">Paller 2001</a>; <a href="./references#CD009864-bbs2-0015" title="AbramovitsW , FleischerABJr , JaraczE , BrenemanD . Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology2008;7(12):1153‐8. [MEDLINE: 19137769] PallerAS , LebwohlM , FleischerABJr , AntayaR , LangleyRG , KirsnerRS , et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology2005;52(5):810‐22. [MEDLINE: 15858471] ">Paller 2005</a>; <a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a>; <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a>), and of those, 2 included only older children (7 to 16 years) (<a href="./references#CD009864-bbs2-0003" title="BoguniewiczM , FiedlerVC , RaimerS , LawrenceID , LeungDY , HanifinJM . A randomized, vehicle‐controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy &amp; Clinical Immunology1998;102(4 Pt 1):637‐44. [MEDLINE: 9802373] ">Boguniewicz 1998</a>; <a href="./references#CD009864-bbs2-0020" title="Sikder MdAU , Al MamunS , KhanRM , ChowdhuryAH , KhanHM , HoqueMM . Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis ‐ An open randomized comparative study. Journal of Pakistan Association of Dermatologists2005;15(4):304‐12. [EMBASE: 2006159825] ">Sikder 2005</a>). Two studies included both adults and paediatric participants with ages ranging from 9 months to 45 years (<a href="./references#CD009864-bbs2-0010" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma, &amp; Immunology 007;98(1):51‐6. [MEDLINE: 17225720] ">Hung 2007</a>; <a href="./references#CD009864-bbs2-0013" title="PacorML , DiLorenzoG , MartinelliN , MansuetoP , RiniGB , CorrocherR . Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clinical &amp; Experimental Allergy2004;34(4):639‐45. [MEDLINE: 15080819] ">Pacor 2004</a>). </p> </section> <section id="CD009864-sec-0059"> <h5 class="title">Sample size</h5> <p>Sample sizes ranged from 16 (<a href="./references#CD009864-bbs2-0004" title="CaproniM , TorchiaD , AntigaE , TerranovaM , VolpiW , delBiancoE , et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. British Journal of Dermatology2007;156(2):312‐9. [MEDLINE: 17223872] ">Caproni 2007</a>) to 972 (<a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a>). </p> </section> <section id="CD009864-sec-0060"> <h5 class="title">Interventions</h5> <p>We searched for trials comparing tacrolimus at any dose, course duration, and follow‐up time with other active treatments. </p> <p> <ul id="CD009864-list-0010"> <li> <p>Three studies, <a href="./references#CD009864-bbs2-0001" title="AntigaE , VolpiW , TorchiaD , FabbriP , CaproniM . Effects of tacrolimus ointment on Toll‐like receptors in atopic dermatitis. Clinical &amp; Experimental Dermatology2011;36(3):235‐41. [MEDLINE: 21070333] ">Antiga 2010</a>; <a href="./references#CD009864-bbs2-0004" title="CaproniM , TorchiaD , AntigaE , TerranovaM , VolpiW , delBiancoE , et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. British Journal of Dermatology2007;156(2):312‐9. [MEDLINE: 17223872] ">Caproni 2007</a>; <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a>, compared tacrolimus 0.1% ointment with a mid‐potency topical corticosteroid (hydrocortisone butyrate 0.1%) administered twice a day (BID). </p> </li> <li> <p>One study, <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a> (1 original study and 2 subanalyses), compared tacrolimus 0.1% ointment with a mid‐potency topical corticosteroid (hydrocortisone butyrate 0.1% ointment) applied to the trunk and extremities and with a low‐potency topical corticosteroid (hydrocortisone acetate 1% ointment) applied to the face and neck areas (BID). </p> </li> <li> <p>Three studies, <a href="./references#CD009864-bbs2-0007" title="DraelosZ , NayakA , PariserD , ShupackJL , ChonK , AbramsB , et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‐blind comparison. Journal of the American Academy of Dermatology2005;53(4):602‐9. [MEDLINE: 16198779] ">Draelos 2005</a>; <a href="./references#CD009864-bbs2-0008" title="FleischerABJr , AbramovitsW , BrenemanD , JaraczE , US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment2007;18(3):151‐7. [MEDLINE: 17538803] ">Fleischer 2007</a>; <a href="./references#CD009864-bbs2-0015" title="AbramovitsW , FleischerABJr , JaraczE , BrenemanD . Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology2008;7(12):1153‐8. [MEDLINE: 19137769] PallerAS , LebwohlM , FleischerABJr , AntayaR , LangleyRG , KirsnerRS , et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology2005;52(5):810‐22. [MEDLINE: 15858471] ">Paller 2005</a>, compared tacrolimus 0.1% ointment with pimecrolimus 1% cream (BID). </p> </li> <li> <p>Four studies, <a href="./references#CD009864-bbs2-0005" title="DossN , KamounMR , DubertretL , CambazardF , RemitzA , LahfaM , et al. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with moderate‐to‐severe atopic dermatitis: evidence from a randomized, double‐blind non‐inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy &amp; Immunology2010;21(2 Pt 1):321‐9. [MEDLINE: 19563466] ">Doss 2010</a>; <a href="./references#CD009864-bbs2-0010" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma, &amp; Immunology 007;98(1):51‐6. [MEDLINE: 17225720] ">Hung 2007</a>; <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a>; <a href="./references#CD009864-bbs2-0020" title="Sikder MdAU , Al MamunS , KhanRM , ChowdhuryAH , KhanHM , HoqueMM . Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis ‐ An open randomized comparative study. Journal of Pakistan Association of Dermatologists2005;15(4):304‐12. [EMBASE: 2006159825] ">Sikder 2005</a>, compared tacrolimus 0.03% ointment with a mid‐potency topical corticosteroid (hydrocortisone butyrate 0.1% ointment, fluticasone propionate 0.05% cream or clobetasol butyrate) (BID). One of the studies, <a href="./references#CD009864-bbs2-0020" title="Sikder MdAU , Al MamunS , KhanRM , ChowdhuryAH , KhanHM , HoqueMM . Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis ‐ An open randomized comparative study. Journal of Pakistan Association of Dermatologists2005;15(4):304‐12. [EMBASE: 2006159825] ">Sikder 2005</a>, also compared it with the combined treatment (topical corticosteroid in the morning and topical tacrolimus in the evening), and <a href="./references#CD009864-bbs2-0010" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma, &amp; Immunology 007;98(1):51‐6. [MEDLINE: 17225720] ">Hung 2007</a> also compared both treatments alone or in combination with fusidic acid 2% cream. </p> </li> <li> <p>Two studies, <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a>; <a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a>, compared tacrolimus 0.03% ointment with low‐potency topical corticosteroids (TCS) (hydrocortisone acetate 1% ointment). The <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a> study compared tacrolimus 0.03% ointment versus tacrolimus 0.1% ointment versus TCS all administered twice a day. The <a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a> study compared tacrolimus 0.03% once a day versus tacrolimus 0.03% twice a day versus TCS once a day. </p> </li> <li> <p><a href="./references#CD009864-bbs2-0002" title="BieberT , VickK , Folster‐HolstR , Belloni‐FortinaA , StadtlerG , WormM , et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy2007;62(2):184‐9. [MEDLINE: 17298428] ">Bieber 2007</a> compared tacrolimus 0.03% ointment (BID) with a high‐potency topical corticosteroid (once a day (QD)) (methylprednisolone aceponate 0.1% ointment). </p> </li> <li> <p>Seven studies (<a href="./references#CD009864-bbs2-0003" title="BoguniewiczM , FiedlerVC , RaimerS , LawrenceID , LeungDY , HanifinJM . A randomized, vehicle‐controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy &amp; Clinical Immunology1998;102(4 Pt 1):637‐44. [MEDLINE: 9802373] ">Boguniewicz 1998</a>; <a href="./references#CD009864-bbs2-0006" title="DouX , LiuL‐L , XieZ‐Q , ChenL‐J , LiL , FengS‐Y , et al. The impact of tacrolimus ointment on health‐related quality of life of Chinese adult and pediatric patients with atopic dermatitis (Chinese). Journal of Clinical Dermatology2006;35(1):50‐2. ">Dou 2006</a>; <a href="./references#CD009864-bbs2-0009" title="HanifinJM , LingMR , LangleyR , BrenemanD , RafalE . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. Journal of the American Academy of Dermatology2001;44(Suppl 1):S28‐38. [EMBASE: 2001020450] SoterNA , Fleischer JrAB , WebsterGF , MonroeE , LawrenceI . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. Journal of the American Academy of Dermatology2001;44(1 Suppl):S39‐46. [DOI: 10.1067/mjd.2001.109817; EMBASE: 2001020451] ">Hanifin 2001</a>; <a href="./references#CD009864-bbs2-0012" title="Otsuki , M , Kawashima , M , Shibata , Y , Nakagawa , H , Harada , S . Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis‐Phase III Double‐blinded Comparison with Vehicle Ointment. Journal of Clinical Therapeutics &amp; Medicines (Rinsho Iyaku)2003;19:569‐95. ">Otsuki 2003</a>; <a href="./references#CD009864-bbs2-0014" title="PallerA , EichenfieldLF , LeungDY , StewartD , AppellM . A 12‐week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology2001;44(1 Suppl):S47‐57. [MEDLINE: 11145795] ">Paller 2001</a>; <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a>; <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a>) compared tacrolimus 0.1% ointment with tacrolimus 0.03% ointment, and <a href="./references#CD009864-bbs2-0003" title="BoguniewiczM , FiedlerVC , RaimerS , LawrenceID , LeungDY , HanifinJM . A randomized, vehicle‐controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy &amp; Clinical Immunology1998;102(4 Pt 1):637‐44. [MEDLINE: 9802373] ">Boguniewicz 1998</a> also compared it to tacrolimus 0.3% ointment. </p> </li> <li> <p><a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a> compared tacrolimus 0.03% ointment with pimecrolimus 1% cream (BID). </p> </li> <li> <p><a href="./references#CD009864-bbs2-0013" title="PacorML , DiLorenzoG , MartinelliN , MansuetoP , RiniGB , CorrocherR . Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clinical &amp; Experimental Allergy2004;34(4):639‐45. [MEDLINE: 15080819] ">Pacor 2004</a> compared tacrolimus 0.1% ointment with oral ciclosporin at a dose of 3 mg/kg. </p> </li> </ul> </p> <p>Duration of treatment was established as a previously determined maximum treatment time period. If complete clearance of the lesion was achieved prior to that maximum period, treatment was continued for another week and then stopped. We carried out the analysis on the maximum time period pre‐established. This period varied from 1 week to 12 months: 2 weeks in 1 study, 3 weeks in 9 studies, 4 weeks in 1 study, 6 weeks in 4 studies, 3 months in 1 study, 6 months in 2 studies, and 12 months in a subanalysis of <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a>. As most of the included studies reported short‐term data, we analysed only the rapid onset of improvement. </p> <p>We only considered including a placebo (vehicle) group in more complex comparisons of combined treatment approaches. Six studies compared more than two treatment options. </p> <p>We did not include in this review comparisons of tacrolimus only with placebo (vehicle), because of the already proven efficacy of the drug over placebo in other systematic reviews (<a href="./references#CD009864-bbs2-0054" title="AshcroftDM , DimmockP , GarsideR , SteinK , WilliamsHC . Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta‐analysis of randomised controlled trials. BMJ2005;330(7490):516. [MEDLINE: 15731121] ">Ashcroft 2005b</a>; <a href="./references#CD009864-bbs2-0072" title="ChenSL , YanJ , WangFS . Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta‐analysis of randomized clinical trials. Journal of Dermatological Treatment2010;21(3):144‐56. [MEDLINE: 20394490] ">Chen 2010</a>; <a href="./references#CD009864-bbs2-0077" title="El‐BatawyMM , BosseilaMA , MashalyHM , HafezVS . Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta‐analysis. Journal of Dermatological Science2009;54(2):76‐87. [MEDLINE: 19303745] ">El‐Batawy 2009</a>; <a href="./references#CD009864-bbs2-0161" title="YanJ , ChenSL , WangXL , ZhouW , WangFS . Meta‐analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatric Dermatology2008;25(1):117‐20. [MEDLINE: 18304172] ">Yan 2008</a>). </p> </section> <section id="CD009864-sec-0061"> <h5 class="title">Outcomes</h5> <p>The following numbers of our included studies addressed our prespecified primary outcomes.</p> <p> <ol id="CD009864-list-0011"> <li> <p>Physician's assessment of global response of improvement*: 15 studies.</p> </li> <li> <p>Participant's self‐assessment of global response of improvement*: five studies.</p> </li> <li> <p>Occurence and severity of adverse effects: 16 studies.</p> </li> </ol> </p> <p>*Physicians and participants grade the skin improvement in a subjective manner<i>.</i> Though subjective, these tools are also used to assess treatment efficacy. They (the tools) evaluate skin improvement, for example, as excellent improvement (&gt; 90% of improvement), marked improvement (75% to 89%), or moderate improvement (50% to 74%) from the participant's or physician's viewpoint. </p> <p>The following numbers of our included studies addressed our prespecified secondary outcomes. </p> <p> <ol id="CD009864-list-0012"> <li> <p>Improvement of disease assessed by a validated or objective measure, such as the following:</p> </li> </ol> <ul class="plain" id="CD009864-list-0013"> <li> <ul id="CD009864-list-0014"> <li> <p>affected Body Surface Area (BSA): 10 studies;</p> </li> <li> <p>Eczema Area and Severity Index (EASI): 5 studies;</p> </li> <li> <p>modified Eczema Area and Severity Index (mEASI): 7 studies;</p> </li> <li> <p>relapse: 0 studies;</p> </li> <li> <p>quality of life: 2 studies; or</p> </li> <li> <p>SCORing Atopic Dermatitis (SCORAD): 4 studies.</p> </li> </ul> </li> </ul> </p> </section> </section> <section id="CD009864-sec-0062"> <h4 class="title">Excluded studies</h4> <p>We excluded 23 studies and list the reasons for exclusion in the '<a href="./references#CD009864-sec-0163" title="">Characteristics of excluded studies</a>' tables. In brief, the reasons were as follows. </p> <p> <ul id="CD009864-list-0015"> <li> <p>In two studies, there was no classification of disease severity (<a href="./references#CD009864-bbs2-0037" title="ReitamoS , MandelinJ , RubinsA , RemitzA , MakelaM , CiruleK , et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. International Journal of Dermatology2009;48(4):348‐55. [MEDLINE: 19335418] ">Reitamo 2009</a>; <a href="./references#CD009864-bbs2-0041" title="TorokHM , Maas‐IrslingerR , SlaytonRM . Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. Cutis2003;72(2):161‐6. [MEDLINE: 12953943] ">Torok 2003</a>). </p> </li> <li> <p>Six studies compared intervention with placebo only and made no comparisons with active treatments (<a href="./references#CD009864-bbs2-0022" title="ChapmanMS , SchachnerLA , BrenemanD , BoguniewiczM , GoldMH , ShullT , et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology2005;53(2 Suppl 2):177‐85. [MEDLINE: 16021173] ">Chapman 2005</a>; <a href="./references#CD009864-bbs2-0027" title="GranlundH , RemitzA , KyllonenH , LauermaAI , ReitamoS . Treatment of Lichenified Atopic Eczema with Tacrolimus Ointment. Acta Dermato‐Venereologica2001;81(4):314‐5. [MEDLINE: 11720192] ">Granlund 2001</a>; <a href="./references#CD009864-bbs2-0030" title="IshibashiY , NakagawaH , EtoT , KawashimaM , HigakiY , HaradaS , et al. Early Phase II Study of FK506 Ointment on Atopic Dermatitis. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)1997;13(2):317‐39. ">Ishibashi 1997</a>; <a href="./references#CD009864-bbs2-0033" title="LiuLL , DouX , XieZQ , WandD , ZhengZZ , WeiMH , et al. Efficacy and Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis in Chinese Children. Chinese Journal of Dermatology2005;38(10):608‐11. ">Liu 2005</a>; <a href="./references#CD009864-bbs2-0036" title="RahmanMF , RashidMM , SikderAU , AkhtarN , BanuLA , WahabMA . Efficacy of topical tacrolimus in atopic dermatitis. Journal of Pakistan Association of Dermatologists2008;18(2):84‐92. [EMBASE: 2008404671] ">Rahman 2008</a>; <a href="./references#CD009864-bbs2-0039" title="SchachnerLA , LamersonC , SheehanMP , BoguniewiczM , MosserJ , RaimerS , et al. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double‐blind, vehicle‐controlled study. Pediatrics2005;116(3):e334‐42. [MEDLINE: 16140675] ">Schachner 2005</a>). </p> </li> <li> <p>Two studies evaluated only the face or the head and neck area (<a href="./references#CD009864-bbs2-0005" title="DossN , KamounMR , DubertretL , CambazardF , RemitzA , LahfaM , et al. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with moderate‐to‐severe atopic dermatitis: evidence from a randomized, double‐blind non‐inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy &amp; Immunology2010;21(2 Pt 1):321‐9. [MEDLINE: 19563466] ">Doss 2010</a>; <a href="./references#CD009864-bbs2-0031" title="KangS , PallerA , SoterN , SatoiY , RicoMJ , HanifinJM . Safe treatment of head/neck AD with tacrolimus ointment. Journal of Dermatological Treatment2003;14(2):86‐94. [MEDLINE: 12775315] ">Kang 2003</a>). </p> </li> <li> <p>Four other studies evaluated only a limited area (<a href="./references#CD009864-bbs2-0023" title="Dähnhardt‐PfeifferS , DähnhardtD , BuchnerM , WalterK , ProkschE , Fölster‐HolstR . Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis. Journal Der Deutschen Dermatologischen Gesellschaft2013;11(5):437‐43. [MEDLINE: 23551950] ">Dähnhardt‐Pfeiffer 2013</a>; <a href="./references#CD009864-bbs2-0024" title="DelRossoJQ , ConteET . An Investigator‐Blinded Evaluation of Fluocinonide 0.1% Cream in the Treatment of Atopic Dermatitis and Psoriasis Vulgaris. Cosmetic Dermatology2007;20(9):545‐52. [EMBASE: 2007500429] ">del Rosso 2007</a>; <a href="./references#CD009864-bbs2-0038" title="RuzickaT , BieberT , SchopfE , RubinsA , DobozyA , BosJD , et al. A short‐term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. New England Journal of Medicine1997;337(12):816‐21. [MEDLINE: 9295241] ">Ruzicka 1997</a>; <a href="./references#CD009864-bbs2-0043" title="Xhauflaire‐UhodaE , ThirionL , Piérard‐FranchimontC , PiérardGE . Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis. Dermatology2007;214(4):328‐32. [MEDLINE: 17460405] ">Xhauflaire‐Uhoda 2007</a>). </p> </li> <li> <p>Four studies included also mild cases in their analyses (<a href="./references#CD009864-bbs2-0026" title="GradmanJ , WolthersOD . Short‐term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus. Acta Paediatrica2007;96(8):1233‐7. [MEDLINE: 17590198] ">Gradman 2007</a>; <a href="./references#CD009864-bbs2-0028" title="HebertAA , KooJ , FowlerJ , BermanB , RosenbergC , LevittJ . Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis. Cutis2006;78(5):357‐63. [MEDLINE: 17186796] ">Hebert 2006</a>; <a href="./references#CD009864-bbs2-0032" title="KirsnerRS , HeffernanMP , AntayaR . Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids. Acta Dermato‐Venereologica2010;90(1):58‐64. [MEDLINE: 20107727] ">Kirsner 2010</a>; <a href="./references#CD009864-bbs2-0040" title="TakeuchiS , SaekiH , TokunagaS , SugayaM , OhmatsuH , TsunemiY , et al. A randomized, open‐label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis. Annals of Dermatology2012;24(2):144‐50. [MEDLINE: 22577263] ">Takeuchi 2012</a>). </p> </li> <li> <p>Three studies were not randomised controlled trials (<a href="./references#CD009864-bbs2-0021" title="ArkwrightPD , GillespieMC , EwingCI , DavidTJ . Blinded side‐to‐side comparison of topical corticosteroid and tacrolimus ointment in children with moderate to severe atopic dermatitis. Clinical &amp; Experimental Dermatology2007;32(2):145‐7. [MEDLINE: 17342794] ">Arkwright 2006</a>; <a href="./references#CD009864-bbs2-0029" title="HjelmgrenJ , SvenssonA , JorgensenET , Lindemalm‐LundstamB , Ragnarson TennvallG . Cost‐effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health‐economic model simulation based on a patient survey and clinical trial data. British Journal of Dermatology2007;156(5):913‐21. [MEDLINE: 17263826] ">Hjelmgren 2007</a>; <a href="./references#CD009864-bbs2-0042" title="WonCH , SeoPG , ParkYM , YangJM , LeeKH , SungKJ , et al. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. Journal of Dermatological Treatment2004;15(1):30‐4. [MEDLINE: 14754647] ">Won 2004</a>). </p> </li> <li> <p><a href="./references#CD009864-bbs2-0035" title="OnumahN , KircikL . Pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis: A pilot study on patient preference. Journal of Drugs in Dermatology2013;12(10):1145‐8. [MEDLINE: 24085050] ">Onumah 2013</a> was an open‐labelled pilot study on patient vehicle (ointment versus cream) preference. </p> </li> <li> <p>In one study, <a href="./references#CD009864-bbs2-0034" title="NeumannE , AmtageD , Bruckner‐TudermanL , MockenhauptM . A single‐center open‐label long‐term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis. Journal Der Deutschen Dermatologischen Gesellschaft2008;6(7):548‐53. [MEDLINE: 18248495] ">Neumann 2008</a>, there was no established medication application frequency (once a day (QD) or twice a day (BID)) on the use of both intervention and control treatments for standardisation and comparison. </p> </li> </ul> </p> </section> </section> <section id="CD009864-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>Please see the '<a href="./references#CD009864-sec-0162" title="">Characteristics of included studies</a>' tables with the 'Risk of bias' assessment for each included study. <a href="#CD009864-fig-0002">Figure 2</a> and <a href="#CD009864-fig-0003">Figure 3</a> summarise the risk of bias. </p> <div class="figure" id="CD009864-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD009864-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD009864-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD009864-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> <section id="CD009864-sec-0064"> <h4 class="title">Allocation</h4> <section id="CD009864-sec-0065"> <h5 class="title">Random sequence generation</h5> <p>Thirteen of the 20 included studies described an adequate method to generate the randomisation sequence (<a href="./references#CD009864-bbs2-0001" title="AntigaE , VolpiW , TorchiaD , FabbriP , CaproniM . Effects of tacrolimus ointment on Toll‐like receptors in atopic dermatitis. Clinical &amp; Experimental Dermatology2011;36(3):235‐41. [MEDLINE: 21070333] ">Antiga 2010</a>; <a href="./references#CD009864-bbs2-0002" title="BieberT , VickK , Folster‐HolstR , Belloni‐FortinaA , StadtlerG , WormM , et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy2007;62(2):184‐9. [MEDLINE: 17298428] ">Bieber 2007</a>; <a href="./references#CD009864-bbs2-0003" title="BoguniewiczM , FiedlerVC , RaimerS , LawrenceID , LeungDY , HanifinJM . A randomized, vehicle‐controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy &amp; Clinical Immunology1998;102(4 Pt 1):637‐44. [MEDLINE: 9802373] ">Boguniewicz 1998</a>; <a href="./references#CD009864-bbs2-0005" title="DossN , KamounMR , DubertretL , CambazardF , RemitzA , LahfaM , et al. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with moderate‐to‐severe atopic dermatitis: evidence from a randomized, double‐blind non‐inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy &amp; Immunology2010;21(2 Pt 1):321‐9. [MEDLINE: 19563466] ">Doss 2010</a>; <a href="./references#CD009864-bbs2-0007" title="DraelosZ , NayakA , PariserD , ShupackJL , ChonK , AbramsB , et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‐blind comparison. Journal of the American Academy of Dermatology2005;53(4):602‐9. [MEDLINE: 16198779] ">Draelos 2005</a>; <a href="./references#CD009864-bbs2-0008" title="FleischerABJr , AbramovitsW , BrenemanD , JaraczE , US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment2007;18(3):151‐7. [MEDLINE: 17538803] ">Fleischer 2007</a>; <a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a>; <a href="./references#CD009864-bbs2-0012" title="Otsuki , M , Kawashima , M , Shibata , Y , Nakagawa , H , Harada , S . Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis‐Phase III Double‐blinded Comparison with Vehicle Ointment. Journal of Clinical Therapeutics &amp; Medicines (Rinsho Iyaku)2003;19:569‐95. ">Otsuki 2003</a>; <a href="./references#CD009864-bbs2-0015" title="AbramovitsW , FleischerABJr , JaraczE , BrenemanD . Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology2008;7(12):1153‐8. [MEDLINE: 19137769] PallerAS , LebwohlM , FleischerABJr , AntayaR , LangleyRG , KirsnerRS , et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology2005;52(5):810‐22. [MEDLINE: 15858471] ">Paller 2005</a>; <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a>; <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a>; <a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a>; <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a>), and we classified these as at a low risk of bias. We considered the remaining studies as presenting an unclear risk of bias for random sequence generation. </p> </section> <section id="CD009864-sec-0066"> <h5 class="title">Allocation sequence concealment</h5> <p>Fourteen studies did not describe allocation methods, so we classified these as "unclear" (<a href="./references#CD009864-bbs2-0001" title="AntigaE , VolpiW , TorchiaD , FabbriP , CaproniM . Effects of tacrolimus ointment on Toll‐like receptors in atopic dermatitis. Clinical &amp; Experimental Dermatology2011;36(3):235‐41. [MEDLINE: 21070333] ">Antiga 2010</a>; <a href="./references#CD009864-bbs2-0002" title="BieberT , VickK , Folster‐HolstR , Belloni‐FortinaA , StadtlerG , WormM , et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy2007;62(2):184‐9. [MEDLINE: 17298428] ">Bieber 2007</a>; <a href="./references#CD009864-bbs2-0003" title="BoguniewiczM , FiedlerVC , RaimerS , LawrenceID , LeungDY , HanifinJM . A randomized, vehicle‐controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy &amp; Clinical Immunology1998;102(4 Pt 1):637‐44. [MEDLINE: 9802373] ">Boguniewicz 1998</a>; <a href="./references#CD009864-bbs2-0004" title="CaproniM , TorchiaD , AntigaE , TerranovaM , VolpiW , delBiancoE , et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. British Journal of Dermatology2007;156(2):312‐9. [MEDLINE: 17223872] ">Caproni 2007</a>; <a href="./references#CD009864-bbs2-0006" title="DouX , LiuL‐L , XieZ‐Q , ChenL‐J , LiL , FengS‐Y , et al. The impact of tacrolimus ointment on health‐related quality of life of Chinese adult and pediatric patients with atopic dermatitis (Chinese). Journal of Clinical Dermatology2006;35(1):50‐2. ">Dou 2006</a>; <a href="./references#CD009864-bbs2-0007" title="DraelosZ , NayakA , PariserD , ShupackJL , ChonK , AbramsB , et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‐blind comparison. Journal of the American Academy of Dermatology2005;53(4):602‐9. [MEDLINE: 16198779] ">Draelos 2005</a>; <a href="./references#CD009864-bbs2-0009" title="HanifinJM , LingMR , LangleyR , BrenemanD , RafalE . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. Journal of the American Academy of Dermatology2001;44(Suppl 1):S28‐38. [EMBASE: 2001020450] SoterNA , Fleischer JrAB , WebsterGF , MonroeE , LawrenceI . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. Journal of the American Academy of Dermatology2001;44(1 Suppl):S39‐46. [DOI: 10.1067/mjd.2001.109817; EMBASE: 2001020451] ">Hanifin 2001</a>; <a href="./references#CD009864-bbs2-0010" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma, &amp; Immunology 007;98(1):51‐6. [MEDLINE: 17225720] ">Hung 2007</a>; <a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a>; <a href="./references#CD009864-bbs2-0012" title="Otsuki , M , Kawashima , M , Shibata , Y , Nakagawa , H , Harada , S . Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis‐Phase III Double‐blinded Comparison with Vehicle Ointment. Journal of Clinical Therapeutics &amp; Medicines (Rinsho Iyaku)2003;19:569‐95. ">Otsuki 2003</a>; <a href="./references#CD009864-bbs2-0013" title="PacorML , DiLorenzoG , MartinelliN , MansuetoP , RiniGB , CorrocherR . Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clinical &amp; Experimental Allergy2004;34(4):639‐45. [MEDLINE: 15080819] ">Pacor 2004</a>; <a href="./references#CD009864-bbs2-0014" title="PallerA , EichenfieldLF , LeungDY , StewartD , AppellM . A 12‐week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology2001;44(1 Suppl):S47‐57. [MEDLINE: 11145795] ">Paller 2001</a>; <a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a>; <a href="./references#CD009864-bbs2-0020" title="Sikder MdAU , Al MamunS , KhanRM , ChowdhuryAH , KhanHM , HoqueMM . Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis ‐ An open randomized comparative study. Journal of Pakistan Association of Dermatologists2005;15(4):304‐12. [EMBASE: 2006159825] ">Sikder 2005</a>). We classified the other six studies as at a low risk of bias. </p> </section> </section> <section id="CD009864-sec-0067"> <h4 class="title">Blinding</h4> <p>We judged 16 studies to be at low risk for performance bias, i.e., the participants and personnel were blinded. We judged 14 of these studies to be at low risk of bias for 'outcome assessment'. Five of the studies, which we judged to be at low risk of bias, were investigator blinded due to the different appearance of the products used (ointments or creams); participants were not allowed to discuss anything about the treatment with the investigators, and the only outcomes evaluated were based on the investigator's assessment or grading, so that the unblinded participants would not interfere with the results (<a href="./references#CD009864-bbs2-0001" title="AntigaE , VolpiW , TorchiaD , FabbriP , CaproniM . Effects of tacrolimus ointment on Toll‐like receptors in atopic dermatitis. Clinical &amp; Experimental Dermatology2011;36(3):235‐41. [MEDLINE: 21070333] ">Antiga 2010</a>; <a href="./references#CD009864-bbs2-0007" title="DraelosZ , NayakA , PariserD , ShupackJL , ChonK , AbramsB , et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‐blind comparison. Journal of the American Academy of Dermatology2005;53(4):602‐9. [MEDLINE: 16198779] ">Draelos 2005</a>; <a href="./references#CD009864-bbs2-0008" title="FleischerABJr , AbramovitsW , BrenemanD , JaraczE , US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment2007;18(3):151‐7. [MEDLINE: 17538803] ">Fleischer 2007</a>; <a href="./references#CD009864-bbs2-0015" title="AbramovitsW , FleischerABJr , JaraczE , BrenemanD . Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology2008;7(12):1153‐8. [MEDLINE: 19137769] PallerAS , LebwohlM , FleischerABJr , AntayaR , LangleyRG , KirsnerRS , et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology2005;52(5):810‐22. [MEDLINE: 15858471] ">Paller 2005</a>; <a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a>). </p> <p>Four studies did not describe the blinding methods, so we judged these as at unclear risk of bias for both domains (<a href="./references#CD009864-bbs2-0004" title="CaproniM , TorchiaD , AntigaE , TerranovaM , VolpiW , delBiancoE , et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. British Journal of Dermatology2007;156(2):312‐9. [MEDLINE: 17223872] ">Caproni 2007</a>; <a href="./references#CD009864-bbs2-0006" title="DouX , LiuL‐L , XieZ‐Q , ChenL‐J , LiL , FengS‐Y , et al. The impact of tacrolimus ointment on health‐related quality of life of Chinese adult and pediatric patients with atopic dermatitis (Chinese). Journal of Clinical Dermatology2006;35(1):50‐2. ">Dou 2006</a>; <a href="./references#CD009864-bbs2-0009" title="HanifinJM , LingMR , LangleyR , BrenemanD , RafalE . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. Journal of the American Academy of Dermatology2001;44(Suppl 1):S28‐38. [EMBASE: 2001020450] SoterNA , Fleischer JrAB , WebsterGF , MonroeE , LawrenceI . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. Journal of the American Academy of Dermatology2001;44(1 Suppl):S39‐46. [DOI: 10.1067/mjd.2001.109817; EMBASE: 2001020451] ">Hanifin 2001</a>; <a href="./references#CD009864-bbs2-0012" title="Otsuki , M , Kawashima , M , Shibata , Y , Nakagawa , H , Harada , S . Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis‐Phase III Double‐blinded Comparison with Vehicle Ointment. Journal of Clinical Therapeutics &amp; Medicines (Rinsho Iyaku)2003;19:569‐95. ">Otsuki 2003</a>). </p> </section> <section id="CD009864-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>Thirteen studies showed no losses or had few losses, and intention‐to‐treat (ITT) analyses were performed with the method described, so they were classified as at low risk of bias (<a href="./references#CD009864-bbs2-0002" title="BieberT , VickK , Folster‐HolstR , Belloni‐FortinaA , StadtlerG , WormM , et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy2007;62(2):184‐9. [MEDLINE: 17298428] ">Bieber 2007</a>; <a href="./references#CD009864-bbs2-0003" title="BoguniewiczM , FiedlerVC , RaimerS , LawrenceID , LeungDY , HanifinJM . A randomized, vehicle‐controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy &amp; Clinical Immunology1998;102(4 Pt 1):637‐44. [MEDLINE: 9802373] ">Boguniewicz 1998</a>; <a href="./references#CD009864-bbs2-0005" title="DossN , KamounMR , DubertretL , CambazardF , RemitzA , LahfaM , et al. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with moderate‐to‐severe atopic dermatitis: evidence from a randomized, double‐blind non‐inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy &amp; Immunology2010;21(2 Pt 1):321‐9. [MEDLINE: 19563466] ">Doss 2010</a>; <a href="./references#CD009864-bbs2-0007" title="DraelosZ , NayakA , PariserD , ShupackJL , ChonK , AbramsB , et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‐blind comparison. Journal of the American Academy of Dermatology2005;53(4):602‐9. [MEDLINE: 16198779] ">Draelos 2005</a>; <a href="./references#CD009864-bbs2-0009" title="HanifinJM , LingMR , LangleyR , BrenemanD , RafalE . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. Journal of the American Academy of Dermatology2001;44(Suppl 1):S28‐38. [EMBASE: 2001020450] SoterNA , Fleischer JrAB , WebsterGF , MonroeE , LawrenceI . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. Journal of the American Academy of Dermatology2001;44(1 Suppl):S39‐46. [DOI: 10.1067/mjd.2001.109817; EMBASE: 2001020451] ">Hanifin 2001</a>; <a href="./references#CD009864-bbs2-0010" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma, &amp; Immunology 007;98(1):51‐6. [MEDLINE: 17225720] ">Hung 2007</a>; <a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a>; <a href="./references#CD009864-bbs2-0012" title="Otsuki , M , Kawashima , M , Shibata , Y , Nakagawa , H , Harada , S . Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis‐Phase III Double‐blinded Comparison with Vehicle Ointment. Journal of Clinical Therapeutics &amp; Medicines (Rinsho Iyaku)2003;19:569‐95. ">Otsuki 2003</a>; <a href="./references#CD009864-bbs2-0013" title="PacorML , DiLorenzoG , MartinelliN , MansuetoP , RiniGB , CorrocherR . Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clinical &amp; Experimental Allergy2004;34(4):639‐45. [MEDLINE: 15080819] ">Pacor 2004</a>; <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a>; <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a>; <a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a>; <a href="./references#CD009864-bbs2-0020" title="Sikder MdAU , Al MamunS , KhanRM , ChowdhuryAH , KhanHM , HoqueMM . Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis ‐ An open randomized comparative study. Journal of Pakistan Association of Dermatologists2005;15(4):304‐12. [EMBASE: 2006159825] ">Sikder 2005</a>). </p> <p>We classified 5 studies as at unclear risk of attrition bias: <a href="./references#CD009864-bbs2-0001" title="AntigaE , VolpiW , TorchiaD , FabbriP , CaproniM . Effects of tacrolimus ointment on Toll‐like receptors in atopic dermatitis. Clinical &amp; Experimental Dermatology2011;36(3):235‐41. [MEDLINE: 21070333] ">Antiga 2010</a> did not perform an ITT analysis, <a href="./references#CD009864-bbs2-0006" title="DouX , LiuL‐L , XieZ‐Q , ChenL‐J , LiL , FengS‐Y , et al. The impact of tacrolimus ointment on health‐related quality of life of Chinese adult and pediatric patients with atopic dermatitis (Chinese). Journal of Clinical Dermatology2006;35(1):50‐2. ">Dou 2006</a> did not mention losses, <a href="./references#CD009864-bbs2-0008" title="FleischerABJr , AbramovitsW , BrenemanD , JaraczE , US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment2007;18(3):151‐7. [MEDLINE: 17538803] ">Fleischer 2007</a> showed high losses (22.8%), and ITT was done with last observation carried forward to analysis. <a href="./references#CD009864-bbs2-0014" title="PallerA , EichenfieldLF , LeungDY , StewartD , AppellM . A 12‐week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology2001;44(1 Suppl):S47‐57. [MEDLINE: 11145795] ">Paller 2001</a> and <a href="./references#CD009864-bbs2-0015" title="AbramovitsW , FleischerABJr , JaraczE , BrenemanD . Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology2008;7(12):1153‐8. [MEDLINE: 19137769] PallerAS , LebwohlM , FleischerABJr , AntayaR , LangleyRG , KirsnerRS , et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology2005;52(5):810‐22. [MEDLINE: 15858471] ">Paller 2005</a>, despite performing analysis by ITT, did not describe the method used to impute data. </p> <p>We classified two studies as at a high risk of bias: <a href="./references#CD009864-bbs2-0004" title="CaproniM , TorchiaD , AntigaE , TerranovaM , VolpiW , delBiancoE , et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. British Journal of Dermatology2007;156(2):312‐9. [MEDLINE: 17223872] ">Caproni 2007</a> did not perform ITT analysis despite losses (20%), and <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a> had 33.7% of losses with an unclear method to perform ITT analysis. </p> </section> <section id="CD009864-sec-0069"> <h4 class="title">Selective reporting</h4> <p>The studies described all relevant outcomes.</p> </section> <section id="CD009864-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>Only three studies, <a href="./references#CD009864-bbs2-0004" title="CaproniM , TorchiaD , AntigaE , TerranovaM , VolpiW , delBiancoE , et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. British Journal of Dermatology2007;156(2):312‐9. [MEDLINE: 17223872] ">Caproni 2007</a>; <a href="./references#CD009864-bbs2-0010" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma, &amp; Immunology 007;98(1):51‐6. [MEDLINE: 17225720] ">Hung 2007</a>; <a href="./references#CD009864-bbs2-0013" title="PacorML , DiLorenzoG , MartinelliN , MansuetoP , RiniGB , CorrocherR . Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clinical &amp; Experimental Allergy2004;34(4):639‐45. [MEDLINE: 15080819] ">Pacor 2004</a>, had no financial support from the pharmaceutical industry. However, we did not use this issue to make judgments about the risk of bias. </p> </section> </section> <section id="CD009864-sec-0071"> <h3 class="title" id="CD009864-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD009864-tbl-0001"><b>Summary of findings for the main comparison</b> Tacrolimus 0.1% compared with corticosteroids for atopic dermatitis</a>; <a href="./full#CD009864-tbl-0002"><b>Summary of findings 2</b> Tacrolimus 0.1% compared with pimecrolimus 1% for atopic dermatitis</a>; <a href="./full#CD009864-tbl-0003"><b>Summary of findings 3</b> Tacrolimus 0.03% compared with corticosteroids for atopic dermatitis</a>; <a href="./full#CD009864-tbl-0004"><b>Summary of findings 4</b> Tacrolimus 0.03% compared with tacrolimus 0.1% for atopic dermatitis</a>; <a href="./full#CD009864-tbl-0005"><b>Summary of findings 5</b> Tacrolimus 0.03% versus pimecrolimus 1% for atopic dermatitis</a>; <a href="./full#CD009864-tbl-0006"><b>Summary of findings 6</b> Tacrolimus 0.1% versus ciclosporin for atopic dermatitis</a> </p> <p>The variability of drug doses, outcomes, and follow‐up periods made ​​it difficult to carry out meta‐analyses. We report below the results for outcomes of this review, with subgroup analysis. Please note that our secondary outcome relapse (over a period of up to one year) was not reported in any of the included studies. </p> <section id="CD009864-sec-0072"> <h4 class="title">Tacrolimus 0.1% versus corticosteroids</h4> <section id="CD009864-sec-0073"> <h5 class="title">Primary outcomes</h5> <section id="CD009864-sec-0074"> <h6 class="title">Physician's assessment of global response of improvement</h6> <p>Three studies, <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a>; <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a>; <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a>, reported this outcome at different follow‐up times (3 weeks, 6 months, and 12 months) and different corticosteroid potencies. A statistically significant difference was measured in the group receiving tacrolimus in the study comparing tacrolimus 0.1% ointment with a low‐potency corticosteroid (hydrocortisone acetate 1% ointment) for 3 weeks (risk ratio (RR) 3.09, 95% confidence interval (CI) 2.14 to 4.45, 1 study (<a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a>), 371 participants). A statistically significant difference in favour of tacrolimus was also measured in the study comparing tacrolimus 0.1% with a mid‐potency corticosteroid (hydrocortisone butyrate 0.1% ointment) used on the trunk and extremities and a low‐potency corticosteroid (hydrocortisone acetate 1% ointment) used on the face and neck areas twice a day for 6 months (RR 1.32, 95% CI 1.17 to 1.49, 1 study (<a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a>), 972 participants; <a href="./references#CD009864-fig-0007" title="">Analysis 1.1</a>). </p> <p>No difference was observed in the 12‐month follow‐up time (RR 1.35, 95% CI 0.86 to 2.12, 1 study, 80 participants) in the Mandelin 2010 study, which was a subanalysis of <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a>. The study comparing tacrolimus 0.1% ointment and a mid‐potency corticosteroid (hydrocortisone butyrate 0.1% ointment) for 3 weeks also found no significant differences between the 2 groups (RR 0.95, 95% CI 0.78 to 1.16, 1 study (<a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a>), 377 participants). </p> </section> <section id="CD009864-sec-0075"> <h6 class="title">Participant's self‐assessment of global response of improvement</h6> <p>Only one study, comparing tacrolimus 0.1% and hydrocortisone butyrate 0.1% (mid‐potency corticosteroid), <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a>, reported this outcome after 6 months of treatment, with a statistically significantly higher number of participants in the tacrolimus group reporting improvement (RR 1.21, 95% CI 1.13 to 1.29, 1 study, 972 participants). </p> </section> <section id="CD009864-sec-0076"> <h6 class="title">Occurence and severity of adverse effects</h6> <p>Four studies evaluated the sensation of burning at the application site of tacrolimus 0.1% compared with different potencies of topical corticosteroids. All four studies showed this adverse event to be statistically significantly more frequent in the tacrolimus 0.1% group compared with the topical corticosteroids, regardless of the corticosteroid potency. To list the results individually, <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a> compared tacrolimus 0.1% to a low‐potency corticosteroid (hydrocortisone acetate 1%) used for 3 weeks (RR 2.91, 95% CI 1.60 to 5.28, 1 study, 371 participants); <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a> compared it to a mid‐potency corticosteroid (hydrocortisone butyrate 0.1%) also used for 3 weeks (RR 4.59, 95% CI 3.10 to 6.78, 1 study, 377 participants); <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a> reported 6‐month and 12‐month follow‐up results comparing tacrolimus 0.1% with a mid‐potency corticosteroid (hydrocortisone butyrate 0.1% ointment) applied to the trunk and extremities and a low‐potency corticosteroid (hydrocortisone acetate 1% ointment) applied to the face and neck areas (RR 3.79, 95% CI 2.99 to 4.81, 1 study, 972 participants; RR 1.17, 95% CI 1.02 to 1.35, 1 study, 80 participants, respectively; <a href="./references#CD009864-fig-0008" title="">Analysis 1.2</a>). In the analyses, we have grouped the two interventions hydrocortisone acetate and butyrate together. </p> <p>When assessing "pruritus" and "skin infection", which represent the second and third most common adverse events, we found no significant differences, even though tacrolimus was associated with more frequent reports of pruritus. The authors note the burning and pruritus adverse effects were mild to moderate and transient in all cases (<a href="./references#CD009864-fig-0009" title="">Analysis 1.3</a>; <a href="./references#CD009864-fig-0010" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD009864-sec-0077"> <h5 class="title">Secondary outcomes</h5> <section id="CD009864-sec-0078"> <h6 class="title">Improvement of disease assessed by a validated or objective measure, such as the following: affected Body Surface Area (BSA) </h6> <p><a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a> observed no differences in improvement of affected BSA between tacrolimus 0.1% and hydrocortisone butyrate 0.1% after 3 weeks. (The study report gave no data, only the images of graphs from which we could not extract data precisely. We contacted the study authors for more information, but we received no response). <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a> reported significant improvement of affected BSA in the group receiving tacrolimus 0.1% compared with hydrocortisone butyrate 0.1% ointment used on the trunk and extremities and hydrocortisone acetate 1% ointment used on the face and neck areas after a 6‐month follow‐up, with a median percentage difference from baseline of ‐88.2% versus ‐80.3%, P &lt; 0.001 (Wilcoxon test). An additional report by Mandelin of the <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a> study, which evaluated a subgroup of 80 participants for 12 months, reported better results with tacrolimus 0.1% compared with hydrocortisone, but with no significant difference: median percentage 5.5% (1.7 to 12.0) and 12.8% (3.1 to 42.3), respectively. </p> </section> <section id="CD009864-sec-0079"> <h6 class="title">Improvement of disease assessed by a validated or objective measure, such as the following: Eczema Area and Severity Index (EASI) </h6> <p>Three studies assessed this outcome at different follow‐up times with a modified EASI score (mEASI ‐ see <a href="./appendices#CD009864-sec-0142">Appendix 1</a>). <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a> compared tacrolimus 0.1% with a mid‐potency corticosteroid (hydrocortisone butyrate 0.1%) for 3 weeks and observed no difference in median improvement compared with baseline between groups (63.5% versus 63.9%, Wilcoxon test). In <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a>, the comparison between tacrolimus 0.1% and a mid‐potency corticosteroid (hydrocortisone butyrate 0.1% ointment) used on the trunk and extremities and a low‐potency corticosteroid (hydrocortisone acetate 1% ointment) used on the face and neck areas twice a day showed a median percentage of improvement of 72.6% versus 52.3% for 3 months and a median percentage of improvement of 87.7% versus 82.5% for 6 months. This difference was significant (P &lt; 0.001 and P &lt; 0.008, respectively, Wilcoxon test). In the comparison with a low‐potency corticosteroid, <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a> observed 60.2% of median improvement with tacrolimus 0.1% compared with 36.0% with hydrocortisone acetate 1%, which represented a significant difference as well (P &lt; 0.001, Wilcoxon test). </p> </section> <section id="CD009864-sec-0080"> <h6 class="title">Improvement of disease assessed by a validated or objective measure, such as the following: quality of life </h6> <p>Only one paper, an additional report by Poole 2010 in the <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a> study, evaluated this outcome reporting quality of life measured by the 36‐Item Short Form Health Survey (SF‐36) (a quality of life assessment tool, see <a href="./references#CD009864-bbs2-0097" title="JenkinsonC , Stewart‐BrownS , PetersenS , PaiceC . Assessment of theSF‐36 version 2 in the United Kingdom. Journal of Epidemiology &amp; Community Health1999;53(1):46‐50. [MEDLINE: 10326053] ">Jenkinson 1999</a>). In both the physical component summary (PCS) and the mental component summary (MCS), change from baseline score was statistically significantly different between the 2 groups, favouring tacrolimus 0.1% when compared with mild corticosteroid used on the trunk and extremities and a moderate‐potency corticosteroid used on the face and neck areas. Evaluating the PCS, tacrolimus group participants obtained a mean of 3.3 points (standard deviation (SD) ± 7.5), and the corticosteroid group participants obtained a mean of 2.3 (SD ± 7.6), representing a relative difference in improvement of 43% (P = 0.03, t‐test). The mean of improvement on MCS in the tacrolimus group was 6.0 points (SD ± 11.3) compared with 3.4 points (SD ± 10.6) in the corticosteroid group, with a relative difference of 76% (P &lt; 0.001, t‐test). </p> </section> <section id="CD009864-sec-0081"> <h6 class="title">Improvement of disease assessed by a validated or objective measure, such as the following: SCORing Atopic Dermatitis (SCORAD) </h6> <p>Two studies used SCORAD to assess the disease outcome (<a href="./references#CD009864-bbs2-0001" title="AntigaE , VolpiW , TorchiaD , FabbriP , CaproniM . Effects of tacrolimus ointment on Toll‐like receptors in atopic dermatitis. Clinical &amp; Experimental Dermatology2011;36(3):235‐41. [MEDLINE: 21070333] ">Antiga 2010</a>; <a href="./references#CD009864-bbs2-0004" title="CaproniM , TorchiaD , AntigaE , TerranovaM , VolpiW , delBiancoE , et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. British Journal of Dermatology2007;156(2):312‐9. [MEDLINE: 17223872] ">Caproni 2007</a>). After 3 weeks of treatment, there was a significant difference favouring the group that received tacrolimus 0.1% when compared with a mid‐potency corticosteroid (hydrocortisone butyrate 0.1%) (mean difference (MD) ‐8.82, 95% CI ‐15.36 to ‐2.27, 2 studies, 37 participants; <a href="./references#CD009864-fig-0011" title="">Analysis 1.5</a>) (a decrease in SCORAD is a sign of improvement). However, these results should be viewed with caution because of the small sample size of the study. </p> </section> </section> </section> <section id="CD009864-sec-0082"> <h4 class="title">Tacrolimus 0.1% versus pimecrolimus 1%</h4> <section id="CD009864-sec-0083"> <h5 class="title">Primary outcomes</h5> <section id="CD009864-sec-0084"> <h6 class="title">Physician's assessment of global response of improvement</h6> <p><a href="./references#CD009864-bbs2-0007" title="DraelosZ , NayakA , PariserD , ShupackJL , ChonK , AbramsB , et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‐blind comparison. Journal of the American Academy of Dermatology2005;53(4):602‐9. [MEDLINE: 16198779] ">Draelos 2005</a> reported this outcome at 13 days of treatment, and 2 studies, <a href="./references#CD009864-bbs2-0008" title="FleischerABJr , AbramovitsW , BrenemanD , JaraczE , US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment2007;18(3):151‐7. [MEDLINE: 17538803] ">Fleischer 2007</a>; <a href="./references#CD009864-bbs2-0015" title="AbramovitsW , FleischerABJr , JaraczE , BrenemanD . Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology2008;7(12):1153‐8. [MEDLINE: 19137769] PallerAS , LebwohlM , FleischerABJr , AntayaR , LangleyRG , KirsnerRS , et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology2005;52(5):810‐22. [MEDLINE: 15858471] ">Paller 2005</a>, reported it at 6 weeks. The tacrolimus group showed significantly more improvement compared with the pimecrolimus group (RR 1.80, 95% CI 1.35 to 2.42, 3 studies, 543 participants; <a href="./references#CD009864-fig-0012" title="">Analysis 2.1</a>; <a href="#CD009864-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD009864-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Tacrolimus 0.1% versus pimecrolimus 1%, outcome: 2.1 Physician's assessment of global response of improvement, clear or excellent" data-id="CD009864-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Tacrolimus 0.1% versus pimecrolimus 1%, outcome: 2.1 Physician's assessment of global response of improvement, clear or excellent </p> </div> </div> </div> </section> <section id="CD009864-sec-0085"> <h6 class="title">Participant's self‐assessment of global response of improvement</h6> <p>This outcome was not reported in any of the studies.</p> </section> <section id="CD009864-sec-0086"> <h6 class="title">Occurence and severity of adverse effects</h6> <p>Two included studies, <a href="./references#CD009864-bbs2-0008" title="FleischerABJr , AbramovitsW , BrenemanD , JaraczE , US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment2007;18(3):151‐7. [MEDLINE: 17538803] ">Fleischer 2007</a>; <a href="./references#CD009864-bbs2-0015" title="AbramovitsW , FleischerABJr , JaraczE , BrenemanD . Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology2008;7(12):1153‐8. [MEDLINE: 19137769] PallerAS , LebwohlM , FleischerABJr , AntayaR , LangleyRG , KirsnerRS , et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology2005;52(5):810‐22. [MEDLINE: 15858471] ">Paller 2005</a>, after 6 weeks found no significant differences in the occurrence of adverse events between the groups (RR 0.89, 95% CI 0.47 to 1.71, 2 studies, 506 participants; <a href="./references#CD009864-fig-0013" title="">Analysis 2.2</a>). Burning and pruritus were the most frequent complaints. </p> <p><a href="./references#CD009864-bbs2-0007" title="DraelosZ , NayakA , PariserD , ShupackJL , ChonK , AbramsB , et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‐blind comparison. Journal of the American Academy of Dermatology2005;53(4):602‐9. [MEDLINE: 16198779] ">Draelos 2005</a> analysed separately the occurrence of application site reactions after 13 days of treatment, with more frequent complaints in the tacrolimus 0.1% group (63.2% versus 27.8%, P = 0.03, Chi² test), and the intensity of local symptoms using a visual analogue scale, with more intense local symptoms also occurring in the tacrolimus 0.1% group (insufficient data for statistical analysis). The sample size of the study was however small (37 participants). </p> </section> </section> <section id="CD009864-sec-0087"> <h5 class="title">Secondary outcomes</h5> <section id="CD009864-sec-0088"> <h6 class="title">Improvement of disease assessed by a validated or objective measure, such as the following: affected Body Surface Area (BSA) </h6> <p><a href="./references#CD009864-bbs2-0008" title="FleischerABJr , AbramovitsW , BrenemanD , JaraczE , US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment2007;18(3):151‐7. [MEDLINE: 17538803] ">Fleischer 2007</a> reported this outcome, and a significant difference was observed favouring the group receiving tacrolimus compared with pimecrolimus after 6 weeks of treatment, with a mean of reduction in the affected BSA of 49% and 34% (P = 0.01), respectively. In the same comparison and follow‐up time, <a href="./references#CD009864-bbs2-0015" title="AbramovitsW , FleischerABJr , JaraczE , BrenemanD . Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology2008;7(12):1153‐8. [MEDLINE: 19137769] PallerAS , LebwohlM , FleischerABJr , AntayaR , LangleyRG , KirsnerRS , et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology2005;52(5):810‐22. [MEDLINE: 15858471] ">Paller 2005</a> also reported a significant difference favouring the tacrolimus group (mean reduction from baseline = 64.1% versus 47.5%, P &lt; 0.001). Nevertheless, meta‐analysis was not feasible due to insufficient data. </p> </section> <section id="CD009864-sec-0089"> <h6 class="title">Improvement of disease assessed by a validated or objective measure, such as the following: Eczema Area and Severity Index (EASI) </h6> <p>Two studies comparing tacrolimus 0.1% with pimecrolimus 1% for 6 weeks reported a significant difference favouring the tacrolimus group: mean of reduction from baseline = 57% versus 39% (P = 0.0002) in <a href="./references#CD009864-bbs2-0008" title="FleischerABJr , AbramovitsW , BrenemanD , JaraczE , US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment2007;18(3):151‐7. [MEDLINE: 17538803] ">Fleischer 2007</a> and 67.2% versus 56.4% (P &lt; 0.001) in <a href="./references#CD009864-bbs2-0015" title="AbramovitsW , FleischerABJr , JaraczE , BrenemanD . Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology2008;7(12):1153‐8. [MEDLINE: 19137769] PallerAS , LebwohlM , FleischerABJr , AntayaR , LangleyRG , KirsnerRS , et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology2005;52(5):810‐22. [MEDLINE: 15858471] ">Paller 2005</a>. </p> </section> </section> </section> <section id="CD009864-sec-0090"> <h4 class="title">Tacrolimus 0.03% versus corticosteroids</h4> <section id="CD009864-sec-0091"> <h5 class="title">Primary outcomes</h5> <section id="CD009864-sec-0092"> <h6 class="title">Physician's assessment of global response of improvement</h6> <p>Five studies reported this outcome with varying doses of tacrolimus and types of corticosteroids with follow up of three to four weeks. One study, <a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a>, showed a statistically significant improvement in the tacrolimus 0.03% (once a day) group compared with a low‐potency corticosteroid twice a day (hydrocortisone acetate 1%) (RR 2.05, 95% CI 1.36 to 3.08, 1 study, 411 participants) in children. Two studies in children, <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a>; <a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a>, observed that groups receiving tacrolimus 0.03% twice a day also showed a statistically significant improvement (clear or excellent) by medical evaluation when compared with the same low‐potency corticosteroid (hydrocortisone acetate 1%) (RR 2.58, 95% CI 1.96 to 3.38, 2 studies, 790 participants). Two studies, <a href="./references#CD009864-bbs2-0020" title="Sikder MdAU , Al MamunS , KhanRM , ChowdhuryAH , KhanHM , HoqueMM . Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis ‐ An open randomized comparative study. Journal of Pakistan Association of Dermatologists2005;15(4):304‐12. [EMBASE: 2006159825] ">Sikder 2005</a>; <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a>, compared tacrolimus 0.03% ointment twice a day with mid‐potency corticosteroids twice a day and found no significant differences between the groups (RR 0.45, 95% CI 0.13 to 1.57, 2 studies, 409 participants). Another study, <a href="./references#CD009864-bbs2-0002" title="BieberT , VickK , Folster‐HolstR , Belloni‐FortinaA , StadtlerG , WormM , et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy2007;62(2):184‐9. [MEDLINE: 17298428] ">Bieber 2007</a>, compared tacrolimus 0.03% twice a day with methylprednisone 0.1% (once a day) and did not find any significant differences in improvement between the 2 groups (RR 1.00, 95% CI 0.85 to 1.19, 1 study, 265 participants; <a href="./references#CD009864-fig-0014" title="">Analysis 3.1</a>; <a href="#CD009864-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD009864-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Tacrolimus 0.03% versus corticosteroids, outcome: 3.1 Physician's assessment of global response of improvement, clear or excellent" data-id="CD009864-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Tacrolimus 0.03% versus corticosteroids, outcome: 3.1 Physician's assessment of global response of improvement, clear or excellent </p> </div> </div> </div> <p><a href="./references#CD009864-bbs2-0005" title="DossN , KamounMR , DubertretL , CambazardF , RemitzA , LahfaM , et al. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with moderate‐to‐severe atopic dermatitis: evidence from a randomized, double‐blind non‐inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy &amp; Immunology2010;21(2 Pt 1):321‐9. [MEDLINE: 19563466] ">Doss 2010</a> reported an improvement in the outcome 'Physician's global assessment' of 93.6% in the tacrolimus group and 92.4% in the mid‐potency corticosteroid group (fluticasone 0.005%) (P = 0.05). </p> </section> <section id="CD009864-sec-0093"> <h6 class="title">Participant's self‐assessment of global response of improvement</h6> <p>Two studies reported participant's self‐assessment of global response of improvement after three weeks of treatment (<a href="./references#CD009864-bbs2-0005" title="DossN , KamounMR , DubertretL , CambazardF , RemitzA , LahfaM , et al. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with moderate‐to‐severe atopic dermatitis: evidence from a randomized, double‐blind non‐inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy &amp; Immunology2010;21(2 Pt 1):321‐9. [MEDLINE: 19563466] ">Doss 2010</a>; <a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a>). In the comparison of tacrolimus 0.03% once or twice a day and hydrocortisone acetate 1%, more participants in the tacrolimus group, in both the once or twice daily application groups, reported better or much better improvement (RR 1.33, 95% CI 1.13 to 1.57, 1 study, 411 participants; RR 1.64, 95% CI 1.41 to 1.90, 1 study, 416 participants, respectively). The comparison of tacrolimus 0.03% and fluticasone 0.005% found no differences between the groups (RR 0.98, 95% CI 0.92 to 1.05, 1 study, 473 participants; <a href="./references#CD009864-fig-0015" title="">Analysis 3.2</a>). </p> </section> <section id="CD009864-sec-0094"> <h6 class="title">Occurence and severity of adverse effects</h6> <p>Five studies reported local adverse events, <a href="./references#CD009864-bbs2-0005" title="DossN , KamounMR , DubertretL , CambazardF , RemitzA , LahfaM , et al. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with moderate‐to‐severe atopic dermatitis: evidence from a randomized, double‐blind non‐inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy &amp; Immunology2010;21(2 Pt 1):321‐9. [MEDLINE: 19563466] ">Doss 2010</a>; <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a>; <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a>; <a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a>; <a href="./references#CD009864-bbs2-0020" title="Sikder MdAU , Al MamunS , KhanRM , ChowdhuryAH , KhanHM , HoqueMM . Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis ‐ An open randomized comparative study. Journal of Pakistan Association of Dermatologists2005;15(4):304‐12. [EMBASE: 2006159825] ">Sikder 2005</a>, and there was a significantly higher incidence of burning and pruritus in the tacrolimus groups compared with the corticosteroid groups for burning (RR 2.48, 95% CI 1.96 to 3.14, 5 studies, 1883 participants; <a href="./references#CD009864-fig-0016" title="">Analysis 3.3</a>) and for pruritus (RR 1.51, 95% CI 1.17 to 1.95, 5 studies, 1883 participants; <a href="./references#CD009864-fig-0017" title="">Analysis 3.4</a>). When assessing skin infection, there was no significant difference between the groups (RR 1.07, 95% CI 0.69 to 1.66, 4 studies, 1643 participants; <a href="./references#CD009864-fig-0018" title="">Analysis 3.5</a>). The authors reported that adverse effects were transitory and not a reason for withdrawal from treatment. </p> <p><a href="./references#CD009864-bbs2-0002" title="BieberT , VickK , Folster‐HolstR , Belloni‐FortinaA , StadtlerG , WormM , et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy2007;62(2):184‐9. [MEDLINE: 17298428] ">Bieber 2007</a> reported drug‐related adverse events in 6 out of 136 participants (4.4%) in the tacrolimus 0.03% twice a day group (pruritus, burning, and hot flushes) and none in the methylprednisolone aceponate 0.1% (once a day) group (n = 129) in a 3‐week follow‐up time. </p> </section> </section> <section id="CD009864-sec-0095"> <h5 class="title">Secondary outcomes</h5> <section id="CD009864-sec-0096"> <h6 class="title">Improvement of disease assessed by a validated or objective measure, such as the following: affected Body Surface Area (BSA) </h6> <p>Two studies found less improvement of the affected BSA in the tacrolimus 0.03% group compared with mid‐ to high‐potency corticosteroids: <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a> (data in graphs, comparison with hydrocortisone butyrate 0.1%, 3 weeks) and <a href="./references#CD009864-bbs2-0020" title="Sikder MdAU , Al MamunS , KhanRM , ChowdhuryAH , KhanHM , HoqueMM . Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis ‐ An open randomized comparative study. Journal of Pakistan Association of Dermatologists2005;15(4):304‐12. [EMBASE: 2006159825] ">Sikder 2005</a> (comparison with clobetasone, 4 weeks, t‐test, MD 26.7, 95% CI 8.1 to 45.3, P = 0.007). Moreover, <a href="./references#CD009864-bbs2-0002" title="BieberT , VickK , Folster‐HolstR , Belloni‐FortinaA , StadtlerG , WormM , et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy2007;62(2):184‐9. [MEDLINE: 17298428] ">Bieber 2007</a>, in a study comparing tacrolimus 0.03% twice a day and methylprednisolone once a day (potent corticosteroid), observed no significant difference between the 2 groups. <a href="./references#CD009864-bbs2-0010" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma, &amp; Immunology 007;98(1):51‐6. [MEDLINE: 17225720] ">Hung 2007</a> compared tacrolimus 0.03% with fluticasone 0.05%, with or without the addition of fusidic acid, and also found no significant difference in affected BSA improvement between groups after 8 weeks of treatment. We were not able to extract any data because the original paper presented these in graphs. </p> </section> <section id="CD009864-sec-0097"> <h6 class="title">Improvement of disease assessed by a validated or objective measure, such as the following: Eczema Area and Severity Index (EASI) </h6> <p>This outcome was reported in six studies; however, we did not perform meta‐analysis because of insufficient data. <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a> observed a significant difference, with less improvement in the group receiving tacrolimus 0.03% when compared with the group receiving hydrocortisone butyrate 0.1% (moderate‐potency corticosteroid) (data in graphs). Another study comparing tacrolimus 0.03% with a mid‐potency corticosteroid (clobetasone butyrate), <a href="./references#CD009864-bbs2-0020" title="Sikder MdAU , Al MamunS , KhanRM , ChowdhuryAH , KhanHM , HoqueMM . Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis ‐ An open randomized comparative study. Journal of Pakistan Association of Dermatologists2005;15(4):304‐12. [EMBASE: 2006159825] ">Sikder 2005</a>, found the same results with less improvement in the group receiving tacrolimus 0.03% compared with the clobetasone group (MD 12.5, 95% CI 2.4 to 22.7, P = 0.018). In the comparison between tacrolimus 0.03% twice a day and methylprednisolone (once a day) (high‐potency corticosteroid), <a href="./references#CD009864-bbs2-0002" title="BieberT , VickK , Folster‐HolstR , Belloni‐FortinaA , StadtlerG , WormM , et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy2007;62(2):184‐9. [MEDLINE: 17298428] ">Bieber 2007</a> found no significant difference in mean change from baseline for mEASI between groups. Similarly, <a href="./references#CD009864-bbs2-0005" title="DossN , KamounMR , DubertretL , CambazardF , RemitzA , LahfaM , et al. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with moderate‐to‐severe atopic dermatitis: evidence from a randomized, double‐blind non‐inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy &amp; Immunology2010;21(2 Pt 1):321‐9. [MEDLINE: 19563466] ">Doss 2010</a> also found no difference between the group receiving tacrolimus 0.03% and fluticasone twice a day (mid‐potency). Compared with a low‐potency corticosteroid (hydrocortisone acetate 1%), <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a> showed that, averaged over the 3‐week course of treatment, participants had a median improvement of mEASI of 55.2% with tacrolimus 0.03%, significantly more effective than the mean 36.0% with hydrocortisone acetate 1% ointment (P &lt; 0.001, Wilcoxon test). Also, in <a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a>, the comparison of tacrolimus 0.03%, once a day and twice a day, with the same low‐potency corticosteroid showed a significantly greater decrease of the median percentage in mEASI for the tacrolimus groups (66.7%, 76.7%, and 47.6%, respectively; P &lt; 0.001, Wilcoxon test). </p> </section> <section id="CD009864-sec-0098"> <h6 class="title">Improvement of disease assessed by a validated or objective measure, such as the following: SCORing Atopic Dermatitis (SCORAD) </h6> <p><a href="./references#CD009864-bbs2-0010" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma, &amp; Immunology 007;98(1):51‐6. [MEDLINE: 17225720] ">Hung 2007</a>, who compared tacrolimus 0.03% with fluticasone 0.05%, with or without the addition of fusidic acid, found no significant improvement in SCORAD between the groups after 8 weeks of treatment (data shown in graphs). </p> </section> </section> </section> <section id="CD009864-sec-0099"> <h4 class="title">Tacrolimus 0.03% versus tacrolimus 0.1%</h4> <section id="CD009864-sec-0100"> <h5 class="title">Primary outcomes</h5> <section id="CD009864-sec-0101"> <h6 class="title">Physician's assessment of global response of improvement</h6> <p>In the 6 studies comparing these 2 formulations of tacrolimus in 3 weeks, <a href="./references#CD009864-bbs2-0003" title="BoguniewiczM , FiedlerVC , RaimerS , LawrenceID , LeungDY , HanifinJM . A randomized, vehicle‐controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy &amp; Clinical Immunology1998;102(4 Pt 1):637‐44. [MEDLINE: 9802373] ">Boguniewicz 1998</a>; <a href="./references#CD009864-bbs2-0012" title="Otsuki , M , Kawashima , M , Shibata , Y , Nakagawa , H , Harada , S . Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis‐Phase III Double‐blinded Comparison with Vehicle Ointment. Journal of Clinical Therapeutics &amp; Medicines (Rinsho Iyaku)2003;19:569‐95. ">Otsuki 2003</a>; <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a>; <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a>, and 12 weeks, <a href="./references#CD009864-bbs2-0009" title="HanifinJM , LingMR , LangleyR , BrenemanD , RafalE . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. Journal of the American Academy of Dermatology2001;44(Suppl 1):S28‐38. [EMBASE: 2001020450] SoterNA , Fleischer JrAB , WebsterGF , MonroeE , LawrenceI . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. Journal of the American Academy of Dermatology2001;44(1 Suppl):S39‐46. [DOI: 10.1067/mjd.2001.109817; EMBASE: 2001020451] ">Hanifin 2001</a>; <a href="./references#CD009864-bbs2-0014" title="PallerA , EichenfieldLF , LeungDY , StewartD , AppellM . A 12‐week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology2001;44(1 Suppl):S47‐57. [MEDLINE: 11145795] ">Paller 2001</a>, there was a statistically significant difference in the physician's assessment of global response (clear or excellent) favouring tacrolimus 0.1% (RR 0.82, 95% CI 0.72 to 0.92, 6 studies, 1640 participants; <a href="./references#CD009864-fig-0019" title="">Analysis 4.1</a>; <a href="#CD009864-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD009864-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Tacrolimus 0.03% versus tacrolimus 0.1%, outcome: 4.1 Physician's assessment of global response of improvement, clear or excellent" data-id="CD009864-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Tacrolimus 0.03% versus tacrolimus 0.1%, outcome: 4.1 Physician's assessment of global response of improvement, clear or excellent </p> </div> </div> </div> </section> <section id="CD009864-sec-0102"> <h6 class="title">Participant's self‐assessment of global response of improvement</h6> <p>Only one study, <a href="./references#CD009864-bbs2-0003" title="BoguniewiczM , FiedlerVC , RaimerS , LawrenceID , LeungDY , HanifinJM . A randomized, vehicle‐controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy &amp; Clinical Immunology1998;102(4 Pt 1):637‐44. [MEDLINE: 9802373] ">Boguniewicz 1998</a>, reported this outcome in the comparison of the 2 tacrolimus formulations, 0.03% versus 0.1%, and no differences were found between the 2 groups: 76% (32 out of 42) versus 91% (38 out of 42) (P = 0.08, Chi² test). </p> </section> <section id="CD009864-sec-0103"> <h6 class="title">Occurence and severity of adverse effects</h6> <p>Four 3‐week studies, <a href="./references#CD009864-bbs2-0003" title="BoguniewiczM , FiedlerVC , RaimerS , LawrenceID , LeungDY , HanifinJM . A randomized, vehicle‐controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy &amp; Clinical Immunology1998;102(4 Pt 1):637‐44. [MEDLINE: 9802373] ">Boguniewicz 1998</a>; <a href="./references#CD009864-bbs2-0012" title="Otsuki , M , Kawashima , M , Shibata , Y , Nakagawa , H , Harada , S . Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis‐Phase III Double‐blinded Comparison with Vehicle Ointment. Journal of Clinical Therapeutics &amp; Medicines (Rinsho Iyaku)2003;19:569‐95. ">Otsuki 2003</a>; <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a>; <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a>, did not find any significant differences in the incidence of adverse events (RR 0.95, 95% CI 0.86 to 1.06, 4 studies, 986 participants; <a href="./references#CD009864-fig-0020" title="">Analysis 4.2</a>). Another 12‐week study, <a href="./references#CD009864-bbs2-0014" title="PallerA , EichenfieldLF , LeungDY , StewartD , AppellM . A 12‐week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology2001;44(1 Suppl):S47‐57. [MEDLINE: 11145795] ">Paller 2001</a>, also failed to find any significant difference between the groups, adjusted incidence of 42.7% versus 33.7% for burning and 41.2% versus 32.2% for pruritus (235 participants, Kaplan‐Meier analyses). </p> </section> </section> <section id="CD009864-sec-0104"> <h5 class="title">Secondary outcomes</h5> <section id="CD009864-sec-0105"> <h6 class="title">Improvement of disease assessed by a validated or objective measure, such as the following: Eczema Area and Severity Index (EASI) </h6> <p><a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a> observed a median improvement of 55.2% in the mEASI with tacrolimus 0.03% and 60.2% with tacrolimus 0.1%, which represented a significant difference (P = 0.006, Wilcoxon test) in children. In <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a>, there was also less improvement in the tacrolimus 0.03% group when used in adults (53.0% versus 63.5% median improvement, P &lt; 0.001, Wilcoxon test). <a href="./references#CD009864-bbs2-0003" title="BoguniewiczM , FiedlerVC , RaimerS , LawrenceID , LeungDY , HanifinJM . A randomized, vehicle‐controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy &amp; Clinical Immunology1998;102(4 Pt 1):637‐44. [MEDLINE: 9802373] ">Boguniewicz 1998</a> reported a mean per cent improvement of 72% with tacrolimus 0.03% and 77% with tacrolimus 0.1%, without providing the necessary data for statistical analysis. Also, <a href="./references#CD009864-bbs2-0009" title="HanifinJM , LingMR , LangleyR , BrenemanD , RafalE . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. Journal of the American Academy of Dermatology2001;44(Suppl 1):S28‐38. [EMBASE: 2001020450] SoterNA , Fleischer JrAB , WebsterGF , MonroeE , LawrenceI . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. Journal of the American Academy of Dermatology2001;44(1 Suppl):S39‐46. [DOI: 10.1067/mjd.2001.109817; EMBASE: 2001020451] ">Hanifin 2001</a> and <a href="./references#CD009864-bbs2-0014" title="PallerA , EichenfieldLF , LeungDY , StewartD , AppellM . A 12‐week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology2001;44(1 Suppl):S47‐57. [MEDLINE: 11145795] ">Paller 2001</a> found similar results, but the study report only presented data as graphs (no numbers were given). </p> </section> <section id="CD009864-sec-0106"> <h6 class="title">Improvement of disease assessed by a validated or objective measure, such as the following: quality of life </h6> <p><a href="./references#CD009864-bbs2-0006" title="DouX , LiuL‐L , XieZ‐Q , ChenL‐J , LiL , FengS‐Y , et al. The impact of tacrolimus ointment on health‐related quality of life of Chinese adult and pediatric patients with atopic dermatitis (Chinese). Journal of Clinical Dermatology2006;35(1):50‐2. ">Dou 2006</a> evaluated the quality of life and presented narrative results referring to significant improvement in the group receiving tacrolimus 0.1% compared with tacrolimus 0.03%. </p> </section> </section> </section> <section id="CD009864-sec-0107"> <h4 class="title">Tacrolimus 0.03% versus pimecrolimus 1%</h4> <section id="CD009864-sec-0108"> <h5 class="title"><sup>Primary outcomes</sup> </h5> <section id="CD009864-sec-0109"> <h6 class="title">Physician's assessment of global response of improvement</h6> <p>One study, <a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a>, compared tacrolimus 0.03% with pimecrolimus 1% for 6 weeks, with a significant difference favouring tacrolimus in the physician's global assessment of "clear" or "almost clear" response (RR 1.42, 95% CI 1.02 to 1.98,1 study, 139 participants; <a href="./references#CD009864-fig-0021" title="">Analysis 5.1</a>). </p> </section> <section id="CD009864-sec-0110"> <h6 class="title">Participant's self‐assessment of global response of improvement</h6> <p>This outcome was not reported in any of the studies.</p> </section> <section id="CD009864-sec-0111"> <h6 class="title">Occurence and severity of adverse effects</h6> <p><a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a> compared tacrolimus 0.03% with pimecrolimus 1% used for 6 weeks (141 participants), with no significant difference at day 4 for application site reaction, burning, itching, or erythema between groups (<a href="./references#CD009864-fig-0022" title="">Analysis 5.2</a>). </p> </section> </section> <section id="CD009864-sec-0112"> <h5 class="title">Secondary outcomes</h5> <section id="CD009864-sec-0113"> <h6 class="title">Improvement of disease assessed by a validated or objective measure, such as the following: affected Body Surface Area (BSA) </h6> <p><a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a> compared tacrolimus 0.03% with pimecrolimus 1% and found no significant differences in the change from baseline of the affected BSA after 6 weeks between groups (44.5% versus 43.4%, Mantel‐Haenszel test, controlling for centre). </p> </section> </section> </section> <section id="CD009864-sec-0114"> <h4 class="title">Tacrolimus 0.1% versus ciclosporin</h4> <section id="CD009864-sec-0115"> <h5 class="title">Primary outcomes</h5> <section id="CD009864-sec-0116"> <h6 class="title">Physician's assessment of global response of improvement</h6> <p>This outcome was not reported in any of the studies.</p> </section> <section id="CD009864-sec-0117"> <h6 class="title">Participant's self‐assessment of global response of improvement</h6> <p>This outcome was not reported in any of the studies.</p> </section> <section id="CD009864-sec-0118"> <h6 class="title">Occurence and severity of adverse effects</h6> <p><a href="./references#CD009864-bbs2-0013" title="PacorML , DiLorenzoG , MartinelliN , MansuetoP , RiniGB , CorrocherR . Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clinical &amp; Experimental Allergy2004;34(4):639‐45. [MEDLINE: 15080819] ">Pacor 2004</a> was the only study that compared topical tacrolimus 0.1% twice a day to a systemic medication (oral ciclosporin 3 mg/kg/day). The number of participants reporting adverse events in the follow‐up period was equal in the 2 groups (4 out of 15 in the ciclosporin group and 4 out of 15 in the tacrolimus group) (<a href="./references#CD009864-fig-0023" title="">Analysis 6.1</a>). In the tacrolimus group, the adverse effects were mild and local (burning), and in the ciclosporin group, they were mild and systemic (gastric intolerance and headache). </p> </section> </section> <section id="CD009864-sec-0119"> <h5 class="title">Secondary outcomes</h5> <section id="CD009864-sec-0120"> <h6 class="title">Improvement of disease assessed by a validated or objective measure, such as the following: SCORing Atopic Dermatitis (SCORAD) </h6> <p><a href="./references#CD009864-bbs2-0013" title="PacorML , DiLorenzoG , MartinelliN , MansuetoP , RiniGB , CorrocherR . Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clinical &amp; Experimental Allergy2004;34(4):639‐45. [MEDLINE: 15080819] ">Pacor 2004</a> reported the outcome of the comparison between tacrolimus 0.1% ointment twice a day and ciclosporin tablets 3 mg/kg/day in a follow‐up period of 6 weeks. After 2 weeks, SCORAD decreased in both groups. Participants in the tacrolimus group reported though a significantly lower SCORAD (that means, more improvement) when compared to those treated with oral ciclosporin. The mean difference in SCORAD in the tacrolimus group compared with SCORAD in the ciclosporin group was MD −12.6 (95% CI −18.7 to −6.5) after 14 days, MD −11.6 (95% CI −17.7 to −5.5) after 21 days, MD −18.7 (95% CI −24.8 to −12.6) after 28 days, and MD −10.1 (95% CI −16.2 to −4.0) after 35 days. After 42 days, however, the mean of SCORAD was not significantly different: MD −1.3 (95% CI−7.4 to 4.8; <a href="./references#CD009864-fig-0024" title="">Analysis 6.2</a>). Overall SCORAD, as assessed by the area under the curve between days 0 to 42 (AUCº to ⁴²) (AUC = area under the curve) that represents the cumulative measurement of drug effect on this period (in the case of SCORAD, the lower the better), was significantly lower in the tacrolimus ointment group when compared with oral ciclosporin (P &lt; 0.001, unpaired Student's test). </p> </section> </section> </section> <section id="CD009864-sec-0121"> <h4 class="title">Safety of topical tacrolimus</h4> <section id="CD009864-sec-0122"> <h5 class="title">Other reported adverse events and serious adverse events</h5> <p>Other reported local adverse events were folliculitis, erythema, maculopapular rash, and alcohol intolerance (local erythema after alcohol ingestion); the last symptom was only in the calcineurin inhibitors groups. All groups reported systemic symptoms that included flu‐like symptoms, headache, and fever. </p> <p>There were rare reports of serious adverse events. The two tacrolimus‐dose groups and the vehicle group in the study by <a href="./references#CD009864-bbs2-0012" title="Otsuki , M , Kawashima , M , Shibata , Y , Nakagawa , H , Harada , S . Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis‐Phase III Double‐blinded Comparison with Vehicle Ointment. Journal of Clinical Therapeutics &amp; Medicines (Rinsho Iyaku)2003;19:569‐95. ">Otsuki 2003</a> reported laboratory‐study abnormalities, and the study authors considered them to be unrelated to the study medication. <a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a> reported increased liver enzymes in 2 participants in the corticosteroid group and 1 participant in the tacrolimus 0.03% group. Also, this group reported one case of a mild and transient decrease in white blood cell count. <a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a> described 1 case of increased liver enzymes in the tacrolimus 0.03% group and 1 case of increased serum creatinine in the corticosteroid group. <a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a> showed 1 case of leukopenia, 1 case of failure to thrive (considered as being unrelated to treatment), and 1 case of Kaposi's varicelliform eruption with bacterial infection in the tacrolimus 0.03% twice‐a‐day group. The tacrolimus 0.03% (once‐a‐day) group reported 1 case of a decreased white blood cell count. The corticosteroid group reported one case of abdominal pain and one case of leg pain (osteoarticular infection). One participant presented with an important erythema on the forehead, with complete resolution after treatment with antihistamines in <a href="./references#CD009864-bbs2-0014" title="PallerA , EichenfieldLF , LeungDY , StewartD , AppellM . A 12‐week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology2001;44(1 Suppl):S47‐57. [MEDLINE: 11145795] ">Paller 2001</a>. (The participant completed the study.) Finally, <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a> reported one case of lymphoma‐like reaction and one case of skin carcinoma in the corticosteroid group. </p> </section> <section id="CD009864-sec-0123"> <h5 class="title">Adverse events in any type of study design</h5> <p>Looking at other sources, we screened more than 3800 abstracts and analysed all the data on tacrolimus safety in atopic dermatitis, independently of study design. Common and non‐serious adverse events were similar to those found in the included studies. We will discuss in detail more controversial risks, especially those that lead to U.S. Food and Drug Administration (FDA) black‐box warnings. We did not include in this review reports of the use of tacrolimus for other diseases, mainly because the diseases themselves carry sometimes intrinsic risks, such as development of malignancy in lichen sclerosus et atrophicus. </p> </section> <section id="CD009864-sec-0124"> <h5 class="title">Risk of malignancies</h5> <p><a href="#CD009864-tbl-0008">Table 2</a>, 'Spontaneous reported malignancies in association with topical tacrolimus use', lists FDA‐reported malignancies (<a href="./references#CD009864-bbs2-0122" title="OrmerodAD . Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?. British Journal of Dermatology2005;153(4):701‐5. [MEDLINE: 16181449] ">Ormerod 2005</a>). The Spanish Pharmacovigilance System (paediatric adverse event reports from 2004 to 2009) reported another case of lymphoma in a 20‐month‐old participant with a T‐cell lymphoma. He had used tacrolimus (the report did not specify if it was topical or systemic) and methylprednisolone (<a href="./references#CD009864-bbs2-0047" title="AldeaA , Garcia Sanchez‐ColomerM , Fernandez QuintanaE , Garcia SaizM . Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009. European Journal of Clinical Pharmacology2012;68(9):1329‐38. [MEDLINE: 22415248] ">Aldea 2012</a>). </p> <div class="table" id="CD009864-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Spontaneous reported malignancies in association with topical tacrolimus use</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Malignancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Application site</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Occurence site</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposure to onset (days)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B‐cell lymphoma, EBV‐associated, and primary lung carcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Face</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kidney</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>730</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cutaneous Kaposi sarcoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Axilla, groin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Axilla, groin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV patient on HAART, treated for inverse psoriasis, developed KS at these sites, which metastasised, and the patient died </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hepatoblastoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Considered unrelated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>455</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymphadenopathy – possible<br/> lymphoma </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Application site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Application site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐existing lymphoma lesions 'looked like' lymphoma and resolved spontaneously*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymphoma or Sézary syndrome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Face</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph nodes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant also had been on systemic ciclosporin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>730</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastatic angiosarcoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Face/neck</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clavicle</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Present before treatment but increased rapidly in size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastatic melanoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastatic disease newly detected from primary 3 years early</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 to 28</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastatic sweat gland carcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not axilla</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Axilla</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nodular follicular lymphoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower limbs, face</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May be associated with EBV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐Hodgkin lymphoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Used tacrolimus for 6 months. Insufficient evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐Hodgkin lymphoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Used tacrolimus on extensive areas: 50% of body. Died from lymphoma. Insufficient evidence </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophageal cancer with metastases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophagus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Panniculitis‐like T‐cell lymphoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trunk, limbs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trunk, limbs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Also used pimecrolimus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Squamous cell carcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Face</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Face</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UV therapy, outdoor sports</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Squamous cell carcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treated for balanitis considered to be lichen sclerosus et atrophicus; non‐specific biopsy </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Squamous cell carcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mouth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long history of pipe smoking</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Squamous cell carcinoma recurrence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vulva</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vulva</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treated for lichen sclerosus et atrophicus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T‐cell lymphoma, anaplastic large cell</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right hip</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right hip</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>EBV: Epstein–Barr virus.<br/> HIV: human immunodeficiency virus.<br/> HAART: highly active antiretroviral therapy.<br/> KS: Kaposi sarcoma.<br/> UV: ultraviolet.<br/> *Questionable if this should be classed as malignant.<br/> Data shown in <a href="./references#CD009864-bbs2-0122" title="OrmerodAD . Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?. British Journal of Dermatology2005;153(4):701‐5. [MEDLINE: 16181449] ">Ormerod 2005</a>. </p> </div> </div> <p><a href="#CD009864-tbl-0009">Table 3</a> and <a href="#CD009864-tbl-0010">Table 4</a> summarise cohort and case‐control studies analysing lymphoma and skin cancer risks related to atopic dermatitis or treatments, respectively. None of the studies found an increased risk of skin cancers other than lymphoma. Regarding the risks of lymphoma, <a href="./references#CD009864-bbs2-0051" title="ArellanoFM , WentworthCE , AranaA , FernandezC , PaulCF . Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. Journal of Investigative Dermatology2007;127(4):808‐16. [MEDLINE: 17096020] ">Arellano 2007</a> and <a href="./references#CD009864-bbs2-0052" title="ArellanoFM , AranaA , WentworthCE , Fernandez‐VidaurreC , SchliengerRG , CondeE . Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. Journal of Allergy &amp; Clinical Immunology2009;123(5):1111‐6. [MEDLINE: 19361841] ">Arellano 2009</a> showed an apparent risk related to atopic dermatitis (and its severity); other authors, <a href="./references#CD009864-bbs2-0148" title="SoderbergKC , HagmarL , SchwartzbaumsJ , FeychtingM . Allergic conditions and the risk of hematological malignancies in adults: a cohort study. BMC Public Health2004;4:51. [MEDLINE: 15527506] ">Soderberg 2004</a>, also suggested a disease‐related risk. <a href="./references#CD009864-bbs2-0067" title="CallenJ , ChamlinS , EichenfieldLF , EllisC , GirardiM , GoldfarbM , et al. A systematic review of the safety of topical therapies for atopic dermatitis. British Journal of Dermatology2007;156(2):203‐21. [MEDLINE: 17223859] ">Callen 2007</a> described 7 studies analysing this subject, and results showed odds ratios of both &gt; 1 and &lt; 1, with no final conclusion. There are two possible explanations for this increased risk: either there is indeed a real increased risk of lymphomas developing in people with atopic dermatitis, or there are cases that were misdiagnosed as atopic dermatitis and were already cases of cutaneous lymphoma to start with. Many cases of skin lymphomas may start with a clinical presentation resembling chronic dermatitis, several years before they are finally diagnosed as cutaneous lymphomas. <a href="./references#CD009864-bbs2-0052" title="ArellanoFM , AranaA , WentworthCE , Fernandez‐VidaurreC , SchliengerRG , CondeE . Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. Journal of Allergy &amp; Clinical Immunology2009;123(5):1111‐6. [MEDLINE: 19361841] ">Arellano 2009</a> also found an increased risk of lymphomas in systemic corticosteroid users, but found insufficient data to make conclusions about users of topical calcineurin inhibitors (TCI). <a href="./references#CD009864-bbs2-0141" title="SchneeweissS , DohertyM , ZhuS , FunchD , SchliengerRG , Fernandez‐VidaurreC , et al. Topical treatments with pimecrolimus, tacrolimus and medium‐ to high‐potency corticosteroids, and risk of lymphoma. Dermatology2009;219(1):7‐21. [MEDLINE: 19293564] ">Schneeweiss 2009</a> noted an increased risk in users of TCI and topical corticosteroids when compared with the general population, but with similar risks between the treatment groups. This might have occurred because of the comparison with non‐atopic dermatitis participants. We noticed similar findings in <a href="./references#CD009864-bbs2-0095" title="HuiRL , LideW , ChanJ , SchottingerJ , YoshinagaM , MillaresM . Association between exposure to topical tacrolimus or pimecrolimus and cancers. Annals of Pharmacotherapy2009;43(12):1956‐63. [MEDLINE: 19903860] ">Hui 2009</a>, with a report of an increased risk in the TCI‐exposed group when compared with non‐exposed individuals. Again, the proportion of participants with the diagnosis of atopic dermatitis was twice as high in the exposed group. It is questionable if the increased risk was due to exposure or due to possible intrinsic risks of lymphoma related to atopic dermatitis as discussed above. The observational studies reported no cases of lymphoma and sparse and probably unrelated cases of skin cancers (see <a href="#CD009864-tbl-0011">Table 5</a>; <a href="./references#CD009864-bbs2-0113" title="MargolisDJ , HoffstadO , Bilker , W . Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology2007;214(4):289‐95. [MEDLINE: 17460399] ">Margolis 2007</a>; <a href="./references#CD009864-bbs2-0120" title="NaylorM , ElmetsC , JaraczE , RicoJM . Non‐melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. Journal of Dermatological Treatment2005;16(3):149‐53. [MEDLINE: 16096180] ">Naylor 2005</a>). </p> <div class="table" id="CD009864-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Lymphoma risk</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Results related to lymphoma risks</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0051" title="ArellanoFM , WentworthCE , AranaA , FernandezC , PaulCF . Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. Journal of Investigative Dermatology2007;127(4):808‐16. [MEDLINE: 17096020] ">Arellano 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294 cases/293,000 controls</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCIs and TCS in participants with AD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Increased risk in AD participants (related to severity)</p> <p>‐ No evidence of increased risk with any of the topical treatments</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0052" title="ArellanoFM , AranaA , WentworthCE , Fernandez‐VidaurreC , SchliengerRG , CondeE . Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. Journal of Allergy &amp; Clinical Immunology2009;123(5):1111‐6. [MEDLINE: 19361841] ">Arellano 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 3,000,000 (cohort)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1992 to 2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD, treatment with topical immunosuppressants, or both</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Increase risk in AD participants (related to severity)</p> <p>‐ Increased risk with topical corticosteroids (related to potency)</p> <p>‐ Insufficient data to assess TCI‐related risks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0095" title="HuiRL , LideW , ChanJ , SchottingerJ , YoshinagaM , MillaresM . Association between exposure to topical tacrolimus or pimecrolimus and cancers. Annals of Pharmacotherapy2009;43(12):1956‐63. [MEDLINE: 19903860] ">Hui 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>953,064 (cohort) (96% unexposed, 4% exposed)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 2.4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD or eczema participants exposed or not to TCI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Increased risk in the exposed group**</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0141" title="SchneeweissS , DohertyM , ZhuS , FunchD , SchliengerRG , Fernandez‐VidaurreC , et al. Topical treatments with pimecrolimus, tacrolimus and medium‐ to high‐potency corticosteroids, and risk of lymphoma. Dermatology2009;219(1):7‐21. [MEDLINE: 19293564] ">Schneeweiss 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ 118,863 for pimecrolimus</p> <p>‐ 38,757 for tacrolimus</p> <p>‐ 1,043,025 mid to potent corticosteroid</p> <p>‐ 118,825 untreated dermatitis</p> <p>‐ 118,863 for general population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002 to 2006</p> <p>(median 1.3 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Increased risk compared with general population*</p> <p>‐ No risk differences between the 3 treatments</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*pre‐existing lymphomas misdiagnosed as AD.<br/> **proportion of people who had diagnosis of AD was 2 times higher in the exposed group (i.e., there was a higher prevalence of AD than eczema in the exposed group). See <a href="#CD009864-sec-0129">Summary of main results</a> (Risk of malignancies).<br/> AD: atopic dermatitis.<br/> TCI: topical calcineurin inhibitor.<br/> TCS: topical corticosteroids. </p> </div> </div> <div class="table" id="CD009864-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Non‐melanoma skin cancer (NMSC) and melanoma (MM) skin cancer risk</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Follow up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Results related to skin cancer risks</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0095" title="HuiRL , LideW , ChanJ , SchottingerJ , YoshinagaM , MillaresM . Association between exposure to topical tacrolimus or pimecrolimus and cancers. Annals of Pharmacotherapy2009;43(12):1956‐63. [MEDLINE: 19903860] ">Hui 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>953,064 (cohort) (96% unexposed, 4% exposed)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 2.4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD participants exposed or not to TCI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Similar risks for NMSC</p> <p>‐ Lower risks for MM</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0113" title="MargolisDJ , HoffstadO , Bilker , W . Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology2007;214(4):289‐95. [MEDLINE: 17460399] ">Margolis 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>875 cases</p> <p>1946 controls</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dermatitis participants (AD, seborrhoeic dermatitis, rosacea, other dermatitis) with or without use of TCI </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ No increased risk of NMSC in TCI‐treated participants</p> <p>‐ MM risk not evaluated</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0120" title="NaylorM , ElmetsC , JaraczE , RicoJM . Non‐melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. Journal of Dermatological Treatment2005;16(3):149‐53. [MEDLINE: 16096180] ">Naylor 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9813 tacrolimus‐treated participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months to 4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD participants with tacrolimus use compared with an aged cohort in the US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ No increased risk of NMSC in tacrolimus treated participants</p> <p>‐ MM risk not evaluated</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AD: atopic dermatitis.<br/> TCI: topical calcineurin inhibitor.<br/> MM: melanoma.<br/> NMSC: non‐melanoma skin cancer. </p> </div> </div> <div class="table" id="CD009864-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Observational non‐comparative studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> 1. Population</b> </p> <p><b> 2. Age group</b> </p> <p><b> 3. Follow‐up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus formulation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Common local effects</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Systemic effects</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Laboratory values</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Malignancies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Others (number of events)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Detectable blood concentration</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0087" title="GontijoB , PiresMC , CestariTF , LaScalaCSK , DuarteIAG , TakaokaR , et al. Evaluate of the efficacy and safety of tacrolimus ointment 0, 03% to treat atopic dermatitis in pediatric patients [Avaliacao da eficacia e seguranca do tacrolimo pomada 0, 03% no tratamento da dermatite atopica em pacientes pediatricos]. Anais Brasileiros De Dermatologia2008;83(6):511‐9. [MEDLINE: 2009148842] ">Gontijo 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 174</p> <p>2. Paediatric<br/> 3. 6 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Asthma (2)</p> <p>‐ Pneumonia (2)</p> <p>‐ Pyodermitis (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0102" title="KooJY , FleischerABJr , AbramovitsW , PariserDM , McCallCO , HornTD , et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. Journal of the American Academy of Dermatology2005;53(2 Suppl 2):S195‐205. [MEDLINE: 16021175] ">Koo 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 7923</p> <p>2. Adult/paediatric</p> <p>3. Median: 210 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1% (92.7%)</p> <p>0.03% (7.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Flu‐like symptoms</p> <p>‐ Headache</p> <p>(frequency similar to that expected of the general population)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ 13 cases of NMSC (no risk with calculated incidence)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Alcohol intolerance 3.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0112" title="MandelinJM , RubinsA , RemitzA , CiruleK , DickinsonJ , HoV , et al. Long‐term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two‐year open‐label study. International Journal of Dermatology2012;51(1):104‐10. [MEDLINE: 21923693] ">Mandelin 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 50</p> <p>2. Paediatric (&lt; 2 years)</p> <p>3. 2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Pruritus</p> <p>‐ Local infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Non‐serious respiratory</p> <p>infection and</p> <p>gastroenteritis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1 ng/ml (in 98%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0129" title="ReitamoS , WollenbergA , SchopfE , PerrotJL , MarksR , RuzickaT , et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis.The European Tacrolimus OintmentStudy Group. Archives of Dermatology2000;136(8):999‐1006. [MEDLINE: 10926735] ">Reitamo 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 316</p> <p>2. Adults</p> <p>3. 6 to 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> <p>‐ Erythema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal</p> <p>(only 1 transient</p> <p>increase in</p> <p>liver enzymes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Alcohol intolerance</p> <p>5 serious events:</p> <p>‐ Eczema herpeticum (1)</p> <p>‐ Cellulitis (1)</p> <p>‐ Varicella (1)</p> <p>‐ AD flare‐up (1)</p> <p>‐ <i>Staphylococcus aureus</i> </p> <p>superinfection (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal &lt; 1 ng/dl in 76% of participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0131" title="ReitamoS , OrtonneJP , SandC , BosJ , CambazardF , BieberT , et al. Long‐term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two‐year, multicentre, non‐comparative study. Acta Dermato‐Venereologica2007;87(5):406‐12. [EMBASE: 17721647] ">Reitamo 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 672</p> <p>2. Adults</p> <p>3. 2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ 2 cases (Bowen and prostate carcinoma) not related</p> <p>‐ Benign neoplasm (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Herpes (7%) (expected in AD participants)</p> <p>‐ Eczema herpeticum (1)</p> <p>‐ Erythroderma (1)</p> <p>‐ AD exacerbation (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0132" title="ReitamoS , RustinM , HarperJ , KalimoK , RubinsA , CambazardF , et al. A 4‐year follow‐up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. British Journal of Dermatology2008;159(4):942‐51. [MEDLINE: 18637898] ">Reitamo 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 782</p> <p>2. Adult/paediatric</p> <p>3. 4 years (median: 1422 days)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> <p>‐ Skin infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Flu‐like symptoms</p> <p>(more in children)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 cases</p> <p>‐ Cervical carcinoma (1)</p> <p>‐ Acute leukaemia (1)</p> <p>‐ Chronic leukaemia (1)</p> <p>‐ Basal cell carcinoma (2 to 3 on the same participant)</p> <p>‐ 34 benign neoplasms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0133" title="RemitzA , HarperJ , RustinM , GoldschmidtWF , PalatsiR , van derValkPG , et al. Long‐term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Dermato‐Venereologica2007;87(1):54‐61. [MEDLINE: 17225017] ">Remitz 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 466</p> <p>2. Paediatric</p> <p>3. 29.5 months (mean: 16.3 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03%</p> <p>0.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Seasonal infection</p> <p>(flu‐syndrome)</p> <p>‐ No growth</p> <p>retardation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Leukopenia (1)*</p> <p>‐ Herpes (4.9%)/eczema herpeticum (0.9%)</p> <p>‐ Molluscum 3%)</p> <p>‐ Warts (3.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0138" title="SapleDG , TorsekarRG , PawanarkarV , WaliV , RavichandranG , DhanalakshmiUR , et al. Evaluation of the efficacy, safety and tolerability of Tacrolimus ointment in Indian patients of moderate to severe atopic dermatitis: a multicentric, open label, phase III study. Indian Journal of Dermatology, Venereology &amp; Leprology2003;69(6):396‐400. [MEDLINE: 17642950] ">Saple 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 125</p> <p>2. 12 to 69 years</p> <p>3. 5 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> <p>‐ Erythema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0042" title="WonCH , SeoPG , ParkYM , YangJM , LeeKH , SungKJ , et al. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. Journal of Dermatological Treatment2004;15(1):30‐4. [MEDLINE: 14754647] ">Won 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 18</p> <p>2. Adult/paediatric</p> <p>3. 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious events (3):</p> <p>‐ Flu‐syndrome (1)</p> <p>‐ Severe skin rash (1)</p> <p>‐ Eczema herpeticum (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0160" title="WongWR , TsaiHJ , HongHS . Efficacy and safety of topically applied tacrolimus ointment in patients with moderate to severe atopic dermatitis. Chang Gung Medical Journal2003;26(7):485‐95. [MEDLINE: 14515971] ">Wong 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 30</p> <p>2. Adult/paediatric</p> <p>3. 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1% adults</p> <p>0.03% paediatric</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 participants</p> <p>&lt; 5 ng/ml</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* 6‐year‐old participant, at month 6, resolution after withdrawn.<br/> AD: atopic dermatitis.<br/> NMSC: non‐melanoma skin cancer. </p> </div> </div> <p>The suggested potential mechanisms responsible for malignancies associated with the use of topical tacrolimus are as follows. </p> <p> <ul id="CD009864-list-0016"> <li> <p>Mutagenesis or genotoxicity: evidence from pre‐clinical development in bacteria and mammalian cells do not support this hypothesis (<a href="./references#CD009864-bbs2-0157" title="USFood , Drug Administration(FDA) . Pediatric Advisory Committee February 15th 2005. Briefing Information. Labeling Information and NDAs. www.fda.gov/ohrms/dockets/ac/05/briefing/2005‐4089b2.htm (accessed 5 December 2013). ">US Food and Drug Administration</a>). </p> </li> <li> <p>Local effects inhibiting immunosurveillance: this effect can be responsible for skin tumours on local application sites, though no evidence from trials support this hypothesis (no increased risk of skin tumours, both melanoma and non‐melanoma skin cancers when compared with the general population in the reported studies). It is important to note that atopic dermatitis itself is associated with immune dysregulation and barrier defects, regardless of the treatment used. </p> </li> <li> <p>Drug absorption leading to systemic immunosuppression: several different facts speak against this hypothesis, as discussed below. </p> </li> </ul> <ul class="plain" id="CD009864-list-0017"> <li> <ul id="CD009864-list-0018"> <li> <p>After topical application of tacrolimus, serum concentrations of the drug are usually low or undetectable, and rates of absorption decrease with improvement of the skin barrier integrity (<a href="./references#CD009864-bbs2-0084" title="FonacierL , SpergelJ , CharlesworthEN , WeldonD , BeltraniV , Bernhisel‐BroadbentJ , et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. Journal of Allergy &amp; Clinical Immunology2005;115(6):1249‐53. [MEDLINE: 15940142] ">Fonacier 2005</a>; <a href="./references#CD009864-bbs2-0091" title="HarperJ , SmithC , RubinsA , GreenA , JacksonK , ZigureS , et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. Journal of Investigative Dermatology2005;124(4):695‐9. [MEDLINE: 15816825] ">Harper 2005</a>; <a href="./references#CD009864-bbs2-0096" title="HultschT , KappA , SpergelJ . Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology2005;211(2):174‐87. [MEDLINE: 16088174] ">Hultsch 2005</a>; <a href="./references#CD009864-bbs2-0157" title="USFood , Drug Administration(FDA) . Pediatric Advisory Committee February 15th 2005. Briefing Information. Labeling Information and NDAs. www.fda.gov/ohrms/dockets/ac/05/briefing/2005‐4089b2.htm (accessed 5 December 2013). ">US Food and Drug Administration</a>). On the other hand, topical corticosteroids may cause thinning of the skin and even increase the absorption of topically applied drugs over time. An exception to this general rule is seen in conditions that show permanent severe barrier dysfunction, such as Netherton's syndrome, lamellar ichthyosis, and others, where higher systemic levels of tacrolimus were found, and their use in these diseases is therefore not recommended. This fact is mentioned on the labelling change, which was put in effect by the FDA in 2011 (<a href="./references#CD009864-bbs2-0048" title="AllenA , SiegfriedE , SilvermanR , WilliamsML , EliasPM , SzaboSK , et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Archives of Dermatology2001;137(6):747‐50. [MEDLINE: 11405764] ">Allen 2001</a>; <a href="./references#CD009864-bbs2-0049" title="AllenDM , EsterlyNB . Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Archives of Dermatology2002;138(9):1259‐60. [MEDLINE: 12225004] ">Allen 2002</a>). </p> </li> <li> <p>Studies analysing possible systemic immunosuppression after the use of topical tacrolimus, measured either by childhood immunisation responses (evaluating B cell immunity) (<a href="./references#CD009864-bbs2-0151" title="StiehmER , RobertsRL , KaplanMS , CorrenJ , JaraczE , RicoMJ . Pneumococcal seroconversion after vaccination in children with atopic dermatitis treated with tacrolimus ointment. Journal of the American Academy of Dermatology2005;53(2 Suppl 2):S206‐13. [MEDLINE: 16021176] ">Stiehm 2005</a>) or a recall antigen test to evaluate delayed‐type hypersensitivity (T cell) (<a href="./references#CD009864-bbs2-0096" title="HultschT , KappA , SpergelJ . Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology2005;211(2):174‐87. [MEDLINE: 16088174] ">Hultsch 2005</a>; <a href="./references#CD009864-bbs2-0129" title="ReitamoS , WollenbergA , SchopfE , PerrotJL , MarksR , RuzickaT , et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis.The European Tacrolimus OintmentStudy Group. Archives of Dermatology2000;136(8):999‐1006. [MEDLINE: 10926735] ">Reitamo 2000</a>) did not show any degree of decreased immunity compared with the baseline. </p> </li> <li> <p>Oral tacrolimus used in transplant recipient participants does carry an increased risk of both lymphoma and non‐lymphoma skin tumour development. Also, murine protocols with topical application of tacrolimus reported a higher risk of lymphoma development. However, the doses used were 26 to 47 times higher than the maximum recommended human doses and much higher than the maximum serum levels detected in people after topical use of this drug. Both examples related to systemic immunosuppression. It is important to note that in this setting of immunosuppression, we find different features characterising the lymphomas, such as occurrence in unusual sites, polymorphous or pleomorphic large cell or Hodgkin's‐like morphology, Epstein‐Barr virus (EBV)‐related lymphomas, B‐cell lymphomas, and lymphomas spontaneously regressing after interruption of immunosuppressive therapy in a significant percentage of cases (<a href="./references#CD009864-bbs2-0067" title="CallenJ , ChamlinS , EichenfieldLF , EllisC , GirardiM , GoldfarbM , et al. A systematic review of the safety of topical therapies for atopic dermatitis. British Journal of Dermatology2007;156(2):203‐21. [MEDLINE: 17223859] ">Callen 2007</a>; <a href="./references#CD009864-bbs2-0084" title="FonacierL , SpergelJ , CharlesworthEN , WeldonD , BeltraniV , Bernhisel‐BroadbentJ , et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. Journal of Allergy &amp; Clinical Immunology2005;115(6):1249‐53. [MEDLINE: 15940142] ">Fonacier 2005</a>; <a href="./references#CD009864-bbs2-0096" title="HultschT , KappA , SpergelJ . Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology2005;211(2):174‐87. [MEDLINE: 16088174] ">Hultsch 2005</a>; <a href="./references#CD009864-bbs2-0101" title="KnowlesDM . Immunodeficiency‐associated lymphoproliferative disorders. Modern Pathology1999;12(2):200‐17. [MEDLINE: 10071343] ">Knowles 1999</a>). The cases identified by the spontaneous reporting systems described none of these features, and as elicited above, there was no evidence of systemic suppression with topical use in humans. While data from animal studies should not be ignored, they often do not accurately reflect the situation of topical treatment of skin diseases and should be evaluated with caution. </p> </li> </ul> </li> </ul> <ul id="CD009864-list-0019"> <li> <p>Protective effect: an in vitro study showed an inhibitory effect of tacrolimus against human liver cancer cells, and another one demonstrated that it can also inhibit 12‐O‐tetradecanoylphorbol‐13‐acetate‐induced promotion of skin papilloma formation in CD‐1 mice (<a href="./references#CD009864-bbs2-0158" title="WeischerM , RockenM , BerneburgM . Calcineurin inhibitors and rapamycin: cancer protection or promotion?. Experimental Dermatology2007;16(5):385‐93. [MEDLINE: 17437481] ">Weischer 2007</a>). Another study, <a href="./references#CD009864-bbs2-0156" title="TranC , LubbeJ , SorgO , DoelkerL , CarrauxP , AntilleC , et al. Topical calcineurin inhibitors decrease the production of UVB‐induced thymine dimers from hairless mouse epidermis. Dermatology2005;211(4):341‐7. [MEDLINE: 16286744] ">Tran 2005</a>, showed that pretreatment with either pimecrolimus or tacrolimus inhibited UV‐mediated thymine dimer formation compared with control mice, demonstrating a possible protective effect for UV‐mediated damage, also reported in other safety reviews (<a href="./references#CD009864-bbs2-0124" title="PatelTS , GreerSC , SkinnerRBJr . Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. American Journal of Clinical Dermatology2007;8(4):189‐94. [MEDLINE: 17645374] ">Patel 2007</a>; <a href="./references#CD009864-bbs2-0136" title="RustinMH . The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. British Journal of Dermatology2007;157(5):861‐73. [MEDLINE: 17854353] ">Rustin 2007</a>). </p> </li> </ul> </p> <p>For all of the reasons presented, the possibility of the majority of lymphomas reported being due to tacrolimus was low, and some of the cases could even have been misdiagnosed as atopic dermatitis, while they represented cases of cutaneous lymphomas from the start. Summarising, there was no evidence of an increased risk of malignancy with TCI. Spontaneous cases have been reported, but they are few in number and seem to be within the expected occurrence rate for the general population. Longer follow‐up periods of more than 10 years might be necessary for a definitive position on this matter. </p> <p>We should also keep in mind that other available treatments for atopic dermatitis, such as oral corticosteroids, oral ciclosporin, and psoralen plus ultraviolet light, are all proven to show increased risk of the development of malignancy associated with their use (<a href="./references#CD009864-bbs2-0099" title="KaragasMR , CushingGLJr , GreenbergER , MottLA , SpencerSK , NierenbergDW . Non‐melanoma skin cancers and glucocorticoid therapy. British Journal of Cancer2001;85(5):683‐6. [MEDLINE: 11531252] ">Karagas 2001</a>; <a href="./references#CD009864-bbs2-0119" title="MomtazK , FitzpatrickTB . The benefits and risks of long‐term PUVAphotochemotherapy. Dermatologic Clinics1998;16(2):227‐34. [MEDLINE: 9589196] ">Momtaz 1998</a>; <a href="./references#CD009864-bbs2-0149" title="SorensenHT , MellemkjaerL , NielsenGL , BaronJA , OlsenJH , KaragasMR . Skin cancers and non‐hodgkin lymphoma among users of systemic glucocorticoids: a population‐based cohort study. Journal of the National Cancer Institute2004;96(9):709‐11. [MEDLINE: 15126608] ">Sorensen 2004</a>; <a href="./references#CD009864-bbs2-0150" title="SternRS , PUVA Follow up Study. The risk of melanoma in association with long‐term exposure to PUVA. Journal of the American Academy of Dermatology2001;44(5):755‐61. [MEDLINE: 11312420] ">Stern 2001</a>; <a href="./references#CD009864-bbs2-0164" title="ZonneveldIM , DeRieMA , BeljaardsRC , Van DerRheeHJ , WuiteJ , ZeegelaarJ , et al. The long‐term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. British Journal of Dermatology1996;135(Suppl 48):15‐20. [MEDLINE: 8881899] ">Zonneveld 1996</a>). The risk of the development of malignancy associated with topical corticosteroids is yet to be determined. </p> </section> <section id="CD009864-sec-0125"> <h5 class="title">Skin atrophy</h5> <p>We found no cases of skin atrophy due to topical tacrolimus use in our search. Nineteen of the included studies did not mention skin atrophy in the reported adverse events. Two papers reported no cases of skin atrophy in any of the groups (tacrolimus 0.03%, tacrolimus 0.1%, and vehicle) (<a href="./references#CD009864-bbs2-0009" title="HanifinJM , LingMR , LangleyR , BrenemanD , RafalE . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. Journal of the American Academy of Dermatology2001;44(Suppl 1):S28‐38. [EMBASE: 2001020450] SoterNA , Fleischer JrAB , WebsterGF , MonroeE , LawrenceI . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. Journal of the American Academy of Dermatology2001;44(1 Suppl):S39‐46. [DOI: 10.1067/mjd.2001.109817; EMBASE: 2001020451] ">Hanifin 2001</a> ‐ in the additional report by Soter 2001; <a href="./references#CD009864-bbs2-0014" title="PallerA , EichenfieldLF , LeungDY , StewartD , AppellM . A 12‐week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology2001;44(1 Suppl):S47‐57. [MEDLINE: 11145795] ">Paller 2001</a>). <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a> reported 2 cases of skin atrophy in the corticosteroid group (2 out of 485) and no cases in the tacrolimus 0.1% ointment group (0 out of 487). </p> <p>Most of the papers affirmed that tacrolimus did not cause atrophy based on the paper by <a href="./references#CD009864-bbs2-0128" title="ReitamoS , RissanenJ , RemitzA , GranlundH , ErkkoP , ElgP , et al. Tacrolimus ointment does not affect collagen synthesis: results of a single‐center randomized trial. Journal of Investigative Dermatology1998;111(3):396‐8. [MEDLINE: 9740230] ">Reitamo 1998</a>. In this randomised trial, 14 atopic dermatitis participants and 12 healthy volunteers used tacrolimus 0.03%, tacrolimus 0.1%, betamethasone‐valerate, and vehicle on non‐symptomatic abdominal skin for 7 days under occlusion. The trial measured propeptides of procollagen I and III (radioimmunoassays) and skin thickness (ultrasound), and bethametasone was the only one with a decrease by the three analysed parameters. <a href="./references#CD009864-bbs2-0103" title="KyllönenH , RemitzA , MandelinJM , ElgP , ReitamoS . Effects of 1‐year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. British Journal of Dermatology2004;150(6):1174‐1181. [MEDLINE: 15214906] ">Kyllönen 2004</a> analysed the same parameters in 56 atopic dermatitis participants treated with tacrolimus 0.1% ointment for 1 year compared with 36 atopic dermatitis participants treated with topical corticosteroid therapy (mostly of moderate potency) and 27 healthy controls. The tacrolimus group, which had lower levels of propeptides of procollagen than the controls at baseline, showed an increase in collagen synthesis and skin thickness. In three participants with visible skin atrophy due to prior treatments with topical corticosteroids, the condition improved after tacrolimus treatment. In the corticosteroid group, collagen synthesis was not significantly affected, but a significant reduction in skin thickness was shown. Another long‐term study evaluating the use of tacrolimus ointment for more than 1 year (568 participants) reported no cases of skin atrophy (<a href="./references#CD009864-bbs2-0083" title="FK506 Ointment Study Group. Long‐term study of FK506 (tacrolimus) ointment in patients with atopic dermatitis ‐ analysis at time of completion of 2‐year observation. Journal of Clinical Therapeutics and Medicines2001;17(5):705‐726. ">FK506 Ointment Study Group 2001</a>). <a href="./references#CD009864-bbs2-0129" title="ReitamoS , WollenbergA , SchopfE , PerrotJL , MarksR , RuzickaT , et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis.The European Tacrolimus OintmentStudy Group. Archives of Dermatology2000;136(8):999‐1006. [MEDLINE: 10926735] ">Reitamo 2000</a>, in an open‐label non‐comparative study, followed 316 adults with moderate to severe atopic dermatitis using tacrolimus 0.1% twice a day for 6 to 12 months and also found no cases of skin atrophy. Also in this study, one of the participants with skin atrophy due to prior treatment with topical corticosteroids had the condition (atrophy) ameliorated after six months of tacrolimus treatment. </p> <p>Studies in vitiligo (a disease that causes loss of pigmentation of areas of skin) also did not show skin thinning after tacrolimus use. In a randomised controlled trial (RCT), <a href="./references#CD009864-bbs2-0104" title="LepeV , MoncadaB , Castanedo‐CazaresJP , Torres‐AlvarezMB , OrtizCA , Torres‐RubalcavaAB . A double‐blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Archives of Dermatology2003;139(5):581‐585. [MEDLINE: 12756094] ">Lepe 2003</a> compared a 2‐month treatment with clobetasol propionate 0.05% versus tacrolimus 0.1% (in symmetrical lesions) in 20 children with vitiligo. Clobetasol‐treated lesions showed atrophy in 3 out of 20 participants and in none of the tacrolimus‐treated lesions. <a href="./references#CD009864-bbs2-0106" title="LottiT , BuggianiG , TroianoM , AssadGB , DelescluseJ , DeGiorgiV , et al. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatologic Therapy2008;21(Suppl 1):S20‐6. [MEDLINE: 18727812] ">Lotti 2008</a> analysed 458 vitiligo participants for 6 months using 11 types of therapy, including tacrolimus 0.1% and betamethasone dipropionate 0.05% with or without 311 nm narrow‐band phototherapy. From the 11 treatment groups, only those using bethametasone showed skin atrophy. </p> <p>Animal studies also found no evidence of skin atrophy with topical tacrolimus use. <a href="./references#CD009864-bbs2-0058" title="BekerskyI , FitzsimmonsW , TanaseA , MaherRM , HodoshE , LawrenceI . Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. Journal of the American Academy of Dermatology2001;44(1 Suppl):S17‐27. [MEDLINE: 11145792] ">Bekersky 2001</a> cites 2 studies: 1 in mice, which noted a reduction in ear thickness with topical corticosteroid regimens (alclometasone dipropionate 0.1% and betamethasone valerate 0.12%), but not with any of the tacrolimus concentrations tested (0.3%, 0.1%, and 1%), and 1 in rats, evaluating skin weight, thickness, and histopathology, which showed no alterations compared with controls in the group using tacrolimus 0.03% ointment for 3 weeks. Animals using moderate to potent topical corticosteroids showed, in contrast, skin thinning, decreased subcutaneous tissue, and suppressed proliferation of epidermal cells. </p> <p>In summary, current evidence supports the fact that tacrolimus ointment does not cause skin atrophy. </p> </section> <section id="CD009864-sec-0126"> <h5 class="title">Conditions with increased risk of systemic absorption</h5> <p>Netherton syndrome is a rare autosomal recessive disease with congenital erythroderma that is sometimes mistaken for atopic dermatitis. Affected infants are at risk of dehydration probably due to the increase in water loss through the severe defective skin barrier. <a href="./references#CD009864-bbs2-0048" title="AllenA , SiegfriedE , SilvermanR , WilliamsML , EliasPM , SzaboSK , et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Archives of Dermatology2001;137(6):747‐50. [MEDLINE: 11405764] ">Allen 2001</a> reported 3 children (3, 5, and 14 years old) with this syndrome with large areas of the skin treated with topical tacrolimus 0.1% with significant systemic absorption of the drug (serum levels above the therapeutic range). Similarly, <a href="./references#CD009864-bbs2-0059" title="BensG , BoraleviF , BuzenetC , TaïebA . Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption. British Journal of Dermatology2003;149(1):224‐226. [MEDLINE: 12890237] ">Bens 2003</a> reported a case of a 17‐year‐old girl treated with tacrolimus 0.03% with increased systemic absorption by the treated area. When limited to small areas, no significant levels were detected. In contrast, <a href="./references#CD009864-bbs2-0137" title="SaifGB , Al‐KhenaizanS . Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings. International Journal of Dermatology2007;46(3):290‐294. [MEDLINE: 17343588] ">Saif 2007</a> reported on 4 affected siblings (a 40‐day‐old and a 3‐, 6‐, and 12‐year‐old), the 3 older children being treated with tacrolimus 0.1% for 2 years, with blood levels checked every 3 to 4 months and being mostly undetectable, and when detectable (occasionally), it was below the therapeutic range of transplant participants. </p> <p>Lamellar ichthyosis is another rare autosomal recessive congenital erythrodermic disease, also with severe barrier defect and great transepidermal water loss. In a report (<a href="./references#CD009864-bbs2-0049" title="AllenDM , EsterlyNB . Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Archives of Dermatology2002;138(9):1259‐60. [MEDLINE: 12225004] ">Allen 2002</a>), a 28‐month‐old child was treated with tacrolimus 0.1% applied to the whole body surface area twice a day for 7 weeks. <a href="./references#CD009864-bbs2-0125" title="PitarchG , TorrijosA , MahiquesL , Sánchez‐CarazoJL , ForteaJM . Systemic absorption of topical tacrolimus in Pyoderma gangrenosum. Acta Dermato‐Venereologica2006;86(1):64‐65. [MEDLINE: 16585995] ">Pitarch 2006</a> reported a case of a 54‐year‐old man with extensive ulcers due to pyoderma gangrenosum (a neutrophilic dermatosis with ulcerations on the skin, frequently associated with other systemic diseases), who was treated with tacrolimus 0.1% once daily for 4 weeks in combination with systemic infliximab, and <a href="./references#CD009864-bbs2-0147" title="SkowronF , DalleS , MarcillyMC , BalmeB , ThomasL . Important systemic absorption of topical tacrolimus during treatment of severe pemphigus vulgaris. Annales de Dermatologie et de Venereologie2005;132(3):263‐5. [MEDLINE: 15924053] ">Skowron 2005</a> reported a case of a 54‐year‐old woman with extensive vulgar pemphigus (an autoimmune bullous disease) treated with tacrolimus 0.1% after refractory treatment with systemic corticosteroids and immunoglobulin. All of the three cases showed marked improvement but with significant systemic absorption although with serum levels within the therapeutic range for transplant participants. <a href="./references#CD009864-bbs2-0061" title="BeyelerM , Schmid‐GrendelmeierP , HafnerJ . Significantly elevated systemic levels after occlusive application of topical tacrolimus in atopic dermatitis. Dermatology2006;212(3):260‐261. [MEDLINE: 16549924] ">Beyeler 2006</a> reported a case of an erythrodermic patient with significant systemic absorption of tacrolimus 0.1% after a 5‐day course of use in an extensive area under occlusion with "Unna's" paste. </p> </section> <section id="CD009864-sec-0127"> <h5 class="title">Other possible adverse effects</h5> <p>Rosacea‐like dermatitis or perioral dermatitis (PD) is a known adverse effect of the chronic use of topical corticosteroid on the face. A few cases have been reported with the use of tacrolimus as well (<a href="./references#CD009864-bbs2-0050" title="AntilleC , SauratJH , LubbeJ . Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Archives of Dermatology2004;140(4):457‐60. [MEDLINE: 15096374] ">Antille 2004</a>; <a href="./references#CD009864-bbs2-0085" title="FujiwaraS , OkuboY , IrisawaR , TsuboiR . Rosaceiform dermatitis associated with topical tacrolimus treatment. Journal of the American Academy of Dermatology2010;62(6):1050‐2. [MEDLINE: 20466178] ">Fujiwara 2010</a>; <a href="./references#CD009864-bbs2-0155" title="TerakiY , HitomiK , SatoY , IzakiS . Tacrolimus‐induced rosacea‐like dermatitis: a clinical analysis of 16 cases associated with tacrolimus ointment application. Dermatology2012;224(4):309‐14. [MEDLINE: 22626964] ">Teraki 2012</a>). On the other hand, we can also find reports of the same condition being successfully treated (off‐label) with tacrolimus (<a href="./references#CD009864-bbs2-0086" title="GoldmanD . Tacrolimus ointment for thetreatment of steroid‐induced rosacea: a preliminary report. Journal of the American Academy of Dermatology2001;44(6):995‐8. [MEDLINE: 11369912] ">Goldman 2001</a>; <a href="./references#CD009864-bbs2-0142" title="SchwarzT , KreiselmaierI , BieberT , ThaciD , SimonJC , MeurerM , et al. A randomized, double‐blind, vehicle‐controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. Journal of the American Academy of Dermatology2008;59(1):34‐40. [MEDLINE: 18462835] ">Schwarz 2008</a>), making this a controversial issue that still needs clarification. </p> <p>With regard to alcohol intolerance, some of the studies and a few case reports described flushing on the face of a few users of tacrolimus ointment after alcohol ingestion, and even in some children receiving ethanol‐containing medications (<a href="./references#CD009864-bbs2-0068" title="CalzaAM , LubbeJ . Tacrolimus ointment‐associated alcohol intolerance in infants receiving ethanol‐containing medication. British Journal of Dermatology2005;152(3):569. [MEDLINE: 15787832] ">Calza 2005</a>; <a href="./references#CD009864-bbs2-0100" title="KnightAK , BoxerM , ChandlerMJ . Alcohol‐induced rash caused by topical tacrolimus. Annals of Allergy, Asthma, &amp; Immunology2005;95(3):291‐2. [MEDLINE: 16200821] ">Knight 2005</a>; <a href="./references#CD009864-bbs2-0117" title="MilingouM , AntilleC , SorgO , SauratJH , LubbeJ . Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Archives of Dermatology2004;140(12):1542‐4. [MEDLINE: 15611445] ">Milingou 2004</a>). The manufacturers reported that this adverse event occurs in approximately 6% of people using the medication. The symptoms resolve after discontinuation of ointment. In some reports, the use of aspirin might also inhibit these symptoms (<a href="./references#CD009864-bbs2-0075" title="EhstBD , WarshawEM . Alcohol‐induced application site erythema after topical immunomodulator use and its inhibition by aspirin. Archives of Dermatology2004;140(8):1014‐5. [MEDLINE: 15313828] ">Ehst 2004</a>); however, the mechanism of action for this is still not clear. </p> <p>The use of tacrolimus in infants (&lt; 2 years) is not recommended since at the time the FDA approved tacrolimus ointment, no efficacy or safety studies had been conducted in this particular population. The issue is still controversial due to the lack of trials involving this age group. <a href="./references#CD009864-bbs2-0123" title="PatelRR , Vander StratenMR , KormanNJ . The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Archives of Dermatology2003;139(9):1184‐6. [MEDLINE: 12975161] ">Patel 2003</a> evaluated 12 infants (younger than 2 years of age) with atopic dermatitis and found no increased levels of the medication in their blood levels after 30 days of their usual treatment and no reports of any significant adverse events either. </p> <p>More recently, another study on infants aged 3 to 24 months and using tacrolimus 0.03% has been conducted. Results showed that there was minimal systemic absorption; however, this was highly variable between participants. The majority of the blood samples (97%) had tacrolimus levels below 1 ng/mL (<a href="./references#CD009864-bbs2-0130" title="ReitamoS , RubinsA , HoV , et al. Pharmacokinetics of topical tacrolimus in paediatric patients aged 3 to 24 months. 15th Congress of the European Academy of Dermatology andVenereology, Rhodes, Greece. 2006. ">Reitamo 2006</a>; <a href="./references#CD009864-bbs2-0136" title="RustinMH . The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. British Journal of Dermatology2007;157(5):861‐73. [MEDLINE: 17854353] ">Rustin 2007</a>). More studies are needed on this age group. </p> <p>In the world literature, there are also reports of tacrolimus‐induced lentiginosis (<a href="./references#CD009864-bbs2-0069" title="Castelo‐SoccioL , DiMarcantonioD , ShahP , LeeLW , TreatJR , YanAC . Induced lentiginosis with use of topical calcineurin inhibitors. Archives of Dermatology2012;148(6):766‐8. [MEDLINE: 22710469] ">Castelo‐Soccio 2012</a>; <a href="./references#CD009864-bbs2-0093" title="HickeyJR , RobsonA , BarkerJN , SmithCH . Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases. British Journal of Dermatology2005;152(1):152‐4. [MEDLINE: 15656817] ">Hickey 2004</a>; <a href="./references#CD009864-bbs2-0163" title="ZattraE , AlbertinC , Belloni FortinaA . Labial melanotic macule after application of topical tacrolimus: two case reports. Acta Dermato‐Venereologica2010;90(5):527. [MEDLINE: 20814635] ">Zattra 2010</a>), benign neoplasms, development of Kaposi's sarcoma lesions on the tacrolimus‐treated areas (in HIV patients) (<a href="./references#CD009864-bbs2-0073" title="ChoM , PumaI , NguyenD , SchutR , GlesneL . Development of Kaposi's sarcoma in an AIDS patient after treatment with topical tacrolimus. Journal of the American Academy of Dermatology2004;50(1):149‐50. [MEDLINE: 14699390] ">Cho 2004</a>; <a href="./references#CD009864-bbs2-0140" title="SchmutzJL , BarbaudA , TrechotP . Kaposi's sarcoma in an AIDS patient after application of tacrolimus (Protopic) [Maladie de Kaposi chez un sujet sideen apres application de tacrolimus (Protopic)]. Annales de Dermatologie et de Venereologie2006;133(3):303. [MEDLINE: 16800194] ">Schmutz 2006</a>), tacrolimus allergic contact dermatitis (<a href="./references#CD009864-bbs2-0144" title="ShawDW , EichenfieldLF , ShainhouseT , MaibachHI . Allergic contact dermatitis from tacrolimus. Journal of the American Academy of Dermatology2004;50(6):962‐5. [MEDLINE: 15153904] ">Shaw 2004</a>), and one anecdotal report of a relapse of schizophrenia (<a href="./references#CD009864-bbs2-0105" title="LinY , SunIW , LiuSI , Lohel‐W , LinYC . Tacrolimus ointment‐induced relapse of schizophrenia: a case report. International Journal of Neuropsychopharmacology2007;10(6):851‐4. [MEDLINE: 18077846] ">Lin 2007</a>). </p> <p>Reports of cutaneous infections in tacrolimus ointment users (molluscum, viral warts, tinea incognito, herpes, eczema herpeticum, etc.) with the suggestion of a possible higher risk will not be discussed again, since those studies with better designs have already proven that there is no increased risk. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009864-sec-0128" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009864-sec-0128"></div> <section id="CD009864-sec-0129"> <h3 class="title" id="CD009864-sec-0129">Summary of main results</h3> <p>An extensive literature search resulted in the inclusion of 20 studies (from 24 papers), with a total of 5885 participants. Sample sizes varied from 16 to 972 participants. Two concentrations of topical tacrolimus (0.03% and 0.1%) were compared with each other, as well as with pimecrolimus 1%, with low‐ and mid‐potency topical corticosteroids, and with oral ciclosporin. The variability of drug doses, outcomes, and follow‐up periods made it difficult to carry out meta‐analyses. </p> <p>Results of several individual trials showed a moderate benefit of tacrolimus 0.1% over low‐potency corticosteroids (physician's assessment, modified Eczema Area and Severity Index (mEASI)), low‐potency corticosteroids used on the face and neck areas, moderate‐potency corticosteroids on the trunk and extremities (quality of life, physician's assessment, Body Surface Area (BSA), mEASI), and pimecrolimus 1% (physician's assessment, BSA, Eczema Area and Severity Index (EASI)). When compared with moderate to potent corticosteroids, we found no significant difference in three of the outcomes analysed (physician's assessment, BSA, mEASI). The participant's assessment and SCORing Atopic Dermatitis (SCORAD) found a statistically significant, but marginal difference, favouring tacrolimus 0.1%. Based on results of a couple of trials, we found tacrolimus 0.03% to be superior to mild topical corticosteroids (physician's and participant's assessment, mEASI). One study compared tacrolimus 0.03% with pimecrolimus 1% with a significant difference favouring tacrolimus by the physician's assessment and with a non‐significant difference when comparing BSA. In the comparison with moderate‐to‐potent corticosteroids, we found no significant difference in most of the outcomes (physician's and participant's assessment, BSA, EASI, mEASI, SCORAD), but in two studies, we observed a slight difference favouring the corticosteroid group (EASI, BSA). The clinical significance of that difference is unlikely to be important. The comparison between both tacrolimus formulations significantly favoured tacrolimus 0.1% in all studies (physician's assessment, mEASI, quality of life), except for one study that found no significant difference in the participant's global assessment. Only one study compared tacrolimus 0.1% with oral ciclosporin, and in the SCORAD evaluation, we found tacrolimus 0.1% to be superior to this systemic drug. Quality of life showed better improvement in the tacrolimus 0.1% group when compared with tacrolimus 0.03% and when compared with topical corticosteroids (low‐potency used on the head and neck areas and mid‐ to high‐potency when used on the trunk and extremities). </p> <section id="CD009864-sec-0130"> <h4 class="title">Adverse effects</h4> <p>When evaluating the adverse events (one of the most controversial and important issues of this review), we carried out two different analyses. First, we analysed the data on adverse events in the included studies and carried out a meta‐analysis whenever it was possible. Second, we looked for all the case reports, observational and cohort studies (see <a href="#CD009864-tbl-0011">Table 5</a>) (<a href="./references#CD009864-bbs2-0087" title="GontijoB , PiresMC , CestariTF , LaScalaCSK , DuarteIAG , TakaokaR , et al. Evaluate of the efficacy and safety of tacrolimus ointment 0, 03% to treat atopic dermatitis in pediatric patients [Avaliacao da eficacia e seguranca do tacrolimo pomada 0, 03% no tratamento da dermatite atopica em pacientes pediatricos]. Anais Brasileiros De Dermatologia2008;83(6):511‐9. [MEDLINE: 2009148842] ">Gontijo 2008</a>; <a href="./references#CD009864-bbs2-0102" title="KooJY , FleischerABJr , AbramovitsW , PariserDM , McCallCO , HornTD , et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. Journal of the American Academy of Dermatology2005;53(2 Suppl 2):S195‐205. [MEDLINE: 16021175] ">Koo 2005</a>; <a href="./references#CD009864-bbs2-0112" title="MandelinJM , RubinsA , RemitzA , CiruleK , DickinsonJ , HoV , et al. Long‐term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two‐year open‐label study. International Journal of Dermatology2012;51(1):104‐10. [MEDLINE: 21923693] ">Mandelin 2012</a>; <a href="./references#CD009864-bbs2-0129" title="ReitamoS , WollenbergA , SchopfE , PerrotJL , MarksR , RuzickaT , et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis.The European Tacrolimus OintmentStudy Group. Archives of Dermatology2000;136(8):999‐1006. [MEDLINE: 10926735] ">Reitamo 2000</a>; <a href="./references#CD009864-bbs2-0131" title="ReitamoS , OrtonneJP , SandC , BosJ , CambazardF , BieberT , et al. Long‐term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two‐year, multicentre, non‐comparative study. Acta Dermato‐Venereologica2007;87(5):406‐12. [EMBASE: 17721647] ">Reitamo 2007</a>; <a href="./references#CD009864-bbs2-0132" title="ReitamoS , RustinM , HarperJ , KalimoK , RubinsA , CambazardF , et al. A 4‐year follow‐up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. British Journal of Dermatology2008;159(4):942‐51. [MEDLINE: 18637898] ">Reitamo 2008</a>; <a href="./references#CD009864-bbs2-0133" title="RemitzA , HarperJ , RustinM , GoldschmidtWF , PalatsiR , van derValkPG , et al. Long‐term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Dermato‐Venereologica2007;87(1):54‐61. [MEDLINE: 17225017] ">Remitz 2007</a>; <a href="./references#CD009864-bbs2-0138" title="SapleDG , TorsekarRG , PawanarkarV , WaliV , RavichandranG , DhanalakshmiUR , et al. Evaluation of the efficacy, safety and tolerability of Tacrolimus ointment in Indian patients of moderate to severe atopic dermatitis: a multicentric, open label, phase III study. Indian Journal of Dermatology, Venereology &amp; Leprology2003;69(6):396‐400. [MEDLINE: 17642950] ">Saple 2003</a>; <a href="./references#CD009864-bbs2-0042" title="WonCH , SeoPG , ParkYM , YangJM , LeeKH , SungKJ , et al. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. Journal of Dermatological Treatment2004;15(1):30‐4. [MEDLINE: 14754647] ">Won 2004</a>; <a href="./references#CD009864-bbs2-0160" title="WongWR , TsaiHJ , HongHS . Efficacy and safety of topically applied tacrolimus ointment in patients with moderate to severe atopic dermatitis. Chang Gung Medical Journal2003;26(7):485‐95. [MEDLINE: 14515971] ">Wong 2003</a>), safety letters, industry and U.S. Food and Drug Administration (FDA) warnings, expert opinions, and so on, to do a narrative analyses of current evidence (<a href="./references#CD009864-bbs2-0047" title="AldeaA , Garcia Sanchez‐ColomerM , Fernandez QuintanaE , Garcia SaizM . Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009. European Journal of Clinical Pharmacology2012;68(9):1329‐38. [MEDLINE: 22415248] ">Aldea 2012</a>; <a href="./references#CD009864-bbs2-0050" title="AntilleC , SauratJH , LubbeJ . Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Archives of Dermatology2004;140(4):457‐60. [MEDLINE: 15096374] ">Antille 2004</a>; <a href="./references#CD009864-bbs2-0065" title="BreuerK , WerfelT , KappA . Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. American Journal of Clinical Dermatology2005;6(2):65‐77. [MEDLINE: 15799678] ">Breuer 2005</a>; <a href="./references#CD009864-bbs2-0067" title="CallenJ , ChamlinS , EichenfieldLF , EllisC , GirardiM , GoldfarbM , et al. A systematic review of the safety of topical therapies for atopic dermatitis. British Journal of Dermatology2007;156(2):203‐21. [MEDLINE: 17223859] ">Callen 2007</a>; <a href="./references#CD009864-bbs2-0068" title="CalzaAM , LubbeJ . Tacrolimus ointment‐associated alcohol intolerance in infants receiving ethanol‐containing medication. British Journal of Dermatology2005;152(3):569. [MEDLINE: 15787832] ">Calza 2005</a>; <a href="./references#CD009864-bbs2-0069" title="Castelo‐SoccioL , DiMarcantonioD , ShahP , LeeLW , TreatJR , YanAC . Induced lentiginosis with use of topical calcineurin inhibitors. Archives of Dermatology2012;148(6):766‐8. [MEDLINE: 22710469] ">Castelo‐Soccio 2012</a>; <a href="./references#CD009864-bbs2-0073" title="ChoM , PumaI , NguyenD , SchutR , GlesneL . Development of Kaposi's sarcoma in an AIDS patient after treatment with topical tacrolimus. Journal of the American Academy of Dermatology2004;50(1):149‐50. [MEDLINE: 14699390] ">Cho 2004</a>; <a href="./references#CD009864-bbs2-0074" title="Czarnecka‐OperaczM , JenerowiczD . Topical calcineurin inhibitors in the treatment of atopic dermatitis ‐ an update on safety issues. Journal Der Deutschen Dermatologischen Gesellschaft2012;10(3):167‐72. [MEDLINE: 21974750] ">Czarnecka‐Operacz 2012</a>; <a href="./references#CD009864-bbs2-0075" title="EhstBD , WarshawEM . Alcohol‐induced application site erythema after topical immunomodulator use and its inhibition by aspirin. Archives of Dermatology2004;140(8):1014‐5. [MEDLINE: 15313828] ">Ehst 2004</a>; <a href="./references#CD009864-bbs2-0084" title="FonacierL , SpergelJ , CharlesworthEN , WeldonD , BeltraniV , Bernhisel‐BroadbentJ , et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. Journal of Allergy &amp; Clinical Immunology2005;115(6):1249‐53. [MEDLINE: 15940142] ">Fonacier 2005</a>; <a href="./references#CD009864-bbs2-0085" title="FujiwaraS , OkuboY , IrisawaR , TsuboiR . Rosaceiform dermatitis associated with topical tacrolimus treatment. Journal of the American Academy of Dermatology2010;62(6):1050‐2. [MEDLINE: 20466178] ">Fujiwara 2010</a>; <a href="./references#CD009864-bbs2-0093" title="HickeyJR , RobsonA , BarkerJN , SmithCH . Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases. British Journal of Dermatology2005;152(1):152‐4. [MEDLINE: 15656817] ">Hickey 2004</a>; <a href="./references#CD009864-bbs2-0095" title="HuiRL , LideW , ChanJ , SchottingerJ , YoshinagaM , MillaresM . Association between exposure to topical tacrolimus or pimecrolimus and cancers. Annals of Pharmacotherapy2009;43(12):1956‐63. [MEDLINE: 19903860] ">Hui 2009</a>; <a href="./references#CD009864-bbs2-0096" title="HultschT , KappA , SpergelJ . Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology2005;211(2):174‐87. [MEDLINE: 16088174] ">Hultsch 2005</a>; <a href="./references#CD009864-bbs2-0100" title="KnightAK , BoxerM , ChandlerMJ . Alcohol‐induced rash caused by topical tacrolimus. Annals of Allergy, Asthma, &amp; Immunology2005;95(3):291‐2. [MEDLINE: 16200821] ">Knight 2005</a>; <a href="./references#CD009864-bbs2-0105" title="LinY , SunIW , LiuSI , Lohel‐W , LinYC . Tacrolimus ointment‐induced relapse of schizophrenia: a case report. International Journal of Neuropsychopharmacology2007;10(6):851‐4. [MEDLINE: 18077846] ">Lin 2007</a>; <a href="./references#CD009864-bbs2-0117" title="MilingouM , AntilleC , SorgO , SauratJH , LubbeJ . Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Archives of Dermatology2004;140(12):1542‐4. [MEDLINE: 15611445] ">Milingou 2004</a>; <a href="./references#CD009864-bbs2-0120" title="NaylorM , ElmetsC , JaraczE , RicoJM . Non‐melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. Journal of Dermatological Treatment2005;16(3):149‐53. [MEDLINE: 16096180] ">Naylor 2005</a>; <a href="./references#CD009864-bbs2-0122" title="OrmerodAD . Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?. British Journal of Dermatology2005;153(4):701‐5. [MEDLINE: 16181449] ">Ormerod 2005</a>; <a href="./references#CD009864-bbs2-0123" title="PatelRR , Vander StratenMR , KormanNJ . The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Archives of Dermatology2003;139(9):1184‐6. [MEDLINE: 12975161] ">Patel 2003</a>; <a href="./references#CD009864-bbs2-0124" title="PatelTS , GreerSC , SkinnerRBJr . Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. American Journal of Clinical Dermatology2007;8(4):189‐94. [MEDLINE: 17645374] ">Patel 2007</a>; <a href="./references#CD009864-bbs2-0136" title="RustinMH . The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. British Journal of Dermatology2007;157(5):861‐73. [MEDLINE: 17854353] ">Rustin 2007</a>; <a href="./references#CD009864-bbs2-0140" title="SchmutzJL , BarbaudA , TrechotP . Kaposi's sarcoma in an AIDS patient after application of tacrolimus (Protopic) [Maladie de Kaposi chez un sujet sideen apres application de tacrolimus (Protopic)]. Annales de Dermatologie et de Venereologie2006;133(3):303. [MEDLINE: 16800194] ">Schmutz 2006</a>; <a href="./references#CD009864-bbs2-0144" title="ShawDW , EichenfieldLF , ShainhouseT , MaibachHI . Allergic contact dermatitis from tacrolimus. Journal of the American Academy of Dermatology2004;50(6):962‐5. [MEDLINE: 15153904] ">Shaw 2004</a>; <a href="./references#CD009864-bbs2-0145" title="SiegfriedEC , JaworskiJC , HebertAA . Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. American Journal of Clinical Dermatology2013;14(3):163‐78. [MEDLINE: 23703374] ">Siegfried 2013</a>; <a href="./references#CD009864-bbs2-0154" title="TennisP , GelfandJM , RothmanKJ . Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. British Journal of Dermatology2011;165(3):465‐73. [MEDLINE: 21466537] ">Tennis 2011</a>; <a href="./references#CD009864-bbs2-0155" title="TerakiY , HitomiK , SatoY , IzakiS . Tacrolimus‐induced rosacea‐like dermatitis: a clinical analysis of 16 cases associated with tacrolimus ointment application. Dermatology2012;224(4):309‐14. [MEDLINE: 22626964] ">Teraki 2012</a>; <a href="./references#CD009864-bbs2-0157" title="USFood , Drug Administration(FDA) . Pediatric Advisory Committee February 15th 2005. Briefing Information. Labeling Information and NDAs. www.fda.gov/ohrms/dockets/ac/05/briefing/2005‐4089b2.htm (accessed 5 December 2013). ">US Food and Drug Administration</a>; <a href="./references#CD009864-bbs2-0158" title="WeischerM , RockenM , BerneburgM . Calcineurin inhibitors and rapamycin: cancer protection or promotion?. Experimental Dermatology2007;16(5):385‐93. [MEDLINE: 17437481] ">Weischer 2007</a>; <a href="./references#CD009864-bbs2-0163" title="ZattraE , AlbertinC , Belloni FortinaA . Labial melanotic macule after application of topical tacrolimus: two case reports. Acta Dermato‐Venereologica2010;90(5):527. [MEDLINE: 20814635] ">Zattra 2010</a>). </p> <p>The three most frequently reported adverse events in the included studies were local side‐effects: burning, pruritus, and skin infection. The comparison between tacrolimus and pimecrolimus, as well as between the two formulations of tacrolimus, showed no significant differences regarding the occurrence of adverse events. In all included studies, burning was significantly more frequent in the tacrolimus group (both formulations) than in the corticosteroid (all potencies) groups. When evaluating pruritus at the application sites, those in the tacrolimus 0.03% twice‐a‐day group made more complaints than those in the topical corticosteroid group, but when comparing corticosteroids with tacrolimus 0.1% (twice a day) and tacrolimus 0.03% (once a day), no difference was found. None of the studies found a significant difference in the occurrence of skin infection (viral, bacterial, or fungal) in the tacrolimus group when compared with the corticosteroid group (any potency). Symptoms of burning and pruritus were mild to moderate in the first few days of treatment and subsequently declined; they were short‐lived (minutes to a few hours) and generally did not lead to discontinuation of treatment. Other reported application site adverse events were folliculitis, erythema, maculopapular rash, and ingested alcohol intolerance (local erythema after alcohol ingestion). The latter was reported only with the use of the topical calcineurin inhibitors. Systemic symptoms included flu‐like symptoms, headache, and fever and were reported in all treatment groups. As detailed in the adverse events section, more serious adverse events were rare and occurred within the tacrolimus, corticosteroid, and vehicle groups and most of the time were considered not to be related to the treatment. None of the trials noted cases of lymphoma. In <a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a>, the corticosteroid group reported one case of lymphoma‐like reaction and one skin carcinoma, which were also considered as probably unrelated to the treatment drug. </p> <p>Attention should be made to the comparison of adverse events between tacrolimus (both formulations) and pimecrolimus. We found no differences in the occurrence of all adverse events (<a href="./references#CD009864-bbs2-0007" title="DraelosZ , NayakA , PariserD , ShupackJL , ChonK , AbramsB , et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‐blind comparison. Journal of the American Academy of Dermatology2005;53(4):602‐9. [MEDLINE: 16198779] ">Draelos 2005</a>; <a href="./references#CD009864-bbs2-0008" title="FleischerABJr , AbramovitsW , BrenemanD , JaraczE , US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment2007;18(3):151‐7. [MEDLINE: 17538803] ">Fleischer 2007</a>; <a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a>; <a href="./references#CD009864-bbs2-0015" title="AbramovitsW , FleischerABJr , JaraczE , BrenemanD . Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology2008;7(12):1153‐8. [MEDLINE: 19137769] PallerAS , LebwohlM , FleischerABJr , AntayaR , LangleyRG , KirsnerRS , et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology2005;52(5):810‐22. [MEDLINE: 15858471] ">Paller 2005</a>). However, <a href="./references#CD009864-bbs2-0007" title="DraelosZ , NayakA , PariserD , ShupackJL , ChonK , AbramsB , et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‐blind comparison. Journal of the American Academy of Dermatology2005;53(4):602‐9. [MEDLINE: 16198779] ">Draelos 2005</a> (the smallest study with 37 participants: tacrolimus 0.1% versus pimecrolimus 1%), when analysing the application site reactions and the intensity of local symptoms, found them to be more frequent and more intense in the tacrolimus 0.1% group. <a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a> (in the comparison between tacrolimus 0.03% and pimecrolimus 1%) also found application site reactions to be a little bit more frequent in tacrolimus participants. Also, the duration of symptoms in this study were longer in tacrolimus participants, with the majority experiencing symptoms between 30 minutes to 12 hours, while none of the pimecrolimus participants had symptoms for more than 30 minutes. Larger studies evaluating this matter might be necessary. </p> <p>After analysing all of the data from animal, observational, cohort, and case‐control studies, and so on, presented in detail in the section <a href="#CD009864-sec-0071">Effects of interventions</a>, we conclude that the possibility of the majority of lymphomas reported being due to tacrolimus is low, and some of the cases could even have been misdiagnosed as atopic dermatitis, while they were actually cases of cutaneous lymphomas from the start. In summary, there is no evidence of an increased risk of malignancy with topical calcineurin inhibitors (TCI). Spontaneous cases have been reported, but they are few in number and seem to be within the expected occurrence rate for the general population. Longer follow‐up periods of more than 10 years might be necessary for a definitive position on this matter. </p> <p>Many safety reviews and expert opinion records have tried to analyse in detail the possible risks of topical tacrolimus and malignancies, and all of them have found insufficient evidence to support the FDA warnings. They all stated their position against it. This includes such important groups as the American Academy of Dermatology (AAD) (<a href="./references#CD009864-bbs2-0060" title="BergerTG , DuvicM , VanVoorheesAS , VanBeekMJ , FriedenIJ , American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. Journal of the American Academy of Dermatology2006;54(5):818‐23. [MEDLINE: 16635663] ">Berger 2006</a>), the Canadian Dermatology Association (CDA) (<a href="./references#CD009864-bbs2-0110" title="MaddinS . Pimecrolimus and tacrolimus: the US FDA public health advisory. Skin Therapy Letter2005;10(4):1‐3. [MEDLINE: 15986080] ">Maddin 2005</a>), the Canadian Society of Allergy and Clinical Immunology (CSACI) (<a href="./references#CD009864-bbs2-0143" title="SegalAO , EllisAK , KimHL . CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy, Asthma, &amp; Clinical Immunology : Official Journal of the Canadian Society of Allergy &amp; Clinical Immunology2013;9(1):24. [MEDLINE: 23837743] ">Segal 2013</a>), the German Society of Dermatology (Deutschen Dermatologischen Gesellschaft ‐ DDG) (<a href="./references#CD009864-bbs2-0107" title="LugerTA , GollnickH . Viewpoint of the German Dermatologic Society (DDG) concerning the decision of the American Food and Drug Administration (FDA) on the use of pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis (neurodermatitis) [Stellungnahme Der Deutschen Dermatologischen Gesellschaft (DDG) Zur Entscheidung Der Amerikanischen Arzneimittelbehorde (FDA) Uber Die Verwendung Von Pimecrolimus‐Creme Und Tacrolimus‐Salbe Zur Behandlung Der Atopischen Dermatitis (Neurodermitis)]. Journal Der Deutschen Dermatologischen Gesellschaft2005;3(6):415‐6. [MEDLINE: 15892843] ">Luger 2005</a>), and the European Dermatology Forum (EDF) (<a href="./references#CD009864-bbs2-0134" title="RingJ , BarkerJ , BehrendtH , BraathenL , DarsowU , DubertretL , et al. Review of the potential photo‐cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. Journal of the European Academy of Dermatology &amp; Venereology2005;19(6):663‐71. [MEDLINE: 16268869] ">Ring 2005</a>). </p> <p>We should also keep in mind that other available treatments for atopic dermatitis, such as oral corticosteroids, oral ciclosporin, and psoralen plus ultraviolet light, are all proven to show increased risk of the development of malignancy associated with their use (<a href="./references#CD009864-bbs2-0099" title="KaragasMR , CushingGLJr , GreenbergER , MottLA , SpencerSK , NierenbergDW . Non‐melanoma skin cancers and glucocorticoid therapy. British Journal of Cancer2001;85(5):683‐6. [MEDLINE: 11531252] ">Karagas 2001</a>; <a href="./references#CD009864-bbs2-0119" title="MomtazK , FitzpatrickTB . The benefits and risks of long‐term PUVAphotochemotherapy. Dermatologic Clinics1998;16(2):227‐34. [MEDLINE: 9589196] ">Momtaz 1998</a>; <a href="./references#CD009864-bbs2-0149" title="SorensenHT , MellemkjaerL , NielsenGL , BaronJA , OlsenJH , KaragasMR . Skin cancers and non‐hodgkin lymphoma among users of systemic glucocorticoids: a population‐based cohort study. Journal of the National Cancer Institute2004;96(9):709‐11. [MEDLINE: 15126608] ">Sorensen 2004</a>; <a href="./references#CD009864-bbs2-0150" title="SternRS , PUVA Follow up Study. The risk of melanoma in association with long‐term exposure to PUVA. Journal of the American Academy of Dermatology2001;44(5):755‐61. [MEDLINE: 11312420] ">Stern 2001</a>; <a href="./references#CD009864-bbs2-0164" title="ZonneveldIM , DeRieMA , BeljaardsRC , Van DerRheeHJ , WuiteJ , ZeegelaarJ , et al. The long‐term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. British Journal of Dermatology1996;135(Suppl 48):15‐20. [MEDLINE: 8881899] ">Zonneveld 1996</a>). The risk of the development of malignancy associated with topical corticosteroids is yet to be determined. </p> <p>In November 2011, the FDA approved a labelling change for topical tacrolimus regarding the risk of systemic absorption in some conditions with severe skin barrier defects, such as Netherton's syndrome, lamellar ichthyosis, generalised erythroderma, or cutaneous Graft Versus Host Disease. This change was due to some reports in the literature. Those reports highlighted the importance of careful use of the drug in such skin conditions, but also showed its great efficacy, even in refractory cases. Treatment of a limited area of skin with close monitoring of serum levels might be an alternative in such cases. </p> <p>We found no cases of skin atrophy due to topical tacrolimus use in our search. We also evaluated clinical trials; case reports; and in vivo, in vitro, and animal studies, but did not find any evidence that topical tacrolimus could cause skin atrophy. </p> <p>Other possible effects, presented as case reports, include perioral dermatitis, alcohol intolerance, tacrolimus‐induced lentiginosis (<a href="./references#CD009864-bbs2-0069" title="Castelo‐SoccioL , DiMarcantonioD , ShahP , LeeLW , TreatJR , YanAC . Induced lentiginosis with use of topical calcineurin inhibitors. Archives of Dermatology2012;148(6):766‐8. [MEDLINE: 22710469] ">Castelo‐Soccio 2012</a>; <a href="./references#CD009864-bbs2-0093" title="HickeyJR , RobsonA , BarkerJN , SmithCH . Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases. British Journal of Dermatology2005;152(1):152‐4. [MEDLINE: 15656817] ">Hickey 2004</a>; <a href="./references#CD009864-bbs2-0163" title="ZattraE , AlbertinC , Belloni FortinaA . Labial melanotic macule after application of topical tacrolimus: two case reports. Acta Dermato‐Venereologica2010;90(5):527. [MEDLINE: 20814635] ">Zattra 2010</a>), benign neoplasms, development of Kaposi's sarcoma lesions in the tacrolimus‐treated areas (in HIV patients) (<a href="./references#CD009864-bbs2-0073" title="ChoM , PumaI , NguyenD , SchutR , GlesneL . Development of Kaposi's sarcoma in an AIDS patient after treatment with topical tacrolimus. Journal of the American Academy of Dermatology2004;50(1):149‐50. [MEDLINE: 14699390] ">Cho 2004</a>; <a href="./references#CD009864-bbs2-0140" title="SchmutzJL , BarbaudA , TrechotP . Kaposi's sarcoma in an AIDS patient after application of tacrolimus (Protopic) [Maladie de Kaposi chez un sujet sideen apres application de tacrolimus (Protopic)]. Annales de Dermatologie et de Venereologie2006;133(3):303. [MEDLINE: 16800194] ">Schmutz 2006</a>), tacrolimus allergic contact dermatitis (<a href="./references#CD009864-bbs2-0144" title="ShawDW , EichenfieldLF , ShainhouseT , MaibachHI . Allergic contact dermatitis from tacrolimus. Journal of the American Academy of Dermatology2004;50(6):962‐5. [MEDLINE: 15153904] ">Shaw 2004</a>), and others. </p> <p>The use of tacrolimus in infants (&lt; 2 years) is not recommended since at the time the FDA approved tacrolimus ointment, no efficacy or safety studies had been conducted in this particular population. The issue is still controversial because of the lack of trials involving this age group. More studies are needed in this age group. </p> </section> <section id="CD009864-sec-0131"> <h4 class="title">Evidence on corticosteroid safety</h4> <p>Topical corticosteroids are the first‐line therapy for atopic dermatitis; however, they are also not indicated for long‐term treatment (&gt; 4 weeks), and only a few are approved in children younger than 2 years. They also have a skin‐thinning potential and possible rebound and tachyphylaxis effects, none of which are seen in tacrolimus‐treated skin. There are no pre‐clinical carcinogenetic studies with topical corticosteroids (TCS), and the risk of malignancy in this group is still to be determined (<a href="./references#CD009864-bbs2-0145" title="SiegfriedEC , JaworskiJC , HebertAA . Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. American Journal of Clinical Dermatology2013;14(3):163‐78. [MEDLINE: 23703374] ">Siegfried 2013</a>). It should be noted that because corticosteroids have been prescribed for so many years, physicians may not feel compelled to report adverse events that may develop with their use. By contrast, the opposite may occur with calcineurin inhibitors, even more so after the FDA warnings, which placed the safety of this relatively new class of drug at the forefront. Also, because topical tacrolimus is a second‐line therapy, indicated for more severe cases, there is a risk that any adverse effects associated with it may have more severe consequences because of the intrinsic risk associated with more severe disease. </p> <p>That being said, in addition to the proven efficacy of tacrolimus showed in this review and given the fact that current evidence does not support significant risks with the use of topical tacrolimus, it should definitely be considered a safe option for the treatment of moderate to severe atopic dermatitis. </p> </section> </section> <section id="CD009864-sec-0132"> <h3 class="title" id="CD009864-sec-0132">Overall completeness and applicability of evidence</h3> <p>Although most of the included studies reported the primary outcomes of interest, it was difficult to pool any data due to the variability of drug doses and potencies, the different outcomes and scores used to evaluate the efficacy of treatment, and the different follow‐up periods. Thus, the lack of data limited our confidence in any findings of this review. The lack of data on many of the secondary outcomes that we intended to evaluate further limits the completeness of evidence. For instance, quality of life and relapse are important issues in this chronic and relapsing disorder, but we found little data on the subject. Future reviews should also try to address the costs of the treatments, since one of the great disadvantages of TCI is that they are much more expensive than TCS. The relatively short follow‐up duration of the included studies further limits the external validity of the review. Most of the studies were short‐term studies (3 months or less) with only a minority reporting data for longer periods (maximum follow‐up time of 12 months); therefore, the safety data especially should be carefully interpreted. Despite that, this review brings some tranquility for prescribers, since we found no evidence to support the most feared risk of possible development of malignancies, neither did we find any evidence of increased risk of skin atrophy, a great advantage over topical corticosteroids, especially in more sensitive areas of the body. </p> </section> <section id="CD009864-sec-0133"> <h3 class="title" id="CD009864-sec-0133">Quality of the evidence</h3> <p>We included 20 studies (from 24 papers), with a total of 5885 participants, and sample sizes varied from 16 to 972 participants. When using Grading of Recommendations Assessment, Development and Evaluation (GRADE) (<a href="./references#CD009864-bbs2-0088" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [EMBASE: 2008218668] ">Guyatt 2008</a>) to evaluate the studies, quality of the evidence varied from high to very low in some comparisons, as indicated in the 'Summary of findings' (SoF) tables (<a href="./full#CD009864-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009864-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD009864-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD009864-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD009864-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD009864-tbl-0006">summary of findings Table 6</a>). </p> <p>The main reasons for downgrading the quality of the studies were incomplete or unclear information on randomisation or allocation concealment; for inconsistency of results, we downgraded studies when there was a moderate level of heterogeneity between studies; for imprecision, we considered downgrading when either sample size was smaller than optimal information size or 95% confidence interval (CI) of the estimate of summary effect included both no effect and appreciable benefit and harm, or both; we also downgraded studies when we only identified one study and strongly suspected publication bias. </p> <p>Despite this, we evaluated some studies with a good number of participants and found statistically significant results in most of the variables, with the exception of the comparison of tacrolimus 0.1% and oral ciclosporin and the comparison of tacrolimus 0.03% and pimecrolimus, which only had 1 small study each (30 and 139 participants, respectively). Though the different doses, outcomes, and follow‐ups made it difficult to use meta‐analysis to summarise all the data, the results of the different subgroups comparing a similar intervention pointed in the same direction, with no major discrepancies. This variability was also the major difficulty when creating the 'Sof' tables, but we tried to summarise the most important data in the tables. </p> </section> <section id="CD009864-sec-0134"> <h3 class="title" id="CD009864-sec-0134">Potential biases in the review process</h3> <p>A comprehensive search from a wide range of databases was conducted with no language restrictions. To reduce the risk of bias, two independent authors screened the trials identified by the literature search and examined the full text of selected studies for compliance with eligibility criteria. Both authors assessed the risk of bias of included studies and extracted the data. With regard to the age groups, as discussed above, we analysed the combined data from adults and children. When we encountered incomplete information, we contacted the study authors. Some replied and were able to provide the necessary information, while others either did not reply or no longer had access to the data requested, and we considered the information as unclear. We also contacted pharmaceutical companies supporting the trials, who could not provide the requested data. </p> <p>The review authors had no conflicts of interest regarding any of the treatments or drugs analysed in this review. </p> </section> <section id="CD009864-sec-0135"> <h3 class="title" id="CD009864-sec-0135">Agreements and disagreements with other studies or reviews</h3> <p>We focused the analysis of the review on people with moderate to severe atopic dermatitis, so that the mild cases, which usually show better and easier response to treatment, would not interfere with the results. We also excluded studies comparing tacrolimus with placebo, since several studies had already proven the drug efficacy in this scenario. Still, this review included the largest number of studies when compared with the others found in the literature (<a href="./references#CD009864-bbs2-0054" title="AshcroftDM , DimmockP , GarsideR , SteinK , WilliamsHC . Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta‐analysis of randomised controlled trials. BMJ2005;330(7490):516. [MEDLINE: 15731121] ">Ashcroft 2005b</a>; <a href="./references#CD009864-bbs2-0072" title="ChenSL , YanJ , WangFS . Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta‐analysis of randomized clinical trials. Journal of Dermatological Treatment2010;21(3):144‐56. [MEDLINE: 20394490] ">Chen 2010</a>; <a href="./references#CD009864-bbs2-0077" title="El‐BatawyMM , BosseilaMA , MashalyHM , HafezVS . Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta‐analysis. Journal of Dermatological Science2009;54(2):76‐87. [MEDLINE: 19303745] ">El‐Batawy 2009</a>; <a href="./references#CD009864-bbs2-0153" title="SvenssonA , ChambersC , GanemoA , MitchellSA . A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Current Medical Research &amp; Opinion2011;27(7):1395‐406. [MEDLINE: 21563877] ">Svensson 2011</a>; <a href="./references#CD009864-bbs2-0161" title="YanJ , ChenSL , WangXL , ZhouW , WangFS . Meta‐analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatric Dermatology2008;25(1):117‐20. [MEDLINE: 18304172] ">Yan 2008</a>; <a href="./references#CD009864-bbs2-0162" title="YinZQ , ZhangWM , SongGX , LuoD . Meta‐analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis. Journal of Dermatology2012;39(6):520‐6. [MEDLINE: 22409418] ">Yin 2012</a>). </p> <p>The results found are in accordance with the results from the other published reviews in terms of efficacy and safety. The review by <a href="./references#CD009864-bbs2-0161" title="YanJ , ChenSL , WangXL , ZhouW , WangFS . Meta‐analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatric Dermatology2008;25(1):117‐20. [MEDLINE: 18304172] ">Yan 2008</a> found the only discrepancy; it reported no differences between either 1 of the 2 tacrolimus concentrations (0.03% and 0.1%), while our analysis showed superior efficacy in the 0.1% formulation. This might have happened because <a href="./references#CD009864-bbs2-0161" title="YanJ , ChenSL , WangXL , ZhouW , WangFS . Meta‐analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatric Dermatology2008;25(1):117‐20. [MEDLINE: 18304172] ">Yan 2008</a> included only 3 studies, with a total of 702 participants, where physician's global assessment was made, while our review on this subject included 6 studies, with a total of 1640 participants, and analysed both physician's and participant's global assessment. With regard to the reporting of safety and adverse events, the results were similar to those in the other reviews that analysed comparative controlled trials, as well as with the results from observational and cohort studies. A few studies, which analysed the paediatric and adult populations separately, reported more complaints of burning in the adult population and more cases of infection in the paediatric population. In this review, we analysed the combined data of both age groups. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009864-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD009864-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD009864-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD009864-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Tacrolimus 0.1% versus pimecrolimus 1%, outcome: 2.1 Physician's assessment of global response of improvement, clear or excellent" data-id="CD009864-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Tacrolimus 0.1% versus pimecrolimus 1%, outcome: 2.1 Physician's assessment of global response of improvement, clear or excellent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Tacrolimus 0.03% versus corticosteroids, outcome: 3.1 Physician's assessment of global response of improvement, clear or excellent" data-id="CD009864-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Tacrolimus 0.03% versus corticosteroids, outcome: 3.1 Physician's assessment of global response of improvement, clear or excellent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Tacrolimus 0.03% versus tacrolimus 0.1%, outcome: 4.1 Physician's assessment of global response of improvement, clear or excellent" data-id="CD009864-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Tacrolimus 0.03% versus tacrolimus 0.1%, outcome: 4.1 Physician's assessment of global response of improvement, clear or excellent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 1 Physician's assessment of global response of improvement, clear or excellent." data-id="CD009864-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 1 Physician's assessment of global response of improvement, clear or excellent. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 2 Adverse effects: burning." data-id="CD009864-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 2 Adverse effects: burning.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 3 Adverse effects: pruritus." data-id="CD009864-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 3 Adverse effects: pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 4 Adverse effects: skin infection." data-id="CD009864-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 4 Adverse effects: skin infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 5 SCORAD: 3 weeks." data-id="CD009864-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 5 SCORAD: 3 weeks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tacrolimus 0.1% versus pimecrolimus 1%, Outcome 1 Physician's assessment of global response of improvement, clear or excellent." data-id="CD009864-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Tacrolimus 0.1% versus pimecrolimus 1%, Outcome 1 Physician's assessment of global response of improvement, clear or excellent. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tacrolimus 0.1% versus pimecrolimus 1%, Outcome 2 Adverse effects ‐ 6 weeks." data-id="CD009864-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Tacrolimus 0.1% versus pimecrolimus 1%, Outcome 2 Adverse effects ‐ 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 1 Physician's assessment of global response of improvement, clear or excellent." data-id="CD009864-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 1 Physician's assessment of global response of improvement, clear or excellent. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 2 Participants's assessment of global response of improvement better or much better." data-id="CD009864-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 2 Participants's assessment of global response of improvement better or much better. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 3 Adverse effects: burning." data-id="CD009864-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 3 Adverse effects: burning.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 4 Adverse effects: pruritus." data-id="CD009864-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 4 Adverse effects: pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 5 Adverse effects: skin infection." data-id="CD009864-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 5 Adverse effects: skin infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-004-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Tacrolimus 0.03% versus tacrolimus 0.1%, Outcome 1 Physician's assessment of global response of improvement, clear or excellent." data-id="CD009864-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Tacrolimus 0.03% versus tacrolimus 0.1%, Outcome 1 Physician's assessment of global response of improvement, clear or excellent. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Tacrolimus 0.03% versus tacrolimus 0.1%, Outcome 2 Adverse effects." data-id="CD009864-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Tacrolimus 0.03% versus tacrolimus 0.1%, Outcome 2 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tacrolimus 0.03% versus pimecrolimus 1%, Outcome 1 Physician's assessment of global response of improvement." data-id="CD009864-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Tacrolimus 0.03% versus pimecrolimus 1%, Outcome 1 Physician's assessment of global response of improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tacrolimus 0.03% versus pimecrolimus 1%, Outcome 2 Adverse effects." data-id="CD009864-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Tacrolimus 0.03% versus pimecrolimus 1%, Outcome 2 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Tacrolimus 0.1% versus ciclosporin, Outcome 1 Adverse effects." data-id="CD009864-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Tacrolimus 0.1% versus ciclosporin, Outcome 1 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009864-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/urn:x-wiley:14651858:media:CD009864:CD009864-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_t/tCD009864-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Tacrolimus 0.1% versus ciclosporin, Outcome 2 SCORAD." data-id="CD009864-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Tacrolimus 0.1% versus ciclosporin, Outcome 2 SCORAD.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/media/CDSR/CD009864/image_n/nCD009864-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009864-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tacrolimus 0.1% compared with corticosteroids for atopic dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus 0.1% compared with corticosteroids for atopic dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atopic dermatitis<br/> <b>Settings:</b> outpatients, Europe and Canada </p> <p><b>Intervention:</b> tacrolimus 0.1%<br/> <b>Comparison:</b> corticosteroids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.1%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.1% versus hydrocortisone acetate 0.1%: 3 weeks</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.09</b> <br/> (2.14 to 4.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>371<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>157 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>484 per 1000</b> <br/> (335 to 698) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>157 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>485 per 1000</b> <br/> (336 to 699) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.1% versus hydrocortisone butyrate: 3 weeks</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> <br/> (0.78 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>377<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹<sup>,</sup> ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>490 per 1000</b> <br/> (403 to 599) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>490 per 1000</b> <br/> (402 to 599) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: short term (6 months)</b> <br/> Follow‐up: 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.32</b> <br/> (1.17 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>972<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>464 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>612 per 1000</b> <br/> (543 to 691) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>464 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>612 per 1000</b> <br/> (543 to 691) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone acetate 0.1%: 3 weeks</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.91</b> <br/> (1.6 to 5.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>371<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> <br/> (112 to 371) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> <br/> (112 to 370) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone butyrate: 3 weeks</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.59</b> <br/> (3.1 to 6.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>377<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>592 per 1000</b> <br/> (400 to 875) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>592 per 1000</b> <br/> (400 to 875) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: 6 months</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.79</b> </p> <p>(2.99 to 4.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>972</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>524 per 1000</b> </p> <p>(413 to 664)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>524 per 1000</b> </p> <p>(413 to 664)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Participant's self‐assessment of global response of improvement</b> </p> <p>Follow‐up: mean 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>RR 1.21</b> </p> <p>(1.13 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>974</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b>¹<sup>,</sup> ³ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>718 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>868 per 1000</b> </p> <p>(811 to 926)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>718 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>869 per 1000</b> </p> <p>(811 to 926)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to publication bias because only one study was identified and publication bias was strongly suspected.<br/> ²Downgraded one level due to Imprecision: sample size falls below the optimal information size; 95% CI of the estimated effect includes both no effect and appreciable benefit.<br/> ³Downgraded one level due to Imprecision: sample size falls below the optimal information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tacrolimus 0.1% compared with corticosteroids for atopic dermatitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009864-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tacrolimus 0.1% compared with pimecrolimus 1% for atopic dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus 0.1% compared with pimecrolimus 1% for atopic dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atopic dermatitis<br/> <b>Settings:</b> outpatients, USA<br/> <b>Intervention:</b> tacrolimus 0.1%<br/> <b>Comparison:</b> pimecrolimus 1% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Pimecrolimus 1%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.1%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.8</b> <br/> (1.34 to 2.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>506<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b> <br/> (270 to 488) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>199 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>358 per 1000</b> <br/> (267 to 482) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ 6 weeks</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.89</b> <br/> (0.47 to 1.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>506<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> <br/> (108 to 392) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b> <br/> (107 to 388) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to publication bias because only one study was identified and publication bias was strongly suspected.<br/> ²Downgraded one level due to inconsistency: there is moderate level of heterogeneity between studies: I² value of 69%.<br/> ³Downgraded one level due to imprecision: 95% CI of the estimate of summary effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tacrolimus 0.1% compared with pimecrolimus 1% for atopic dermatitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009864-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Tacrolimus 0.03% compared with corticosteroids for atopic dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus 0.03% compared with corticosteroids for atopic dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atopic dermatitis<br/> <b>Settings:</b> outpatients, Europe, Tunisia, Pakistan, Morocco, Taiwan<br/> <b>Intervention:</b> tacrolimus 0.03%<br/> <b>Comparison:</b> corticosteroids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Ilustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.03%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.03% 1x/day versus hydrocortisone acetate 1% 2x/day</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.05</b> <br/> (1.36 to 3.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>411<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>136 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>279 per 1000</b> <br/> (185 to 419) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>136 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>279 per 1000</b> <br/> (185 to 419) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.58</b> <br/> (1.96 to 3.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>790<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>376 per 1000</b> <br/> (286 to 493) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>377 per 1000</b> <br/> (286 to 493) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.03% 2x/day versus corticosteroids moderate‐potency 2x/day</b> <br/> Follow‐up: 3 to 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.45</b> <br/> (0.13 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>409<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>527 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> <br/> (69 to 828) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>591 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>266 per 1000</b> <br/> (77 to 928) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.03% 2x/day versus methylprednisolone 0.03% 1x/day</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1</b> <br/> (0.85 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>265<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> <br/> (567 to 793) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> <br/> (567 to 794) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: burning ‐ tacrolimus 0.03% versus steroids</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR2.48</b> <br/> (1.96 to 3.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1883<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>221 per 1000</b> <br/> (174 to 279) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>174 per 1000</b> <br/> (137 to 220) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Participant's self‐assessment of global response of improvement: tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day</b> </p> <p>Follow‐up: 3 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>RR 1.64</b> </p> <p>(1.41 to 1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>416</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>505 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>828 per 1000</b> </p> <p>(712 to 959)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>505 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>828 per 1000</b> </p> <p>(712 to 959)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to publication bias because only very small number of studies were identified and publication bias was strongly suspected.<br/> ²Downgraded one level due to inconsistency: there is moderate level of heterogeneity between studies: I² value of 79%.<br/> ³Downgraded one level due to imprecision: 95% CI of estimated summary effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Tacrolimus 0.03% compared with corticosteroids for atopic dermatitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009864-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Tacrolimus 0.03% compared with tacrolimus 0.1% for atopic dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus 0.03% compared with tacrolimus 0.1% for atopic dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atopic dermatitis<br/> <b>Settings:</b> outpatients, USA, Japan, China<br/> <b>Intervention:</b> tacrolimus 0.03%<br/> <b>Comparison:</b> tacrolimus 0.1% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.1%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.03%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement, clear or excellent</b> <br/> Follow‐up: 3 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.82</b> <br/> (0.72 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1640<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>430 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>353 per 1000</b> <br/> (310 to 396) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>445 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b> <br/> (320 to 409) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects</b> <br/> Follow‐up: mean 3 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> <br/> (0.86 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>986<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>573 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>544 per 1000</b> <br/> (492 to 607) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>426 per 1000</b> <br/> (385 to 475) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to imprecision: sample size is below the optimal information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Tacrolimus 0.03% compared with tacrolimus 0.1% for atopic dermatitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009864-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Tacrolimus 0.03% versus pimecrolimus 1% for atopic dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus 0.03% versus pimecrolimus 1% for atopic dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atopic dermatitis<br/> <b>Settings:</b> outpatients, USA<br/> <b>Intervention:</b> tacrolimus 0.03% versus pimecrolimus 1% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.03% versus pimecrolimus 1%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Physician's assessment of global response of improvement</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.42</b> <br/> (1.02 to 1.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>139<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹<sup>,</sup> ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>609 per 1000</b> <br/> (437 to 849) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>609 per 1000</b> <br/> (438 to 849) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ application site reaction</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.07</b> <br/> (0.6 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>141<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b> <br/> (144 to 457) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b> <br/> (143 to 456) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ burning</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.87</b> <br/> (0.43 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>141<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>197 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>172 per 1000</b> <br/> (85 to 345) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>197 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> <br/> (85 to 345) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ itching</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.37</b> <br/> (0.96 to 5.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>141<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> (81 to 491) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b> <br/> (82 to 494) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ erythema</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.2</b> <br/> (0.89 to 5.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>141<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>186 per 1000</b> <br/> (75 to 461) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>187 per 1000</b> <br/> (76 to 464) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to imprecision: sample size is smaller than the optimal information size.<br/> ²Downgraded one level due to publication bias because only one study was identified and publication bias was strongly suspected.<br/> ³Downgraded one level due to imprecision: 95% CI of the estimate of summary effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Tacrolimus 0.03% versus pimecrolimus 1% for atopic dermatitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009864-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Tacrolimus 0.1% versus ciclosporin for atopic dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus 0.1% versus ciclosporin for atopic dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atopic dermatitis<br/> <b>Settings:</b> outpatients, Italy<br/> <b>Intervention:</b> tacrolimus 0.1% versus ciclosporin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus 0.1% versus ciclosporin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1</b> <br/> (0.31 to 3.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> <br/> (83 to 875) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> <br/> (83 to 876) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to risk of bias: randomisation and allocation concealment procedures were unclear.<br/> ²Downgraded one level due to imprecision: sample size is smaller than optimal information size; 95% CI of the estimate of summary effect includes both no effect and appreciable benefit and harm.<br/> ³Downgraded one level due to publication bias because only one study was identified and publication bias was strongly suspected. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Tacrolimus 0.1% versus ciclosporin for atopic dermatitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009864-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of treatment and participants in included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number of participants </b> </p> <p><b> (n = 5885)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Age</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Follow up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Classification of AD</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0001" title="AntigaE , VolpiW , TorchiaD , FabbriP , CaproniM . Effects of tacrolimus ointment on Toll‐like receptors in atopic dermatitis. Clinical &amp; Experimental Dermatology2011;36(3):235‐41. [MEDLINE: 21070333] ">Antiga 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (21 to 65 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs hydrocortisone butyrate 0.1% ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (SCORAD)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0002" title="BieberT , VickK , Folster‐HolstR , Belloni‐FortinaA , StadtlerG , WormM , et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy2007;62(2):184‐9. [MEDLINE: 17298428] ">Bieber 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> <p>(2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment (BID) vs methylprednisolone aceponate 0.1% ointment (evening) and vehicle ointment (morning) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe flare (IGA &gt; 4) history of moderate to severe AD</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0003" title="BoguniewiczM , FiedlerVC , RaimerS , LawrenceID , LeungDY , HanifinJM . A randomized, vehicle‐controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy &amp; Clinical Immunology1998;102(4 Pt 1):637‐44. [MEDLINE: 9802373] ">Boguniewicz 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Older children</p> <p>(7 to 16 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment vs tacrolimus 0.1% ointment vs tacrolimus 0.3% ointment vs vehicle ointment (BID) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0004" title="CaproniM , TorchiaD , AntigaE , TerranovaM , VolpiW , delBiancoE , et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. British Journal of Dermatology2007;156(2):312‐9. [MEDLINE: 17223872] ">Caproni 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs hydrocortisone butyrate 0.1% ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (SCORAD)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0005" title="DossN , KamounMR , DubertretL , CambazardF , RemitzA , LahfaM , et al. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with moderate‐to‐severe atopic dermatitis: evidence from a randomized, double‐blind non‐inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy &amp; Immunology2010;21(2 Pt 1):321‐9. [MEDLINE: 19563466] ">Doss 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> <p>(2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment vs fluticasone 0.005% ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) and with prior inadequate response to topical corticosteroids </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0006" title="DouX , LiuL‐L , XieZ‐Q , ChenL‐J , LiL , FengS‐Y , et al. The impact of tacrolimus ointment on health‐related quality of life of Chinese adult and pediatric patients with atopic dermatitis (Chinese). Journal of Clinical Dermatology2006;35(1):50‐2. ">Dou 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment vs tacrolimus 0.1% ointment vs vehicle ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0007" title="DraelosZ , NayakA , PariserD , ShupackJL , ChonK , AbramsB , et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‐blind comparison. Journal of the American Academy of Dermatology2005;53(4):602‐9. [MEDLINE: 16198779] ">Draelos 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs pimecrolimus 1% cream (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (IGA)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0008" title="FleischerABJr , AbramovitsW , BrenemanD , JaraczE , US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment2007;18(3):151‐7. [MEDLINE: 17538803] ">Fleischer 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; = 16 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs pimecrolimus 1% cream (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (IGA)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0009" title="HanifinJM , LingMR , LangleyR , BrenemanD , RafalE . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. Journal of the American Academy of Dermatology2001;44(Suppl 1):S28‐38. [EMBASE: 2001020450] SoterNA , Fleischer JrAB , WebsterGF , MonroeE , LawrenceI . Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. Journal of the American Academy of Dermatology2001;44(1 Suppl):S39‐46. [DOI: 10.1067/mjd.2001.109817; EMBASE: 2001020451] ">Hanifin 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>632</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; = 16 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs tacrolimus 0.03% ointment vs vehicle ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0010" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma, &amp; Immunology 007;98(1):51‐6. [MEDLINE: 17225720] ">Hung 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults and</p> <p>children</p> <p>(9 months to 33 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment (BID) alone or with fusidic acid 2% cream vs fluticasone propionate 0.05% cream (BID) alone or with fusidic acid 2% cream </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0011" title="KempersS , BoguniewiczM , CarterE , JarrattM , PariserD , StewartD , et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology2004;51(4):515‐25. [MEDLINE: 15389185] ">Kempers 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 (for safety)</p> <p>139 (for efficacy)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (2 to 17 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment vs pimecrolimus 1% cream (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate (IGA)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0012" title="Otsuki , M , Kawashima , M , Shibata , Y , Nakagawa , H , Harada , S . Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis‐Phase III Double‐blinded Comparison with Vehicle Ointment. Journal of Clinical Therapeutics &amp; Medicines (Rinsho Iyaku)2003;19:569‐95. ">Otsuki 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment vs tacrolimus 0.1% ointment vs vehicle ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0013" title="PacorML , DiLorenzoG , MartinelliN , MansuetoP , RiniGB , CorrocherR . Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clinical &amp; Experimental Allergy2004;34(4):639‐45. [MEDLINE: 15080819] ">Pacor 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults and</p> <p>children (13 to 45 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment (BID) vs ciclosporin 3 mg/kg orally</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0014" title="PallerA , EichenfieldLF , LeungDY , StewartD , AppellM . A 12‐week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology2001;44(1 Suppl):S47‐57. [MEDLINE: 11145795] ">Paller 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment vs tacrolimus 0.1% ointment vs vehicle ointment (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0015" title="AbramovitsW , FleischerABJr , JaraczE , BrenemanD . Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology2008;7(12):1153‐8. [MEDLINE: 19137769] PallerAS , LebwohlM , FleischerABJr , AntayaR , LangleyRG , KirsnerRS , et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology2005;52(5):810‐22. [MEDLINE: 15858471] ">Paller 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs pimecrolimus 1% cream (BID)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (IGA)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0016" title="ReitamoS , RustinM , RuzickaT , CambazardF , KalimoK , FriedmannPS , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):547‐55. [MEDLINE: 11898005] ">Reitamo 2002a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>570</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (16 to 70 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs tacrolimus 0.03% ointment vs hydrocortisone butyrate 0.1% ointment (BID) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0017" title="ReitamoS , VanLeentEJ , HoV , HarperJ , RuzickaT , KalimoK , et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2002;109(3):539‐46. [MEDLINE: 11898004] ">Reitamo 2002b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>560</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs tacrolimus 0.03% ointment vs hydrocortisone acetate 1% ointment (BID) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0018" title="ReitamoS , HarperJ , BosJD , CambazardF , Bruijnzeel‐KoomenC , ValkP , et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology2004;150(3):554‐62. [MEDLINE: 15030341] ">Reitamo 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (2 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment (OD) vs tacrolimus 0.03% ointment (BID) vs hydrocortisone acetate 1% ointment (BID) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0019" title="MandelinJ , RemitzA , VirtanenH , ReitamoS . One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica2010;90(2):170‐4. [DOI: 10.2340/00015555‐0803; MEDLINE: 20169301] PooleCD , ChambersC , AllsoppR , CurrieCJ . Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology &amp; Venereology2010;24(6):674‐8. [DOI: 10.1111/j.1468‐3083.2009.03485.x; MEDLINE: 20565562] ReitamoS , OrtonneJP , SandC , CambazardF , BieberT , Folster‐HolstR , et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology2005;152(6):1282‐9. [MEDLINE: 15948994] ">Reitamo 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>972</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; = 18 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.1% ointment vs hydrocortisone butyrate 0.1% ointment (on trunk and extremities) and hydrocortisone acetate 1% ointment (on face and neck) (BID) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0020" title="Sikder MdAU , Al MamunS , KhanRM , ChowdhuryAH , KhanHM , HoqueMM . Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis ‐ An open randomized comparative study. Journal of Pakistan Association of Dermatologists2005;15(4):304‐12. [EMBASE: 2006159825] ">Sikder 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Older children (7 to 15 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tacrolimus 0.03% ointment (BID) vs clobetasone butyrate 0.05% cream (BID) vs clobetasone butyrate 0.05% cream (morning) and tacrolimus 0.03% ointment (evening) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe (Rajka and Langeland (<a href="./references#CD009864-bbs2-0126" title="RajkaG , LangelandT . Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum1989;144:13‐4. [MEDLINE: 2800895] ">Rajka 1989</a>)) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>AD: atopic dermatitis.<br/> BID: twice a day.<br/> IGA: Investigators' Global Assessment.<br/> OD: once daily.<br/> SCORAD: SCORing Atopic Dermatitis.<br/> vs: versus. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of treatment and participants in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009864-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Spontaneous reported malignancies in association with topical tacrolimus use</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Malignancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Application site</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Occurence site</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposure to onset (days)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B‐cell lymphoma, EBV‐associated, and primary lung carcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Face</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kidney</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>730</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cutaneous Kaposi sarcoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Axilla, groin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Axilla, groin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV patient on HAART, treated for inverse psoriasis, developed KS at these sites, which metastasised, and the patient died </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hepatoblastoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Considered unrelated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>455</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymphadenopathy – possible<br/> lymphoma </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Application site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Application site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐existing lymphoma lesions 'looked like' lymphoma and resolved spontaneously*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymphoma or Sézary syndrome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Face</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph nodes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant also had been on systemic ciclosporin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>730</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastatic angiosarcoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Face/neck</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clavicle</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Present before treatment but increased rapidly in size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastatic melanoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastatic disease newly detected from primary 3 years early</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 to 28</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastatic sweat gland carcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not axilla</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Axilla</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nodular follicular lymphoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower limbs, face</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May be associated with EBV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐Hodgkin lymphoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Used tacrolimus for 6 months. Insufficient evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐Hodgkin lymphoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Used tacrolimus on extensive areas: 50% of body. Died from lymphoma. Insufficient evidence </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophageal cancer with metastases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophagus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Panniculitis‐like T‐cell lymphoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trunk, limbs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trunk, limbs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Also used pimecrolimus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Squamous cell carcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Face</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Face</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UV therapy, outdoor sports</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Squamous cell carcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treated for balanitis considered to be lichen sclerosus et atrophicus; non‐specific biopsy </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Squamous cell carcinoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mouth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long history of pipe smoking</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Squamous cell carcinoma recurrence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vulva</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vulva</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treated for lichen sclerosus et atrophicus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T‐cell lymphoma, anaplastic large cell</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right hip</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right hip</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>EBV: Epstein–Barr virus.<br/> HIV: human immunodeficiency virus.<br/> HAART: highly active antiretroviral therapy.<br/> KS: Kaposi sarcoma.<br/> UV: ultraviolet.<br/> *Questionable if this should be classed as malignant.<br/> Data shown in <a href="./references#CD009864-bbs2-0122" title="OrmerodAD . Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?. British Journal of Dermatology2005;153(4):701‐5. [MEDLINE: 16181449] ">Ormerod 2005</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Spontaneous reported malignancies in association with topical tacrolimus use</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009864-tbl-0009"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Lymphoma risk</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Results related to lymphoma risks</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0051" title="ArellanoFM , WentworthCE , AranaA , FernandezC , PaulCF . Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. Journal of Investigative Dermatology2007;127(4):808‐16. [MEDLINE: 17096020] ">Arellano 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294 cases/293,000 controls</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCIs and TCS in participants with AD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Increased risk in AD participants (related to severity)</p> <p>‐ No evidence of increased risk with any of the topical treatments</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0052" title="ArellanoFM , AranaA , WentworthCE , Fernandez‐VidaurreC , SchliengerRG , CondeE . Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. Journal of Allergy &amp; Clinical Immunology2009;123(5):1111‐6. [MEDLINE: 19361841] ">Arellano 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 3,000,000 (cohort)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1992 to 2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD, treatment with topical immunosuppressants, or both</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Increase risk in AD participants (related to severity)</p> <p>‐ Increased risk with topical corticosteroids (related to potency)</p> <p>‐ Insufficient data to assess TCI‐related risks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0095" title="HuiRL , LideW , ChanJ , SchottingerJ , YoshinagaM , MillaresM . Association between exposure to topical tacrolimus or pimecrolimus and cancers. Annals of Pharmacotherapy2009;43(12):1956‐63. [MEDLINE: 19903860] ">Hui 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>953,064 (cohort) (96% unexposed, 4% exposed)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 2.4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD or eczema participants exposed or not to TCI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Increased risk in the exposed group**</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0141" title="SchneeweissS , DohertyM , ZhuS , FunchD , SchliengerRG , Fernandez‐VidaurreC , et al. Topical treatments with pimecrolimus, tacrolimus and medium‐ to high‐potency corticosteroids, and risk of lymphoma. Dermatology2009;219(1):7‐21. [MEDLINE: 19293564] ">Schneeweiss 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ 118,863 for pimecrolimus</p> <p>‐ 38,757 for tacrolimus</p> <p>‐ 1,043,025 mid to potent corticosteroid</p> <p>‐ 118,825 untreated dermatitis</p> <p>‐ 118,863 for general population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002 to 2006</p> <p>(median 1.3 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Increased risk compared with general population*</p> <p>‐ No risk differences between the 3 treatments</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*pre‐existing lymphomas misdiagnosed as AD.<br/> **proportion of people who had diagnosis of AD was 2 times higher in the exposed group (i.e., there was a higher prevalence of AD than eczema in the exposed group). See <a href="#CD009864-sec-0129">Summary of main results</a> (Risk of malignancies).<br/> AD: atopic dermatitis.<br/> TCI: topical calcineurin inhibitor.<br/> TCS: topical corticosteroids. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Lymphoma risk</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009864-tbl-0010"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Non‐melanoma skin cancer (NMSC) and melanoma (MM) skin cancer risk</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Follow up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Results related to skin cancer risks</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0095" title="HuiRL , LideW , ChanJ , SchottingerJ , YoshinagaM , MillaresM . Association between exposure to topical tacrolimus or pimecrolimus and cancers. Annals of Pharmacotherapy2009;43(12):1956‐63. [MEDLINE: 19903860] ">Hui 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>953,064 (cohort) (96% unexposed, 4% exposed)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 2.4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD participants exposed or not to TCI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Similar risks for NMSC</p> <p>‐ Lower risks for MM</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0113" title="MargolisDJ , HoffstadO , Bilker , W . Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology2007;214(4):289‐95. [MEDLINE: 17460399] ">Margolis 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>875 cases</p> <p>1946 controls</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dermatitis participants (AD, seborrhoeic dermatitis, rosacea, other dermatitis) with or without use of TCI </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ No increased risk of NMSC in TCI‐treated participants</p> <p>‐ MM risk not evaluated</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0120" title="NaylorM , ElmetsC , JaraczE , RicoJM . Non‐melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. Journal of Dermatological Treatment2005;16(3):149‐53. [MEDLINE: 16096180] ">Naylor 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9813 tacrolimus‐treated participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months to 4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD participants with tacrolimus use compared with an aged cohort in the US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ No increased risk of NMSC in tacrolimus treated participants</p> <p>‐ MM risk not evaluated</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>AD: atopic dermatitis.<br/> TCI: topical calcineurin inhibitor.<br/> MM: melanoma.<br/> NMSC: non‐melanoma skin cancer. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Non‐melanoma skin cancer (NMSC) and melanoma (MM) skin cancer risk</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009864-tbl-0011"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Observational non‐comparative studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> 1. Population</b> </p> <p><b> 2. Age group</b> </p> <p><b> 3. Follow‐up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Tacrolimus formulation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Common local effects</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Systemic effects</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Laboratory values</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Malignancies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Others (number of events)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Detectable blood concentration</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0087" title="GontijoB , PiresMC , CestariTF , LaScalaCSK , DuarteIAG , TakaokaR , et al. Evaluate of the efficacy and safety of tacrolimus ointment 0, 03% to treat atopic dermatitis in pediatric patients [Avaliacao da eficacia e seguranca do tacrolimo pomada 0, 03% no tratamento da dermatite atopica em pacientes pediatricos]. Anais Brasileiros De Dermatologia2008;83(6):511‐9. [MEDLINE: 2009148842] ">Gontijo 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 174</p> <p>2. Paediatric<br/> 3. 6 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Asthma (2)</p> <p>‐ Pneumonia (2)</p> <p>‐ Pyodermitis (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0102" title="KooJY , FleischerABJr , AbramovitsW , PariserDM , McCallCO , HornTD , et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. Journal of the American Academy of Dermatology2005;53(2 Suppl 2):S195‐205. [MEDLINE: 16021175] ">Koo 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 7923</p> <p>2. Adult/paediatric</p> <p>3. Median: 210 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1% (92.7%)</p> <p>0.03% (7.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Flu‐like symptoms</p> <p>‐ Headache</p> <p>(frequency similar to that expected of the general population)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ 13 cases of NMSC (no risk with calculated incidence)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Alcohol intolerance 3.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0112" title="MandelinJM , RubinsA , RemitzA , CiruleK , DickinsonJ , HoV , et al. Long‐term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two‐year open‐label study. International Journal of Dermatology2012;51(1):104‐10. [MEDLINE: 21923693] ">Mandelin 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 50</p> <p>2. Paediatric (&lt; 2 years)</p> <p>3. 2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Pruritus</p> <p>‐ Local infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Non‐serious respiratory</p> <p>infection and</p> <p>gastroenteritis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1 ng/ml (in 98%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0129" title="ReitamoS , WollenbergA , SchopfE , PerrotJL , MarksR , RuzickaT , et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis.The European Tacrolimus OintmentStudy Group. Archives of Dermatology2000;136(8):999‐1006. [MEDLINE: 10926735] ">Reitamo 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 316</p> <p>2. Adults</p> <p>3. 6 to 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> <p>‐ Erythema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal</p> <p>(only 1 transient</p> <p>increase in</p> <p>liver enzymes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Alcohol intolerance</p> <p>5 serious events:</p> <p>‐ Eczema herpeticum (1)</p> <p>‐ Cellulitis (1)</p> <p>‐ Varicella (1)</p> <p>‐ AD flare‐up (1)</p> <p>‐ <i>Staphylococcus aureus</i> </p> <p>superinfection (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal &lt; 1 ng/dl in 76% of participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0131" title="ReitamoS , OrtonneJP , SandC , BosJ , CambazardF , BieberT , et al. Long‐term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two‐year, multicentre, non‐comparative study. Acta Dermato‐Venereologica2007;87(5):406‐12. [EMBASE: 17721647] ">Reitamo 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 672</p> <p>2. Adults</p> <p>3. 2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ 2 cases (Bowen and prostate carcinoma) not related</p> <p>‐ Benign neoplasm (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Herpes (7%) (expected in AD participants)</p> <p>‐ Eczema herpeticum (1)</p> <p>‐ Erythroderma (1)</p> <p>‐ AD exacerbation (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0132" title="ReitamoS , RustinM , HarperJ , KalimoK , RubinsA , CambazardF , et al. A 4‐year follow‐up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. British Journal of Dermatology2008;159(4):942‐51. [MEDLINE: 18637898] ">Reitamo 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 782</p> <p>2. Adult/paediatric</p> <p>3. 4 years (median: 1422 days)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> <p>‐ Skin infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Flu‐like symptoms</p> <p>(more in children)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 cases</p> <p>‐ Cervical carcinoma (1)</p> <p>‐ Acute leukaemia (1)</p> <p>‐ Chronic leukaemia (1)</p> <p>‐ Basal cell carcinoma (2 to 3 on the same participant)</p> <p>‐ 34 benign neoplasms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0133" title="RemitzA , HarperJ , RustinM , GoldschmidtWF , PalatsiR , van derValkPG , et al. Long‐term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Dermato‐Venereologica2007;87(1):54‐61. [MEDLINE: 17225017] ">Remitz 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 466</p> <p>2. Paediatric</p> <p>3. 29.5 months (mean: 16.3 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03%</p> <p>0.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Seasonal infection</p> <p>(flu‐syndrome)</p> <p>‐ No growth</p> <p>retardation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Leukopenia (1)*</p> <p>‐ Herpes (4.9%)/eczema herpeticum (0.9%)</p> <p>‐ Molluscum 3%)</p> <p>‐ Warts (3.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0138" title="SapleDG , TorsekarRG , PawanarkarV , WaliV , RavichandranG , DhanalakshmiUR , et al. Evaluation of the efficacy, safety and tolerability of Tacrolimus ointment in Indian patients of moderate to severe atopic dermatitis: a multicentric, open label, phase III study. Indian Journal of Dermatology, Venereology &amp; Leprology2003;69(6):396‐400. [MEDLINE: 17642950] ">Saple 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 125</p> <p>2. 12 to 69 years</p> <p>3. 5 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> <p>‐ Erythema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0042" title="WonCH , SeoPG , ParkYM , YangJM , LeeKH , SungKJ , et al. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. Journal of Dermatological Treatment2004;15(1):30‐4. [MEDLINE: 14754647] ">Won 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 18</p> <p>2. Adult/paediatric</p> <p>3. 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious events (3):</p> <p>‐ Flu‐syndrome (1)</p> <p>‐ Severe skin rash (1)</p> <p>‐ Eczema herpeticum (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009864-bbs2-0160" title="WongWR , TsaiHJ , HongHS . Efficacy and safety of topically applied tacrolimus ointment in patients with moderate to severe atopic dermatitis. Chang Gung Medical Journal2003;26(7):485‐95. [MEDLINE: 14515971] ">Wong 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. n = 30</p> <p>2. Adult/paediatric</p> <p>3. 4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1% adults</p> <p>0.03% paediatric</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Burning</p> <p>‐ Pruritus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 participants</p> <p>&lt; 5 ng/ml</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>* 6‐year‐old participant, at month 6, resolution after withdrawn.<br/> AD: atopic dermatitis.<br/> NMSC: non‐melanoma skin cancer. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Observational non‐comparative studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/full#CD009864-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009864-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tacrolimus 0.1% versus steroids</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Physician's assessment of global response of improvement, clear or excellent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Tacrolimus 0.1% versus hydrocortisone acetate 0.1%: 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tacrolimus 0.1% versus hydrocortisone butyrate: 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: short‐term (6 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: long‐term (12 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects: burning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Tacrolimus 0.1% versus hydrocortisone acetate 0.1%: 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Tacrolimus 0.1% versus hydrocortisone butyrate: 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: short‐term (6 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: long‐term (12 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects: pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Tacrolimus 0.1% versus hydrocortisone acetate 0.1%: 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Tacrolimus 0.1% versus hydrocortisone butyrate: 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: short‐term (6 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects: skin infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Tacrolimus 0.1% versus hydrocortisone acetate 0.1%: 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Tacrolimus 0.1% versus hydrocortisone butyrate: 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: short‐term (6 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 SCORAD: 3 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.82 [‐15.36, ‐2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tacrolimus 0.1% versus steroids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009864-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tacrolimus 0.1% versus pimecrolimus 1%</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Physician's assessment of global response of improvement, clear or excellent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.35, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 13 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [0.19, 19.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.34, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects ‐ 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.47, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tacrolimus 0.1% versus pimecrolimus 1%</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009864-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Tacrolimus 0.03% versus steroids</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Physician's assessment of global response of improvement, clear or excellent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Tacrolimus 0.03% 1x/day versus hydrocortisone acetate 1% 2x/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.36, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [1.96, 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Tacrolimus 0.03% 2x/day versus steroids moderate potency 2x/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.13, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Tacrolimus 0.03% 2x/day versus methylprednisolone 0.03% 1x/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.85, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants's assessment of global response of improvement better or much better <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Tacrolimus 0.03 1x/day versus hydrocortisone acetate 1% 2x/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Tacrolimus 0.03% 2x/day versus fluticasone 0.005% 2x/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects: burning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1883</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.48 [1.96, 3.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Tacrolimus 0.03% versus hydrocortisone acetate 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.36, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Tacrolimus 0.03% versus steroids moderate potency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.52 [2.45, 5.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects: pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1883</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.17, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Tacrolimus 0.03% versus hydrocortisone acetate 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.00, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Tacrolimus 0.03% versus steroids of moderate potency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.18, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: skin infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.69, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Tacrolimus 0.03% versus hydrocortisone acetate 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.49, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Tacrolimus 0.03% versus steroids of moderate potency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.65, 2.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Tacrolimus 0.03% versus steroids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009864-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Tacrolimus 0.03% versus tacrolimus 0.1%</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Physician's assessment of global response of improvement, clear or excellent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.72, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.71, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.64, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.86, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Tacrolimus 0.03% versus tacrolimus 0.1%</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009864-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Tacrolimus 0.03% versus pimecrolimus 1%</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Physician's assessment of global response of improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Application site reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Burning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Tacrolimus 0.03% versus pimecrolimus 1%</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009864-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Tacrolimus 0.1% versus ciclosporin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 SCORAD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 35 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 42 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Tacrolimus 0.1% versus ciclosporin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009864.pub2/references#CD009864-tbl-0017">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009864.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009864-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009864-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009864-note-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD009864-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD009864-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD009864-note-0004">Polski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009864\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009864\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009864\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009864\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009864\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009864.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009864.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009864.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009864.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009864.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725646092"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009864.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725646096"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009864.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e804ffb07f466',t:'MTc0MDcyNTY0Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 